Transplantation of stem cells collected from the peripheral blood. It is a less invasive alternative to direct marrow harvesting of hematopoietic stem cells. Enrichment of stem cells in peripheral blood can be achieved by inducing mobilization of stem cells from the BONE MARROW.
Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
Transplantation of an individual's own tissue from one site to another site.
Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.
The release of stem cells from the bone marrow into the peripheral blood circulation for the purpose of leukapheresis, prior to stem cell transplantation. Hematopoietic growth factors or chemotherapeutic agents often are used to stimulate the mobilization.
Preparative treatment of transplant recipient with various conditioning regimens including radiation, immune sera, chemotherapy, and/or immunosuppressive agents, prior to transplantation. Transplantation conditioning is very common before bone marrow transplantation.
The transfer of STEM CELLS from one individual to another within the same species (TRANSPLANTATION, HOMOLOGOUS) or between species (XENOTRANSPLANTATION), or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). The source and location of the stem cells determines their potency or pluripotency to differentiate into various cell types.
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.
The preparation of leukocyte concentrates with the return of red cells and leukocyte-poor plasma to the donor.
A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.
An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.
Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow.
Any procedure in which blood is withdrawn from a donor, a portion is separated and retained and the remainder is returned to the donor.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Progenitor cells from which all blood cells derive.
An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Agents that destroy bone marrow activity. They are used to prepare patients for BONE MARROW TRANSPLANTATION or STEM CELL TRANSPLANTATION.
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Relatively undifferentiated cells that retain the ability to divide and proliferate throughout postnatal life to provide progenitor cells that can differentiate into specialized cells.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Transplantation of STEM CELLS collected from the fetal blood remaining in the UMBILICAL CORD and the PLACENTA after delivery. Included are the HEMATOPOIETIC STEM CELLS.
An organism that, as a result of transplantation of donor tissue or cells, consists of two or more cell lines descended from at least two zygotes. This state may result in the induction of donor-specific TRANSPLANTATION TOLERANCE.
The return of a sign, symptom, or disease after a remission.
Individuals supplying living tissue, organs, cells, blood or blood components for transfer or transplantation to histocompatible recipients.
Therapeutic act or process that initiates a response to a complete or partial remission level.
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
The degree of antigenic similarity between the tissues of different individuals, which determines the acceptance or rejection of allografts.
A multisystemic disorder characterized by a sensorimotor polyneuropathy (POLYNEUROPATHIES), organomegaly, endocrinopathy, monoclonal gammopathy, and pigmentary skin changes. Other clinical features which may be present include EDEMA; CACHEXIA; microangiopathic glomerulopathy; pulmonary hypertension (HYPERTENSION, PULMONARY); cutaneous necrosis; THROMBOCYTOSIS; and POLYCYTHEMIA. This disorder is frequently associated with osteosclerotic myeloma. (From Adams et al., Principles of Neurology, 6th ed, p1335; Rev Med Interne 1997;18(7):553-62)
A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
Irradiation of the whole body with ionizing or non-ionizing radiation. It is applicable to humans or animals but not to microorganisms.
Identification of the major histocompatibility antigens of transplant DONORS and potential recipients, usually by serological tests. Donor and recipient pairs should be of identical ABO blood group, and in addition should be matched as closely as possible for HISTOCOMPATIBILITY ANTIGENS in order to minimize the likelihood of allograft rejection. (King, Dictionary of Genetics, 4th ed)
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
Invasion of the host organism by microorganisms that can cause pathological conditions or diseases.
Transplantation between genetically identical individuals, i.e., members of the same species with identical histocompatibility antigens, such as monozygotic twins, members of the same inbred strain, or members of a hybrid population produced by crossing certain inbred strains.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
A group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of AMYLOID. As the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. Various signs and symptoms depend on the location and size of the deposits.
The development and formation of various types of BLOOD CELLS. Hematopoiesis can take place in the BONE MARROW (medullary) or outside the bone marrow (HEMATOPOIESIS, EXTRAMEDULLARY).
A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
The cells found in the body fluid circulating throughout the CARDIOVASCULAR SYSTEM.
Immunological rejection of leukemia cells following bone marrow transplantation.
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
The number of PLATELETS per unit volume in a sample of venous BLOOD.
Elements of limited time intervals, contributing to particular results or situations.
Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.
A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.
The number of LEUKOCYTES and ERYTHROCYTES per unit volume in a sample of venous BLOOD. A complete blood count (CBC) also includes measurement of the HEMOGLOBIN; HEMATOCRIT; and ERYTHROCYTE INDICES.
A general term for various neoplastic diseases of the lymphoid tissue.
The engulfment and degradation of cells by other cells.
The transference of a part of or an entire liver from one human or animal to another.
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
Immunosuppression by reduction of circulating lymphocytes or by T-cell depletion of bone marrow. The former may be accomplished in vivo by thoracic duct drainage or administration of antilymphocyte serum. The latter is performed ex vivo on bone marrow before its transplantation.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
A condition characterized by a reticular or fishnet pattern on the skin of lower extremities and other parts of the body. This red and blue pattern is due to deoxygenated blood in unstable dermal blood vessels. The condition is intensified by cold exposure and relieved by rewarming.
Group of disorders which feature accumulations of active HISTIOCYTES and LYMPHOCYTES, but where the histiocytes are not LANGERHANS CELLS. The group includes HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; SINUS HISTIOCYTOSIS; xanthogranuloma; reticulohistiocytoma; JUVENILE XANTHOGRANULOMA; xanthoma disseminatum; as well as the lipid storage diseases (SEA-BLUE HISTIOCYTE SYNDROME; and NIEMANN-PICK DISEASES).
Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.
Disorders of the blood and blood forming tissues.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).
Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases.
'Blood donors' are individuals who voluntarily and safely donate a specific amount of their own blood, which can be further separated into components, to be used for transfusion purposes or for manufacturing medical products, without receiving remuneration that is intended to reward them financially.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry.
Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
Proteins prepared by recombinant DNA technology.
Transfer of MESENCHYMAL STEM CELLS between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS).
A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes.
Techniques for the removal of subpopulations of cells (usually residual tumor cells) from the bone marrow ex vivo before it is infused. The purging is achieved by a variety of agents including pharmacologic agents, biophysical agents (laser photoirradiation or radioisotopes) and immunologic agents. Bone marrow purging is used in both autologous and allogeneic BONE MARROW TRANSPLANTATION.
Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work.
A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
An organoplatinum compound that possesses antineoplastic activity.
Bone marrow diseases, also known as hematologic or blood disorders, refer to conditions that affect the production and function of blood cells within the bone marrow, such as leukemia, lymphoma, myeloma, and aplastic anemia, potentially leading to complications like anemia, neutropenia, thrombocytopenia, and increased susceptibility to infections or bleeding.
Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
An antigenic mismatch between donor and recipient blood. Antibodies present in the recipient's serum may be directed against antigens in the donor product. Such a mismatch may result in a transfusion reaction in which, for example, donor blood is hemolyzed. (From Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984).
Remnant of a tumor or cancer after primary, potentially curative therapy. (Dr. Daniel Masys, written communication)
The transference of a kidney from one human or animal to another.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Transference of cells within an individual, between individuals of the same species, or between individuals of different species.
A general term for the complex phenomena involved in allo- and xenograft rejection by a host and graft vs host reaction. Although the reactions involved in transplantation immunology are primarily thymus-dependent phenomena of cellular immunity, humoral factors also play a part in late rejection.
The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells.
An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.
Cells derived from the BLASTOCYST INNER CELL MASS which forms before implantation in the uterine wall. They retain the ability to divide, proliferate and provide progenitor cells that can differentiate into specialized cells.
A classification of lymphocytes based on structurally or functionally different populations of cells.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
An anti-inflammatory 9-fluoro-glucocorticoid.
Immunological rejection of tumor tissue/cells following bone marrow transplantation.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
Disease having a short and relatively severe course.
Persons or animals having at least one parent in common. (American College Dictionary, 3d ed)
A family composed of spouses and their children.
Cell separation is the process of isolating and distinguishing specific cell types or individual cells from a heterogeneous mixture, often through the use of physical or biological techniques.
The transfer of lymphocytes from a donor to a recipient or reinfusion to the donor.
Mature LYMPHOCYTES and MONOCYTES transported by the blood to the body's extravascular space. They are morphologically distinguishable from mature granulocytic leukocytes by their large, non-lobed nuclei and lack of coarse, heavily stained cytoplasmic granules.
Cells contained in the bone marrow including fat cells (see ADIPOCYTES); STROMAL CELLS; MEGAKARYOCYTES; and the immediate precursors of most blood cells.
Cells with high proliferative and self renewal capacities derived from adults.
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
The transfer of blood platelets from a donor to a recipient or reinfusion to the donor.
A cell-separation technique where magnetizable microspheres or beads are first coated with monoclonal antibody, allowed to search and bind to target cells, and are then selectively removed when passed through a magnetic field. Among other applications, the technique is commonly used to remove tumor cells from the marrow (BONE MARROW PURGING) of patients who are to undergo autologous bone marrow transplantation.
Blood of the fetus. Exchange of nutrients and waste between the fetal and maternal blood occurs via the PLACENTA. The cord blood is blood contained in the umbilical vessels (UMBILICAL CORD) at the time of delivery.
Providers of tissues for transplant to non-related individuals.
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care. (Dictionary of Health Services Management, 2d ed)
Serum containing GAMMA-GLOBULINS which are antibodies for lymphocyte ANTIGENS. It is used both as a test for HISTOCOMPATIBILITY and therapeutically in TRANSPLANTATION.
Tumors or cancer of the human BREAST.
The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases, new or old, in the population at a given time.
The transfer of leukocytes from a donor to a recipient or reinfusion to the donor.
A decrease in the number of NEUTROPHILS found in the blood.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612)
The procedure established to evaluate the health status and risk factors of the potential DONORS of biological materials. Donors are selected based on the principles that their health will not be compromised in the process, and the donated materials, such as TISSUES or organs, are safe for reuse in the recipients.
A cytologic technique for measuring the functional capacity of stem cells by assaying their activity.
Summarizing techniques used to describe the pattern of mortality and survival in populations. These methods can be applied to the study not only of death, but also of any defined endpoint such as the onset of disease or the occurrence of disease complications.
The number of LYMPHOCYTES per unit volume of BLOOD.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
An abnormal elevation of body temperature, usually as a result of a pathologic process.
The transference of a heart from one human or animal to another.
Cells that can give rise to cells of the three different GERM LAYERS.
A PREDNISOLONE derivative with similar anti-inflammatory action.
Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.
Liver disease that is caused by injuries to the ENDOTHELIAL CELLS of the vessels and subendothelial EDEMA, but not by THROMBOSIS. Extracellular matrix, rich in FIBRONECTINS, is usually deposited around the HEPATIC VEINS leading to venous outflow occlusion and sinusoidal obstruction.
A hematopoietic growth factor and the ligand of the cell surface c-kit protein (PROTO-ONCOGENE PROTEINS C-KIT). It is expressed during embryogenesis and is a growth factor for a number of cell types including the MAST CELLS and the MELANOCYTES in addition to the HEMATOPOIETIC STEM CELLS.
A lignan (LIGNANS) found in PODOPHYLLIN resin from the roots of PODOPHYLLUM plants. It is a potent spindle poison, toxic if taken internally, and has been used as a cathartic. It is very irritating to skin and mucous membranes, has keratolytic actions, has been used to treat warts and keratoses, and may have antineoplastic properties, as do some of its congeners and derivatives.
The occurrence in an individual of two or more cell populations of different chromosomal constitutions, derived from different individuals. This contrasts with MOSAICISM in which the different cell populations are derived from a single individual.
The transference of either one or both of the lungs from one human or animal to another.
A particular zone of tissue composed of a specialized microenvironment where stem cells are retained in a undifferentiated, self-renewable state.
Self-renewing cells that generate the main phenotypes of the nervous system in both the embryo and adult. Neural stem cells are precursors to both NEURONS and NEUROGLIA.
Preservation of cells, tissues, organs, or embryos by freezing. In histological preparations, cryopreservation or cryofixation is used to maintain the existing form, structure, and chemical composition of all the constituent elements of the specimens.
The procedure of removing TISSUES, organs, or specimens from DONORS for reuse, such as TRANSPLANTATION.
The number of CELLS of a specific kind, usually measured per unit volume or area of sample.
An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient.
Bone-marrow-derived, non-hematopoietic cells that support HEMATOPOETIC STEM CELLS. They have also been isolated from other organs and tissues such as UMBILICAL CORD BLOOD, umbilical vein subendothelium, and WHARTON JELLY. These cells are considered to be a source of multipotent stem cells because they include subpopulations of mesenchymal stem cells.
White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS.
An acidic glycoprotein of MW 23 kDa with internal disulfide bonds. The protein is produced in response to a number of inflammatory mediators by mesenchymal cells present in the hemopoietic environment and at peripheral sites of inflammation. GM-CSF is able to stimulate the production of neutrophilic granulocytes, macrophages, and mixed granulocyte-macrophage colonies from bone marrow cells and can stimulate the formation of eosinophil colonies from fetal liver progenitor cells. GM-CSF can also stimulate some functional activities in mature granulocytes and macrophages.
Antibodies produced by a single clone of cells.
A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.
A human or animal whose immunologic mechanism is deficient because of an immunodeficiency disorder or other disease or as the result of the administration of immunosuppressive drugs or radiation.
An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.
Transference of an organ between individuals of the same species or between individuals of different species.
A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)
Cells from adult organisms that have been reprogrammed into a pluripotential state similar to that of EMBRYONIC STEM CELLS.
A pediatric acute myeloid leukemia involving both myeloid and monocytoid precursors. At least 20% of non-erythroid cells are of monocytic origin.
An anthracenedione-derived antineoplastic agent.
The developmental history of specific differentiated cell types as traced back to the original STEM CELLS in the embryo.
Exfoliate neoplastic cells circulating in the blood and associated with metastasizing tumors.
The relationship between the dose of an administered drug and the response of the organism to the drug.
Antibodies obtained from a single clone of cells grown in mice or rats.
Leukocytes with abundant granules in the cytoplasm. They are divided into three groups according to the staining properties of the granules: neutrophilic, eosinophilic, and basophilic. Mature granulocytes are the NEUTROPHILS; EOSINOPHILS; and BASOPHILS.
An ACYCLOVIR analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.
Transference of a tissue or organ from either an alive or deceased donor, within an individual, between individuals of the same species, or between individuals of different species.
A rare, X-linked immunodeficiency syndrome characterized by ECZEMA; LYMPHOPENIA; and, recurrent pyogenic infection. It is seen exclusively in young boys. Typically, IMMUNOGLOBULIN M levels are low and IMMUNOGLOBULIN A and IMMUNOGLOBULIN E levels are elevated. Lymphoreticular malignancies are common.
Specialized stem cells that are committed to give rise to cells that have a particular function; examples are MYOBLASTS; MYELOID PROGENITOR CELLS; and skin stem cells. (Stem Cells: A Primer [Internet]. Bethesda (MD): National Institutes of Health (US); 2000 May [cited 2002 Apr 5]. Available from: http://www.nih.gov/news/stemcell/primer.htm)
The process by which blood or its components are kept viable outside of the organism from which they are derived (i.e., kept from decay by means of a chemical agent, cooling, or a fluid substitute that mimics the natural state within the organism).
The major human blood type system which depends on the presence or absence of two antigens A and B. Type O occurs when neither A nor B is present and AB when both are present. A and B are genetic factors that determine the presence of enzymes for the synthesis of certain glycoproteins mainly in the red cell membrane.
The transference of pancreatic islets within an individual, between individuals of the same species, or between individuals of different species.
The transfer of erythrocytes from a donor to a recipient or reinfusion to the donor.
Ring compounds having atoms other than carbon in their nuclei. (Grant & Hackh's Chemical Dictionary, 5th ed)
Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.
A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE.
Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type.
Inbred C57BL mice are a strain of laboratory mice that have been produced by many generations of brother-sister matings, resulting in a high degree of genetic uniformity and homozygosity, making them widely used for biomedical research, including studies on genetics, immunology, cancer, and neuroscience.
Cells derived from a FETUS that retain the ability to divide, proliferate and provide progenitor cells that can differentiate into specialized cells.
Freedom from exposure to danger and protection from the occurrence or risk of injury or loss. It suggests optimal precautions in the workplace, on the street, in the home, etc., and includes personal safety as well as the safety of property.
Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner.
Transplantation between animals of different species.
Methods for maintaining or growing CELLS in vitro.
Disorders characterized by proliferation of lymphoid tissue, general or unspecified.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
Non-cadaveric providers of organs for transplant to related or non-related recipients.
The mechanism by which latent viruses, such as genetically transmitted tumor viruses (PROVIRUSES) or PROPHAGES of lysogenic bacteria, are induced to replicate and then released as infectious viruses. It may be effected by various endogenous and exogenous stimuli, including B-cell LIPOPOLYSACCHARIDES, glucocorticoid hormones, halogenated pyrimidines, IONIZING RADIATION, ultraviolet light, and superinfecting viruses.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
A type of analysis in which subjects in a study group and a comparison group are made comparable with respect to extraneous factors by individually pairing study subjects with the comparison group subjects (e.g., age-matched controls).
The transference of a pancreas from one human or animal to another.
Placement of an intravenous CATHETER in the subclavian, jugular, or other central vein.
A malignant tumor of the bone which always arises in the medullary tissue, occurring more often in cylindrical bones. The tumor occurs usually before the age of 20, about twice as frequently in males as in females.
A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.
A subnormal level of BLOOD PLATELETS.

Application of autologous peripheral blood stem cell transplantation in children with malignant tumor. (1/564)

OBJECTIVE: To investigate if low dose total body irradiation (TBI, 6.0-9.0 Gy) combined with intensified chemotherapy followed by autologous peripheral blood stem cell transplantation results in better survival in children with refractory leukemia or solid tumors. METHODS: Twenty-one children with malignant tumors were included in this study. There were 14 males and 7 females aged 3.5-12 years. Underlying disease included high-risk acute lymphoblastic leukemia (ALL, CR1 in 3 children and CR2 in 5 children), acute myeloblastic leukemia (AML, 9 children), non-Hodgkin's lymphoma stage IV (2 children), and neuroblastoma stage IV (2 children). The peripheral hematopoietic stem cells were collected six to eleven months after complete response, mobilized with high dose chemotherapy alone or combined with GM-CSF or G-CSF. The conditioning regimen consisted of chemotherapy with two to three combinations of the following drugs: cyclophosphamide, arabinosylcytosine, McNU, etopside, and ldarubicin on the basis of TBI (6.0-9.0 Gy). A mean of (1.8 +/- 0.5) x 10(8)/kg autologous mononuclear cells were transplanted. The patients were followed up after transplantation. RESULTS: Severe bone marrow suppression occurred in all patients around day +7. Peripheral white blood cell count decreased to 0 in all patients at day +4.8 +/- 2.9, and platelet count decreased to less than 20 x 10(9)/L at day +9.0 +/- 2.6. Successful engraftment was achieved in 21 patients, but four died of infection at day +17, +20, +31 and +67, respectively. Recovery of white blood cell (WBC) to 10 x 10(9)/L, absolute neutrophil count to 0.5 x 10(9)/L, platelet count to 20 x 10(9)/L occurred on 21 +/- 12, 26 +/- 13, and 27 +/- 10 days, respectively. During the follow up period, three patients relapsed at months, +1.5 years, and +2 years 10 months, respectively. One patient died of intracranial hemorrhage at +8 months. Thirteen patients had event-free survival for 2-12 years, with a mean of 6.7 +/- 3.4 years. CONCLUSION: Our preliminary data suggest that myeloablative therapy with low dose TBI (6.0-9.0 Gy) combined with intensified chemotherapy followed by autologous peripheral blood stem cell transplantation might be associated with favorable results in children with refractory leukemia or solid tumors.  (+info)

Allogeneic CD34+ -selected peripheral stem cell transplantation from parental donors in children with non-malignant diseases. (2/564)

Allogeneic peripheral stem cell transplantation in six children with non-malignant hematologic or metabolic diseases which are eventually fatal was carried out with parental donors. Given three to five HLA mismatches, all grafts underwent CD34+ cell selection as graft-versus-host prophylaxis. The patients received median doses of 16.7 x 10(6) CD34+ cells/kg and 1.2 x 10(4) CD3+ cells/kg. All transplants engrafted. Neutrophils >0.5/nl were reached on day 11 (9-19) and platelets >50/nl on day 13 (10-25). Acute GVHD responding to steriods occured in three of six patients; it was restricted to the skin and overall did not exceed grade I. Two patients died of viral infections and four are alive with stable blood counts for 13, 15, 25 and 26 months. For children with non-malignant diseases which will eventually be fatal and which can be cured or ameliorated by allogeneic BMT, CD34+-selected stem cell transplants from mismatched or even haploidentical parents can be used if no other suitable donor is available. With high CD34+ cell doses and low CD3+ cell numbers, engraftment and avoidance of acute GVHD can be expected. Infections after transplantation remain the primary threat to survival.  (+info)

Technique for PBSC harvesting in children of weight under 10 kg. (3/564)

Peripheral blood stem cell (PBSC) harvesting in the smallest children (weight <10 kg) using separators is complicated by specific problems. The volume of the separation set exceeds 25% of the total blood volume and the vascular access is generally not sufficient. Therefore, a simple manual technique for PBSC harvesting was developed. Three children (6-9 kg), with newly diagnosed tumours were scheduled to be treated with three to six sequential courses of high-dose chemotherapy, each followed by PBSC support. PBSC harvests were started after mobilization using cyclophosphamide and G-CSF when the peripheral blood CD34+ cell count exceeded 50/microl. About 50 ml of blood was drawn from a venous catheter, injected into a transfer bag containing ACD-A, and centrifuged. The buffy coat obtained was pooled in a collection bag, remaining plasma and erythrocytes were immediately reinfused and a subsequent cycle started. From three to 13 cycles were performed in 1-3 days and 18.0-32.2 x 10(6) CD34+cells/kg were collected. We did not detect any bacterial contamination or any notable complications. Fifteen PBSC reinfusions have been performed to date, each with rapid engraftment taking between 7 and 13 days. Patients are in very good PR (18 months from diagnosis) or in CR (6 and 8 months). We can conclude that this procedure is feasible and safe.  (+info)

Nonmyeloablative allogeneic peripheral blood stem cell transplantation for multifocal extramedullary plasmacytomas progressing after autologous transplantation. (4/564)

Multifocal extramedullary plasmacytomas (EMP) are an uncommon manifestation of plasma cell malignancies. We report two patients with multiple EMP who developed rapidly progressive and ultimately fatal disease shortly after undergoing nonmyeloablative, matched-related donor allogeneic peripheral blood stem cell transplantation (PBSCT). We have not observed a similar course in patients transplanted for multiple myeloma without extramedullary manifestations and hypothesize that the intense immunosuppression associated with the fludarabine, busulfan and anti-thymocyte globulin conditioning regimen may have contributed to rapid disease progression in the two EMP patients. Our observations support the assertion that extramedullary disease is a marker for an aggressive, refractory plasma cell malignancy and suggest that patients should be treated intensively from the time of diagnosis. The utility of a graft-versus-tumor effect and the role of nonmyeloablative allogeneic PBSCT is yet to be defined in patients with extramedullary plasma cell malignancies, but it is logical to consider using it at the time of minimal residual disease rather than at disease relapse or progression. Nevertheless, we recommend circumspection in the administration of highly immunosuppressive conditioning regimens to patients with refractory EMP and encourage further clinical research in this area.  (+info)

Resolution of chronic idiopathic thrombocytopenia purpura following syngeneic peripheral blood progenitor transplant. (5/564)

Idiopathic thrombocytopenia purpura (ITP) is an acquired disease of children and adults characterized by a low platelet count, an essentially normal bone marrow, and absence of evidence for other disease. We report the use of syngeneic peripheral blood progenitor transplantation (PBPT) in a 19-year-old male with chronic refractory ITP since the age of 5. Engraftment was successful and has resulted in resolution of his disease. We conclude that syngeneic PBPT is a potentially curative option for refractory ITP.  (+info)

Stem cell mobilisation with 16 microg/kg vs 10 microg/kg of G-CSF for allogeneic transplantation in healthy donors. (6/564)

We compared two doses of recombinant human granulocyte-stimulating factor (G-CSF) for stem cell mobilisation in 90 healthy donors for allogeneic stem cell transplantation in a retrospective analysis. Group I (n = 46) received 10 microg/kg G-CSF (filgrastim) given as 5 microg/kg twice daily, and group II (n = 44) received 16 microg/kg, given as 8 microg/kg twice daily with a 12-h interval. The groups were well-balanced for age and body-weight. G-CSF application was performed on an out-patient basis, and leukapheresis was started in all donors on day 5. The most frequent side-effects of G-CSF were grade I/II, bone pain, headache and fatigue in both groups, whereas grade III of bone pain, headache and fatigue occurred in the 2 x 8 microg/kg group only. One serious non-fatal event with non-traumatic spleen rupture occurred in the 2 x 5 microg/kg group. The CD34(+)cell count in the first apheresis of all donors was 5.1 x 10(6)/kg donor weight (range, 1.5-19.3). The CD34(+) cell harvest was higher in the 2 x 8 microg/kg group than in the 2 x 5 microg/kg group (7.1 x 10(6)/kg vs 4.9 x 10(6)/kg; P = 0.09). The target of collecting >5.0 x 10(6) CD34(+) cells/kg donor weight with one apheresis procedure was achieved in 45% of group I and in 61% of group II, respectively. Administering G-CSF at a dosage of 8 microg/kg twice daily leads to a higher CD34(+) cell yield than a dosage of 2 x 5 microg/kg, but is associated with increased toxicity and higher cost.  (+info)

Isolation and transplantation of highly purified autologous peripheral CD34(+) progenitor cells: purging efficacy, hematopoietic reconstitution and long-term outcome in children with high-risk neuroblastoma. (7/564)

We have investigated the purging efficacy of positive selection of autologous mobilized CD34(+) peripheral stem cells in 22 children with high-risk neuroblastoma. CD34(+) cell selection was performed using the method of magnetic-activated cell sorting (MACS). The median purity of the CD34(+) cells post selection was 97.6% (range 81.7-99.7). For detection of contaminating neuroblastoma cells before and after CD34(+) selection, the chimeric anti-disialoganglioside GD2 antibody delta ch 14.18 was used. Prior to positive selection, various numbers of contaminating neuroblastoma cells were found in 17 patients. After positive CD34(+) cell selection, low numbers of neuroblastoma cells were only detectable in four patients. In 18 patients, high-dose chemotherapy was performed and the isolated CD34(+) cells were reinfused. In all patients, a rapid neutrophil recovery was seen with a median time to reach 0.5 x 10(9)/l neutrophils of 12 days (range 8-24 days). Nine of the 18 patients are free of progression with a median follow-up of 55 months (range 45-70 months). Two patients are alive with relapse, six patients died due to progression or relapse and one patient died due to secondary AML 10 months after transplant while in remission from neuroblastoma. In summary, we show that, through a highly effective positive selection method, a high purging efficacy can be obtained without compromising the hematopoietic reconstitution capacity of the graft.  (+info)

The role of granulocyte colony-stimulating factor (G-CSF) in the post-transplant period. (8/564)

The administration of G-CSF post transplant has been shown to accelerate the time to neutrophil engraftment. However, this does not necessarily translate into a meaningful clinical benefit to the patient. This randomized study was designed to determine the role of G-CSF following transplantation in patients with breast cancer (BC). A total of 241 evaluable patients with BC were included. There were 200 patients with high-risk BC, and 41 had disseminated BC in complete remission. All patients received conventional dose chemotherapy prior to transplantation. Patients were mobilized with G-CSF, received the STAMP V regimen, were transplanted with > or = 2.5 x 10(6) of CD34(+) cells/kg and were then randomized to receive 5 microg/kg of G-CSF starting on the day of infusion (arm A), five days later (arm B), or no G-CSF (arm C). The need for transfusion support, infectious complications and length of hospitalization were the variables chosen to demonstrate clinical benefit. Patients receiving G-CSF reached 500 and 1000 neutrophils significantly faster (P = 0.001) than patients with no G-CSF. This translated into a significantly (P < 0.05) shorter hospitalization time for patients receiving G-CSF. Arm C was closed and, after recruiting 110 patients in arm A, and 106 in arm B, the significant difference in neutrophil recovery persisted with no difference in the time of hospitalization between arms A and B. Therefore, G-CSF significantly accelerates the time to neutrophil engraftment. This translates into a shorter time of hospitalization. There is no difference in this variable regarding the time of administering the G-CSF: day 0 vs day +5. Therefore, G-CSF on day +5 should be the standard in this setting.  (+info)

Peripheral Blood Stem Cell Transplantation (PBSCT) is a medical procedure that involves the transplantation of stem cells, which are immature cells found in the bone marrow that can develop into different types of blood cells. In PBSCT, these stem cells are collected from the peripheral blood instead of directly from the bone marrow.

The process begins with mobilization, where a growth factor medication is given to the donor to stimulate the release of stem cells from the bone marrow into the peripheral blood. After several days, the donor's blood is then removed through a procedure called apheresis, where the stem cells are separated and collected while the remaining blood components are returned to the donor.

The collected stem cells are then infused into the recipient's bloodstream, where they migrate to the bone marrow and begin to repopulate, leading to the production of new blood cells. This procedure is often used as a treatment for various malignant and non-malignant disorders, such as leukemia, lymphoma, multiple myeloma, and aplastic anemia.

PBSCT offers several advantages over traditional bone marrow transplantation, including faster engraftment, lower risk of graft failure, and reduced procedure-related morbidity. However, it also has its own set of challenges, such as the potential for increased incidence of chronic graft-versus-host disease (GVHD) and the need for more stringent HLA matching between donor and recipient.

Hematopoietic Stem Cell Transplantation (HSCT) is a medical procedure where hematopoietic stem cells (immature cells that give rise to all blood cell types) are transplanted into a patient. This procedure is often used to treat various malignant and non-malignant disorders affecting the hematopoietic system, such as leukemias, lymphomas, multiple myeloma, aplastic anemia, inherited immune deficiency diseases, and certain genetic metabolic disorders.

The transplantation can be autologous (using the patient's own stem cells), allogeneic (using stem cells from a genetically matched donor, usually a sibling or unrelated volunteer), or syngeneic (using stem cells from an identical twin).

The process involves collecting hematopoietic stem cells, most commonly from the peripheral blood or bone marrow. The collected cells are then infused into the patient after the recipient's own hematopoietic system has been ablated (or destroyed) using high-dose chemotherapy and/or radiation therapy. This allows the donor's stem cells to engraft, reconstitute, and restore the patient's hematopoietic system.

HSCT is a complex and potentially risky procedure with various complications, including graft-versus-host disease, infections, and organ damage. However, it offers the potential for cure or long-term remission in many patients with otherwise fatal diseases.

Autologous transplantation is a medical procedure where cells, tissues, or organs are removed from a person, stored and then returned back to the same individual at a later time. This is different from allogeneic transplantation where the tissue or organ is obtained from another donor. The term "autologous" is derived from the Greek words "auto" meaning self and "logos" meaning study.

In autologous transplantation, the patient's own cells or tissues are used to replace or repair damaged or diseased ones. This reduces the risk of rejection and eliminates the need for immunosuppressive drugs, which are required in allogeneic transplants to prevent the body from attacking the foreign tissue.

Examples of autologous transplantation include:

* Autologous bone marrow or stem cell transplantation, where stem cells are removed from the patient's blood or bone marrow, stored and then reinfused back into the same individual after high-dose chemotherapy or radiation therapy to treat cancer.
* Autologous skin grafting, where a piece of skin is taken from one part of the body and transplanted to another area on the same person.
* Autologous chondrocyte implantation, where cartilage cells are harvested from the patient's own knee, cultured in a laboratory and then implanted back into the knee to repair damaged cartilage.

Homologous transplantation is a type of transplant surgery where organs or tissues are transferred between two genetically non-identical individuals of the same species. The term "homologous" refers to the similarity in structure and function of the donated organ or tissue to the recipient's own organ or tissue.

For example, a heart transplant from one human to another is an example of homologous transplantation because both organs are hearts and perform the same function. Similarly, a liver transplant, kidney transplant, lung transplant, and other types of organ transplants between individuals of the same species are also considered homologous transplantations.

Homologous transplantation is in contrast to heterologous or xenogeneic transplantation, where organs or tissues are transferred from one species to another, such as a pig heart transplanted into a human. Homologous transplantation is more commonly performed than heterologous transplantation due to the increased risk of rejection and other complications associated with xenogeneic transplants.

Hematopoietic Stem Cell Mobilization is the process of mobilizing hematopoietic stem cells (HSCs) from the bone marrow into the peripheral blood. HSCs are immature cells that have the ability to differentiate into all types of blood cells, including red and white blood cells and platelets.

Mobilization is often achieved through the use of medications such as granulocyte-colony stimulating factor (G-CSF) or plerixafor, which stimulate the release of HSCs from the bone marrow into the peripheral blood. This allows for the collection of HSCs from the peripheral blood through a procedure called apheresis.

Mobilized HSCs can be used in stem cell transplantation procedures to reconstitute a patient's hematopoietic system after high-dose chemotherapy or radiation therapy. It is an important process in the field of regenerative medicine and has been used to treat various diseases such as leukemia, lymphoma, and sickle cell disease.

Transplantation conditioning, also known as preparative regimen or immunoablative therapy, refers to the use of various treatments prior to transplantation of cells, tissues or organs. The main goal of transplantation conditioning is to suppress the recipient's immune system, allowing for successful engraftment and minimizing the risk of rejection of the donor tissue.

There are two primary types of transplantation conditioning: myeloablative and non-myeloablative.

1. Myeloablative conditioning is a more intensive regimen that involves the use of high-dose chemotherapy, radiation therapy or both. This approach eliminates not only immune cells but also stem cells in the bone marrow, requiring the recipient to receive a hematopoietic cell transplant (HCT) from the donor to reconstitute their blood and immune system.
2. Non-myeloablative conditioning is a less intensive regimen that primarily targets immune cells while sparing the stem cells in the bone marrow. This approach allows for mixed chimerism, where both recipient and donor immune cells coexist, reducing the risk of severe complications associated with myeloablative conditioning.

The choice between these two types of transplantation conditioning depends on various factors, including the type of transplant, patient's age, overall health, and comorbidities. Both approaches carry risks and benefits, and the decision should be made carefully by a multidisciplinary team of healthcare professionals in consultation with the patient.

Stem cell transplantation is a medical procedure where stem cells, which are immature and unspecialized cells with the ability to differentiate into various specialized cell types, are introduced into a patient. The main purpose of this procedure is to restore the function of damaged or destroyed tissues or organs, particularly in conditions that affect the blood and immune systems, such as leukemia, lymphoma, aplastic anemia, and inherited metabolic disorders.

There are two primary types of stem cell transplantation: autologous and allogeneic. In autologous transplantation, the patient's own stem cells are collected, stored, and then reinfused back into their body after high-dose chemotherapy or radiation therapy to destroy the diseased cells. In allogeneic transplantation, stem cells are obtained from a donor (related or unrelated) whose human leukocyte antigen (HLA) type closely matches that of the recipient.

The process involves several steps: first, the patient undergoes conditioning therapy to suppress their immune system and make space for the new stem cells. Then, the harvested stem cells are infused into the patient's bloodstream, where they migrate to the bone marrow and begin to differentiate and produce new blood cells. This procedure requires close monitoring and supportive care to manage potential complications such as infections, graft-versus-host disease, and organ damage.

Hematologic neoplasms, also known as hematological malignancies, are a group of diseases characterized by the uncontrolled growth and accumulation of abnormal blood cells or bone marrow cells. These disorders can originate from the myeloid or lymphoid cell lines, which give rise to various types of blood cells, including red blood cells, white blood cells, and platelets.

Hematologic neoplasms can be broadly classified into three categories:

1. Leukemias: These are cancers that primarily affect the bone marrow and blood-forming tissues. They result in an overproduction of abnormal white blood cells, which interfere with the normal functioning of the blood and immune system. There are several types of leukemia, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML).
2. Lymphomas: These are cancers that develop from the lymphatic system, which is a part of the immune system responsible for fighting infections. Lymphomas can affect lymph nodes, spleen, bone marrow, and other organs. The two main types of lymphoma are Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).
3. Myelomas: These are cancers that arise from the plasma cells, a type of white blood cell responsible for producing antibodies. Multiple myeloma is the most common type of myeloma, characterized by an excessive proliferation of malignant plasma cells in the bone marrow, leading to the production of abnormal amounts of monoclonal immunoglobulins (M proteins) and bone destruction.

Hematologic neoplasms can have various symptoms, such as fatigue, weakness, frequent infections, easy bruising or bleeding, weight loss, swollen lymph nodes, and bone pain. The diagnosis typically involves a combination of medical history, physical examination, laboratory tests, imaging studies, and sometimes bone marrow biopsy. Treatment options depend on the type and stage of the disease and may include chemotherapy, radiation therapy, targeted therapy, immunotherapy, stem cell transplantation, or a combination of these approaches.

Graft-versus-host disease (GVHD) is a condition that can occur after an allogeneic hematopoietic stem cell transplantation (HSCT), where the donated immune cells (graft) recognize the recipient's tissues (host) as foreign and attack them. This results in inflammation and damage to various organs, particularly the skin, gastrointestinal tract, and liver.

Acute GVHD typically occurs within 100 days of transplantation and is characterized by symptoms such as rash, diarrhea, and liver dysfunction. Chronic GVHD, on the other hand, can occur after 100 days or even years post-transplant and may present with a wider range of symptoms, including dry eyes and mouth, skin changes, lung involvement, and issues with mobility and flexibility in joints.

GVHD is a significant complication following allogeneic HSCT and can have a substantial impact on the patient's quality of life and overall prognosis. Preventative measures, such as immunosuppressive therapy, are often taken to reduce the risk of GVHD, but its management remains a challenge in transplant medicine.

Leukapheresis is a medical procedure that involves the separation and removal of white blood cells (leukocytes) from the blood. It is performed using a specialized machine called an apheresis instrument, which removes the desired component (in this case, leukocytes) and returns the remaining components (red blood cells, platelets, and plasma) back to the donor or patient. This procedure is often used in the treatment of certain blood disorders, such as leukemia and lymphoma, where high white blood cell counts can cause complications. It may also be used to collect stem cells for transplantation purposes. Leukapheresis is generally a safe procedure with minimal side effects, although it may cause temporary discomfort or bruising at the site of needle insertion.

Granulocyte Colony-Stimulating Factor (G-CSF) is a type of growth factor that specifically stimulates the production and survival of granulocytes, a type of white blood cell crucial for fighting off infections. G-CSF works by promoting the proliferation and differentiation of hematopoietic stem cells into mature granulocytes, primarily neutrophils, in the bone marrow.

Recombinant forms of G-CSF are used clinically as a medication to boost white blood cell production in patients undergoing chemotherapy or radiation therapy for cancer, those with congenital neutropenia, and those who have had a bone marrow transplant. By increasing the number of circulating neutrophils, G-CSF helps reduce the risk of severe infections during periods of intense immune suppression.

Examples of recombinant G-CSF medications include filgrastim (Neupogen), pegfilgrastim (Neulasta), and lipegfilgrastim (Lonquex).

Melphalan is an antineoplastic agent, specifically an alkylating agent. It is used in the treatment of multiple myeloma and other types of cancer. The medical definition of Melphalan is:

A nitrogen mustard derivative that is used as an alkylating agent in the treatment of cancer, particularly multiple myeloma and ovarian cancer. Melphalan works by forming covalent bonds with DNA, resulting in cross-linking of the double helix and inhibition of DNA replication and transcription. This ultimately leads to cell cycle arrest and apoptosis (programmed cell death) in rapidly dividing cells, such as cancer cells.

Melphalan is administered orally or intravenously, and its use is often accompanied by other anticancer therapies, such as radiation therapy or chemotherapy. Common side effects of Melphalan include nausea, vomiting, diarrhea, and bone marrow suppression, which can lead to anemia, neutropenia, and thrombocytopenia. Other potential side effects include hair loss, mucositis, and secondary malignancies.

It is important to note that Melphalan should be used under the close supervision of a healthcare professional, as it can cause serious adverse reactions if not administered correctly.

CD34 is a type of antigen that is found on the surface of certain cells in the human body. Specifically, CD34 antigens are present on hematopoietic stem cells, which are immature cells that can develop into different types of blood cells. These stem cells are found in the bone marrow and are responsible for producing red blood cells, white blood cells, and platelets.

CD34 antigens are a type of cell surface marker that is used in medical research and clinical settings to identify and isolate hematopoietic stem cells. They are also used in the development of stem cell therapies and transplantation procedures. CD34 antigens can be detected using various laboratory techniques, such as flow cytometry or immunohistochemistry.

It's important to note that while CD34 is a useful marker for identifying hematopoietic stem cells, it is not exclusive to these cells and can also be found on other cell types, such as endothelial cells that line blood vessels. Therefore, additional markers are often used in combination with CD34 to more specifically identify and isolate hematopoietic stem cells.

Blood component removal, also known as blood component therapy or apheresis, is a medical procedure that involves separating and removing specific components of the blood, such as red blood cells, white blood cells, platelets, or plasma, while returning the remaining components back to the donor or patient. This process can be used for therapeutic purposes, such as in the treatment of certain diseases and conditions, or for donation, such as in the collection of blood products for transfusion. The specific method and equipment used to perform blood component removal may vary depending on the intended application and the particular component being removed.

Combined modality therapy (CMT) is a medical treatment approach that utilizes more than one method or type of therapy simultaneously or in close succession, with the goal of enhancing the overall effectiveness of the treatment. In the context of cancer care, CMT often refers to the combination of two or more primary treatment modalities, such as surgery, radiation therapy, and systemic therapies (chemotherapy, immunotherapy, targeted therapy, etc.).

The rationale behind using combined modality therapy is that each treatment method can target cancer cells in different ways, potentially increasing the likelihood of eliminating all cancer cells and reducing the risk of recurrence. The specific combination and sequence of treatments will depend on various factors, including the type and stage of cancer, patient's overall health, and individual preferences.

For example, a common CMT approach for locally advanced rectal cancer may involve preoperative (neoadjuvant) chemoradiation therapy, followed by surgery to remove the tumor, and then postoperative (adjuvant) chemotherapy. This combined approach allows for the reduction of the tumor size before surgery, increases the likelihood of complete tumor removal, and targets any remaining microscopic cancer cells with systemic chemotherapy.

It is essential to consult with a multidisciplinary team of healthcare professionals to determine the most appropriate CMT plan for each individual patient, considering both the potential benefits and risks associated with each treatment method.

Bone marrow transplantation (BMT) is a medical procedure in which damaged or destroyed bone marrow is replaced with healthy bone marrow from a donor. Bone marrow is the spongy tissue inside bones that produces blood cells. The main types of BMT are autologous, allogeneic, and umbilical cord blood transplantation.

In autologous BMT, the patient's own bone marrow is used for the transplant. This type of BMT is often used in patients with lymphoma or multiple myeloma who have undergone high-dose chemotherapy or radiation therapy to destroy their cancerous bone marrow.

In allogeneic BMT, bone marrow from a genetically matched donor is used for the transplant. This type of BMT is often used in patients with leukemia, lymphoma, or other blood disorders who have failed other treatments.

Umbilical cord blood transplantation involves using stem cells from umbilical cord blood as a source of healthy bone marrow. This type of BMT is often used in children and adults who do not have a matched donor for allogeneic BMT.

The process of BMT typically involves several steps, including harvesting the bone marrow or stem cells from the donor, conditioning the patient's body to receive the new bone marrow or stem cells, transplanting the new bone marrow or stem cells into the patient's body, and monitoring the patient for signs of engraftment and complications.

BMT is a complex and potentially risky procedure that requires careful planning, preparation, and follow-up care. However, it can be a life-saving treatment for many patients with blood disorders or cancer.

Graft survival, in medical terms, refers to the success of a transplanted tissue or organ in continuing to function and integrate with the recipient's body over time. It is the opposite of graft rejection, which occurs when the recipient's immune system recognizes the transplanted tissue as foreign and attacks it, leading to its failure.

Graft survival depends on various factors, including the compatibility between the donor and recipient, the type and location of the graft, the use of immunosuppressive drugs to prevent rejection, and the overall health of the recipient. A successful graft survival implies that the transplanted tissue or organ has been accepted by the recipient's body and is functioning properly, providing the necessary physiological support for the recipient's survival and improved quality of life.

Cyclophosphamide is an alkylating agent, which is a type of chemotherapy medication. It works by interfering with the DNA of cancer cells, preventing them from dividing and growing. This helps to stop the spread of cancer in the body. Cyclophosphamide is used to treat various types of cancer, including lymphoma, leukemia, multiple myeloma, and breast cancer. It can be given orally as a tablet or intravenously as an injection.

Cyclophosphamide can also have immunosuppressive effects, which means it can suppress the activity of the immune system. This makes it useful in treating certain autoimmune diseases, such as rheumatoid arthritis and lupus. However, this immunosuppression can also increase the risk of infections and other side effects.

Like all chemotherapy medications, cyclophosphamide can cause a range of side effects, including nausea, vomiting, hair loss, fatigue, and increased susceptibility to infections. It is important for patients receiving cyclophosphamide to be closely monitored by their healthcare team to manage these side effects and ensure the medication is working effectively.

Hematopoietic stem cells (HSCs) are immature, self-renewing cells that give rise to all the mature blood and immune cells in the body. They are capable of both producing more hematopoietic stem cells (self-renewal) and differentiating into early progenitor cells that eventually develop into red blood cells, white blood cells, and platelets. HSCs are found in the bone marrow, umbilical cord blood, and peripheral blood. They have the ability to repair damaged tissues and offer significant therapeutic potential for treating various diseases, including hematological disorders, genetic diseases, and cancer.

Busulfan is a chemotherapy medication used to treat various types of cancer, including chronic myelogenous leukemia (CML) and acute myeloid leukemia (AML). It is an alkylating agent that works by damaging the DNA of cancer cells, which prevents them from dividing and growing.

The medical definition of Busulfan is:

A white crystalline powder used in chemotherapy to treat various types of cancer. Busulfan works by alkylating and cross-linking DNA, which inhibits DNA replication and transcription, leading to cell cycle arrest and apoptosis (programmed cell death) in rapidly dividing cells, including cancer cells. It is administered orally or intravenously and is often used in combination with other chemotherapy agents. Common side effects include nausea, vomiting, diarrhea, and bone marrow suppression, which can lead to anemia, neutropenia, thrombocytopenia, and increased susceptibility to infection. Long-term use of busulfan has been associated with pulmonary fibrosis, infertility, and an increased risk of secondary malignancies.

I'm sorry for any confusion, but "Myeloablative Agonists" is not a recognized medical term. Myeloablation is a medical process that involves destroying or damaging the bone marrow, often as part of a preparatory regimen before a stem cell transplant. Agonists are substances that bind to receptors and activate them, causing a response in the body. However, combining these two terms doesn't form a recognized medical concept. If you have any questions about myeloablation or agonists individually, I'd be happy to help clarify those concepts!

Multiple myeloma is a type of cancer that forms in a type of white blood cell called a plasma cell. Plasma cells help your body fight infection by producing antibodies. In multiple myeloma, cancerous plasma cells accumulate in the bone marrow and crowd out healthy blood cells. Rather than producing useful antibodies, the cancer cells produce abnormal proteins that can cause complications such as kidney damage, bone pain and fractures.

Multiple myeloma is a type of cancer called a plasma cell neoplasm. Plasma cell neoplasms are diseases in which there is an overproduction of a single clone of plasma cells. In multiple myeloma, this results in the crowding out of normal plasma cells, red and white blood cells and platelets, leading to many of the complications associated with the disease.

The abnormal proteins produced by the cancer cells can also cause damage to organs and tissues in the body. These abnormal proteins can be detected in the blood or urine and are often used to monitor the progression of multiple myeloma.

Multiple myeloma is a relatively uncommon cancer, but it is the second most common blood cancer after non-Hodgkin lymphoma. It typically occurs in people over the age of 65, and men are more likely to develop multiple myeloma than women. While there is no cure for multiple myeloma, treatments such as chemotherapy, radiation therapy, and stem cell transplantation can help manage the disease and its symptoms, and improve quality of life.

Treatment outcome is a term used to describe the result or effect of medical treatment on a patient's health status. It can be measured in various ways, such as through symptoms improvement, disease remission, reduced disability, improved quality of life, or survival rates. The treatment outcome helps healthcare providers evaluate the effectiveness of a particular treatment plan and make informed decisions about future care. It is also used in clinical research to compare the efficacy of different treatments and improve patient care.

According to the National Institutes of Health (NIH), stem cells are "initial cells" or "precursor cells" that have the ability to differentiate into many different cell types in the body. They can also divide without limit to replenish other cells for as long as the person or animal is still alive.

There are two main types of stem cells: embryonic stem cells, which come from human embryos, and adult stem cells, which are found in various tissues throughout the body. Embryonic stem cells have the ability to differentiate into all cell types in the body, while adult stem cells have more limited differentiation potential.

Stem cells play an essential role in the development and repair of various tissues and organs in the body. They are currently being studied for their potential use in the treatment of a wide range of diseases and conditions, including cancer, diabetes, heart disease, and neurological disorders. However, more research is needed to fully understand the properties and capabilities of these cells before they can be used safely and effectively in clinical settings.

Antineoplastic combined chemotherapy protocols refer to a treatment plan for cancer that involves the use of more than one antineoplastic (chemotherapy) drug given in a specific sequence and schedule. The combination of drugs is used because they may work better together to destroy cancer cells compared to using a single agent alone. This approach can also help to reduce the likelihood of cancer cells becoming resistant to the treatment.

The choice of drugs, dose, duration, and frequency are determined by various factors such as the type and stage of cancer, patient's overall health, and potential side effects. Combination chemotherapy protocols can be used in various settings, including as a primary treatment, adjuvant therapy (given after surgery or radiation to kill any remaining cancer cells), neoadjuvant therapy (given before surgery or radiation to shrink the tumor), or palliative care (to alleviate symptoms and prolong survival).

It is important to note that while combined chemotherapy protocols can be effective in treating certain types of cancer, they can also cause significant side effects, including nausea, vomiting, hair loss, fatigue, and an increased risk of infection. Therefore, patients undergoing such treatment should be closely monitored and managed by a healthcare team experienced in administering chemotherapy.

Cord blood stem cell transplantation is a medical procedure that involves the infusion of stem cells derived from the umbilical cord blood into a patient. These stem cells, specifically hematopoietic stem cells, have the ability to differentiate into various types of blood cells, including red and white blood cells and platelets.

Cord blood stem cell transplantation is often used as a treatment for patients with various malignant and non-malignant disorders, such as leukemia, lymphoma, sickle cell disease, and metabolic disorders. The procedure involves collecting cord blood from the umbilical cord and placenta after the birth of a baby, processing and testing it for compatibility with the recipient's immune system, and then infusing it into the patient through a vein in a process similar to a blood transfusion.

The advantages of using cord blood stem cells include their availability, low risk of transmission of infectious diseases, and reduced risk of graft-versus-host disease compared to other sources of hematopoietic stem cells, such as bone marrow or peripheral blood. However, the number of stem cells in a cord blood unit is generally lower than that found in bone marrow or peripheral blood, which can limit its use in some patients, particularly adults.

Overall, cord blood stem cell transplantation is an important and promising area of regenerative medicine, offering hope for patients with a wide range of disorders.

A transplantation chimera is a rare medical condition that occurs after an organ or tissue transplant, where the recipient's body accepts and integrates the donor's cells or tissues to such an extent that the two sets of DNA coexist and function together. This phenomenon can lead to the presence of two different genetic profiles in one individual.

In some cases, this may result in the development of donor-derived cells or organs within the recipient's body, which can express the donor's unique genetic traits. Transplantation chimerism is more commonly observed in bone marrow transplants, where the donor's immune cells can repopulate and establish themselves within the recipient's bone marrow and bloodstream.

It is important to note that while transplantation chimerism can be beneficial for the success of the transplant, it may also pose some risks, such as an increased likelihood of developing graft-versus-host disease (GVHD), where the donor's immune cells attack the recipient's tissues.

Recurrence, in a medical context, refers to the return of symptoms or signs of a disease after a period of improvement or remission. It indicates that the condition has not been fully eradicated and may require further treatment. Recurrence is often used to describe situations where a disease such as cancer comes back after initial treatment, but it can also apply to other medical conditions. The likelihood of recurrence varies depending on the type of disease and individual patient factors.

A tissue donor is an individual who has agreed to allow organs and tissues to be removed from their body after death for the purpose of transplantation to restore the health or save the life of another person. The tissues that can be donated include corneas, heart valves, skin, bone, tendons, ligaments, veins, and cartilage. These tissues can enhance the quality of life for many recipients and are often used in reconstructive surgeries. It is important to note that tissue donation does not interfere with an open casket funeral or other cultural or religious practices related to death and grieving.

Remission induction is a treatment approach in medicine, particularly in the field of oncology and hematology. It refers to the initial phase of therapy aimed at reducing or eliminating the signs and symptoms of active disease, such as cancer or autoimmune disorders. The primary goal of remission induction is to achieve a complete response (disappearance of all detectable signs of the disease) or a partial response (a decrease in the measurable extent of the disease). This phase of treatment is often intensive and may involve the use of multiple drugs or therapies, including chemotherapy, immunotherapy, or targeted therapy. After remission induction, patients may receive additional treatments to maintain the remission and prevent relapse, known as consolidation or maintenance therapy.

Antineoplastic agents, alkylating, are a class of chemotherapeutic drugs that work by alkylating (adding alkyl groups) to DNA, which can lead to the death or dysfunction of cancer cells. These agents can form cross-links between strands of DNA, preventing DNA replication and transcription, ultimately leading to cell cycle arrest and apoptosis (programmed cell death). Examples of alkylating agents include cyclophosphamide, melphalan, and cisplatin. While these drugs are designed to target rapidly dividing cancer cells, they can also affect normal cells that divide quickly, such as those in the bone marrow and digestive tract, leading to side effects like anemia, neutropenia, thrombocytopenia, and nausea/vomiting.

Non-Hodgkin lymphoma (NHL) is a type of cancer that originates in the lymphatic system, which is part of the immune system. It involves the abnormal growth and proliferation of malignant lymphocytes (a type of white blood cell), leading to the formation of tumors in lymph nodes, spleen, bone marrow, or other organs. NHL can be further classified into various subtypes based on the specific type of lymphocyte involved and its characteristics.

The symptoms of Non-Hodgkin lymphoma may include:

* Painless swelling of lymph nodes in the neck, armpits, or groin
* Persistent fatigue
* Unexplained weight loss
* Fever
* Night sweats
* Itchy skin

The exact cause of Non-Hodgkin lymphoma is not well understood, but it has been associated with certain risk factors such as age (most common in people over 60), exposure to certain chemicals, immune system deficiencies, and infection with viruses like Epstein-Barr virus or HIV.

Treatment for Non-Hodgkin lymphoma depends on the stage and subtype of the disease, as well as the patient's overall health. Treatment options may include chemotherapy, radiation therapy, immunotherapy, targeted therapy, stem cell transplantation, or a combination of these approaches. Regular follow-up care is essential to monitor the progression of the disease and manage any potential long-term side effects of treatment.

Etoposide is a chemotherapy medication used to treat various types of cancer, including lung cancer, testicular cancer, and certain types of leukemia. It works by inhibiting the activity of an enzyme called topoisomerase II, which is involved in DNA replication and transcription. By doing so, etoposide can interfere with the growth and multiplication of cancer cells.

Etoposide is often administered intravenously in a hospital or clinic setting, although it may also be given orally in some cases. The medication can cause a range of side effects, including nausea, vomiting, hair loss, and an increased risk of infection. It can also have more serious side effects, such as bone marrow suppression, which can lead to anemia, bleeding, and a weakened immune system.

Like all chemotherapy drugs, etoposide is not without risks and should only be used under the close supervision of a qualified healthcare provider. It is important for patients to discuss the potential benefits and risks of this medication with their doctor before starting treatment.

Histocompatibility is the compatibility between tissues or organs from different individuals in terms of their histological (tissue) structure and antigenic properties. The term is most often used in the context of transplantation, where it refers to the degree of match between the human leukocyte antigens (HLAs) and other proteins on the surface of donor and recipient cells.

A high level of histocompatibility reduces the risk of rejection of a transplanted organ or tissue by the recipient's immune system, as their immune cells are less likely to recognize the donated tissue as foreign and mount an attack against it. Conversely, a low level of histocompatibility increases the likelihood of rejection, as the recipient's immune system recognizes the donated tissue as foreign and attacks it.

Histocompatibility testing is therefore an essential part of organ and tissue transplantation, as it helps to identify the best possible match between donor and recipient and reduces the risk of rejection.

POEMS syndrome is a rare and complex disorder that affects multiple parts of the body. The name POEMS is an acronym that stands for the following symptoms: Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy, and Skin changes.

Here's a brief definition of each component of the syndrome:

* Polyneuropathy: This refers to damage to the peripheral nerves that can cause symptoms such as numbness, tingling, pain, and weakness in the arms and legs.
* Organomegaly: This means enlargement of organs, such as the liver, spleen, or lymph nodes.
* Endocrinopathy: This refers to abnormalities in hormone-producing glands, which can lead to symptoms such as diabetes, low testosterone levels, and thyroid dysfunction.
* Monoclonal gammopathy: This is an abnormal production of a single type of immunoglobulin (a protein produced by the immune system) in the bone marrow.
* Skin changes: These can include skin thickening, darkening, or redness, as well as skin lesions.

POEMS syndrome is typically caused by an underlying plasma cell disorder, such as multiple myeloma or a related condition called Waldenstrom macroglobulinemia. Treatment for POEMS syndrome usually involves addressing the underlying plasma cell disorder, as well as managing specific symptoms of the syndrome.

Thiotepa is an antineoplastic (cancer-fighting) drug. It belongs to a class of medications called alkylating agents, which work by interfering with the DNA of cancer cells, preventing them from dividing and growing. Thiotepa is used in the treatment of various types of cancers, including breast, ovarian, and bladder cancer.

It may be administered intravenously (into a vein), intravesically (into the bladder), or intrathecally (into the spinal cord). The specific dosage and duration of treatment will depend on the type and stage of cancer being treated, as well as the patient's overall health status.

Like all chemotherapy drugs, thiotepa can have significant side effects, including nausea, vomiting, hair loss, and a weakened immune system. It is important for patients to discuss these potential risks with their healthcare provider before starting treatment.

Whole-Body Irradiation (WBI) is a medical procedure that involves the exposure of the entire body to a controlled dose of ionizing radiation, typically used in the context of radiation therapy for cancer treatment. The purpose of WBI is to destroy cancer cells or suppress the immune system prior to a bone marrow transplant. It can be delivered using various sources of radiation, such as X-rays, gamma rays, or electrons, and is carefully planned and monitored to minimize harm to healthy tissues while maximizing the therapeutic effect on cancer cells. Potential side effects include nausea, vomiting, fatigue, and an increased risk of infection due to decreased white blood cell counts.

Histocompatibility testing, also known as tissue typing, is a medical procedure that determines the compatibility of tissues between two individuals, usually a potential donor and a recipient for organ or bone marrow transplantation. The test identifies specific antigens, called human leukocyte antigens (HLAs), found on the surface of most cells in the body. These antigens help the immune system distinguish between "self" and "non-self" cells.

The goal of histocompatibility testing is to find a donor whose HLA markers closely match those of the recipient, reducing the risk of rejection of the transplanted organ or tissue. The test involves taking blood samples from both the donor and the recipient and analyzing them for the presence of specific HLA antigens using various laboratory techniques such as molecular typing or serological testing.

A high degree of histocompatibility between the donor and recipient is crucial to ensure the success of the transplantation procedure, minimize complications, and improve long-term outcomes.

Disease-free survival (DFS) is a term used in medical research and clinical practice, particularly in the field of oncology. It refers to the length of time after primary treatment for a cancer during which no evidence of the disease can be found. This means that the patient shows no signs or symptoms of the cancer, and any imaging studies or other tests do not reveal any tumors or other indications of the disease.

DFS is often used as an important endpoint in clinical trials to evaluate the effectiveness of different treatments for cancer. By measuring the length of time until the cancer recurs or a new cancer develops, researchers can get a better sense of how well a particular treatment is working and whether it is improving patient outcomes.

It's important to note that DFS is not the same as overall survival (OS), which refers to the length of time from primary treatment until death from any cause. While DFS can provide valuable information about the effectiveness of cancer treatments, it does not necessarily reflect the impact of those treatments on patients' overall survival.

Infection is defined medically as the invasion and multiplication of pathogenic microorganisms such as bacteria, viruses, fungi, or parasites within the body, which can lead to tissue damage, illness, and disease. This process often triggers an immune response from the host's body in an attempt to eliminate the infectious agents and restore homeostasis. Infections can be transmitted through various routes, including airborne particles, direct contact with contaminated surfaces or bodily fluids, sexual contact, or vector-borne transmission. The severity of an infection may range from mild and self-limiting to severe and life-threatening, depending on factors such as the type and quantity of pathogen, the host's immune status, and any underlying health conditions.

Isogeneic transplantation is a type of transplant where the donor and recipient are genetically identical, meaning they are identical twins or have the same genetic makeup. In this case, the immune system recognizes the transplanted organ or tissue as its own and does not mount an immune response to reject it. This reduces the need for immunosuppressive drugs, which are typically required in other types of transplantation to prevent rejection.

In medical terms, isogeneic transplantation is defined as the transfer of genetic identical tissues or organs between genetically identical individuals, resulting in minimal risk of rejection and no need for immunosuppressive therapy.

Immunosuppressive agents are medications that decrease the activity of the immune system. They are often used to prevent the rejection of transplanted organs and to treat autoimmune diseases, where the immune system mistakenly attacks the body's own tissues. These drugs work by interfering with the immune system's normal responses, which helps to reduce inflammation and damage to tissues. However, because they suppress the immune system, people who take immunosuppressive agents are at increased risk for infections and other complications. Examples of immunosuppressive agents include corticosteroids, azathioprine, cyclophosphamide, mycophenolate mofetil, tacrolimus, and sirolimus.

Vidarabine is an antiviral medication used to treat herpes simplex infections, particularly severe cases such as herpes encephalitis (inflammation of the brain caused by the herpes simplex virus). It works by interfering with the DNA replication of the virus.

In medical terms, vidarabine is a nucleoside analogue that is phosphorylated intracellularly to the active form, vidarabine triphosphate. This compound inhibits viral DNA polymerase and incorporates into viral DNA, causing termination of viral DNA synthesis.

Vidarabine was previously used as an injectable medication but has largely been replaced by more modern antiviral drugs such as acyclovir due to its greater efficacy and lower toxicity.

Retrospective studies, also known as retrospective research or looking back studies, are a type of observational study that examines data from the past to draw conclusions about possible causal relationships between risk factors and outcomes. In these studies, researchers analyze existing records, medical charts, or previously collected data to test a hypothesis or answer a specific research question.

Retrospective studies can be useful for generating hypotheses and identifying trends, but they have limitations compared to prospective studies, which follow participants forward in time from exposure to outcome. Retrospective studies are subject to biases such as recall bias, selection bias, and information bias, which can affect the validity of the results. Therefore, retrospective studies should be interpreted with caution and used primarily to generate hypotheses for further testing in prospective studies.

Amyloidosis is a medical condition characterized by the abnormal accumulation of insoluble proteins called amyloid in various tissues and organs throughout the body. These misfolded protein deposits can disrupt the normal function of affected organs, leading to a range of symptoms depending on the location and extent of the amyloid deposition.

There are different types of amyloidosis, classified based on the specific proteins involved:

1. Primary (AL) Amyloidosis: This is the most common form, accounting for around 80% of cases. It results from the overproduction and misfolding of immunoglobulin light chains, typically by clonal plasma cells in the bone marrow. The amyloid deposits can affect various organs, including the heart, kidneys, liver, and nervous system.
2. Secondary (AA) Amyloidosis: This form is associated with chronic inflammatory diseases, such as rheumatoid arthritis, tuberculosis, or familial Mediterranean fever. The amyloid fibrils are composed of serum amyloid A protein (SAA), an acute-phase reactant produced during the inflammatory response. The kidneys are commonly affected in this type of amyloidosis.
3. Hereditary or Familial Amyloidosis: These forms are caused by genetic mutations that result in the production of abnormal proteins prone to misfolding and amyloid formation. Examples include transthyretin (TTR) amyloidosis, fibrinogen amyloidosis, and apolipoprotein AI amyloidosis. These forms can affect various organs, including the heart, nerves, and kidneys.
4. Dialysis-Related Amyloidosis: This form is seen in patients undergoing long-term dialysis for chronic kidney disease. The amyloid fibrils are composed of beta-2 microglobulin, a protein that accumulates due to impaired clearance during dialysis. The joints and bones are commonly affected in this type of amyloidosis.

The diagnosis of amyloidosis typically involves a combination of clinical evaluation, imaging studies, and tissue biopsy with the demonstration of amyloid deposition using special stains (e.g., Congo red). Treatment depends on the specific type and extent of organ involvement and may include supportive care, medications to target the underlying cause (e.g., chemotherapy, immunomodulatory agents), and organ transplantation in some cases.

Hematopoiesis is the process of forming and developing blood cells. It occurs in the bone marrow and includes the production of red blood cells (erythropoiesis), white blood cells (leukopoiesis), and platelets (thrombopoiesis). This process is regulated by various growth factors, hormones, and cytokines. Hematopoiesis begins early in fetal development and continues throughout a person's life. Disorders of hematopoiesis can result in conditions such as anemia, leukopenia, leukocytosis, thrombocytopenia, or thrombocytosis.

Salvage therapy, in the context of medical oncology, refers to the use of treatments that are typically considered less desirable or more aggressive, often due to greater side effects or lower efficacy, when standard treatment options have failed. These therapies are used to attempt to salvage a response or delay disease progression in patients with refractory or relapsed cancers.

In other words, salvage therapy is a last-resort treatment approach for patients who have not responded to first-line or subsequent lines of therapy. It may involve the use of different drug combinations, higher doses of chemotherapy, immunotherapy, targeted therapy, or radiation therapy. The goal of salvage therapy is to extend survival, improve quality of life, or achieve disease stabilization in patients with limited treatment options.

Leukemia is a type of cancer that originates from the bone marrow - the soft, inner part of certain bones where new blood cells are made. It is characterized by an abnormal production of white blood cells, known as leukocytes or blasts. These abnormal cells accumulate in the bone marrow and interfere with the production of normal blood cells, leading to a decrease in red blood cells (anemia), platelets (thrombocytopenia), and healthy white blood cells (leukopenia).

There are several types of leukemia, classified based on the specific type of white blood cell affected and the speed at which the disease progresses:

1. Acute Leukemias - These types of leukemia progress rapidly, with symptoms developing over a few weeks or months. They involve the rapid growth and accumulation of immature, nonfunctional white blood cells (blasts) in the bone marrow and peripheral blood. The two main categories are:
- Acute Lymphoblastic Leukemia (ALL) - Originates from lymphoid progenitor cells, primarily affecting children but can also occur in adults.
- Acute Myeloid Leukemia (AML) - Develops from myeloid progenitor cells and is more common in older adults.

2. Chronic Leukemias - These types of leukemia progress slowly, with symptoms developing over a period of months to years. They involve the production of relatively mature, but still abnormal, white blood cells that can accumulate in large numbers in the bone marrow and peripheral blood. The two main categories are:
- Chronic Lymphocytic Leukemia (CLL) - Affects B-lymphocytes and is more common in older adults.
- Chronic Myeloid Leukemia (CML) - Originates from myeloid progenitor cells, characterized by the presence of a specific genetic abnormality called the Philadelphia chromosome. It can occur at any age but is more common in middle-aged and older adults.

Treatment options for leukemia depend on the type, stage, and individual patient factors. Treatments may include chemotherapy, targeted therapy, immunotherapy, stem cell transplantation, or a combination of these approaches.

Ifosfamide is an alkylating agent, which is a type of chemotherapy medication. It works by interfering with the DNA of cancer cells, preventing them from dividing and growing. Ifosfamide is used to treat various types of cancers, such as testicular cancer, small cell lung cancer, ovarian cancer, cervical cancer, and certain types of sarcomas.

The medical definition of Ifosfamide is:

Ifosfamide is a synthetic antineoplastic agent, an oxazaphosphorine derivative, with the chemical formula C6H15Cl2N2O2P. It is used in the treatment of various malignancies, including germ cell tumors, sarcomas, lymphomas, and testicular cancer. The drug is administered intravenously and exerts its cytotoxic effects through the alkylation and cross-linking of DNA, leading to the inhibition of DNA replication and transcription. Ifosfamide can cause significant myelosuppression and has been associated with urotoxicity, neurotoxicity, and secondary malignancies. Therefore, it is essential to monitor patients closely during treatment and manage any adverse effects promptly.

Medical survival rate is a statistical measure used to determine the percentage of patients who are still alive for a specific period of time after their diagnosis or treatment for a certain condition or disease. It is often expressed as a five-year survival rate, which refers to the proportion of people who are alive five years after their diagnosis. Survival rates can be affected by many factors, including the stage of the disease at diagnosis, the patient's age and overall health, the effectiveness of treatment, and other health conditions that the patient may have. It is important to note that survival rates are statistical estimates and do not necessarily predict an individual patient's prognosis.

Vincristine is an antineoplastic agent, specifically a vinca alkaloid. It is derived from the Madagascar periwinkle plant (Catharanthus roseus). Vincristine binds to tubulin, a protein found in microtubules, and inhibits their polymerization, which results in disruption of mitotic spindles leading to cell cycle arrest and apoptosis (programmed cell death). It is used in the treatment of various types of cancer including leukemias, lymphomas, and solid tumors. Common side effects include peripheral neuropathy, constipation, and alopecia.

Survival analysis is a branch of statistics that deals with the analysis of time to event data. It is used to estimate the time it takes for a certain event of interest to occur, such as death, disease recurrence, or treatment failure. The event of interest is called the "failure" event, and survival analysis estimates the probability of not experiencing the failure event until a certain point in time, also known as the "survival" probability.

Survival analysis can provide important information about the effectiveness of treatments, the prognosis of patients, and the identification of risk factors associated with the event of interest. It can handle censored data, which is common in medical research where some participants may drop out or be lost to follow-up before the event of interest occurs.

Survival analysis typically involves estimating the survival function, which describes the probability of surviving beyond a certain time point, as well as hazard functions, which describe the instantaneous rate of failure at a given time point. Other important concepts in survival analysis include median survival times, restricted mean survival times, and various statistical tests to compare survival curves between groups.

Carmustine is a chemotherapy drug used to treat various types of cancer, including brain tumors, multiple myeloma, and Hodgkin's lymphoma. It belongs to a class of drugs called alkylating agents, which work by damaging the DNA in cancer cells, preventing them from dividing and growing.

Carmustine is available as an injectable solution that is administered intravenously (into a vein) or as implantable wafers that are placed directly into the brain during surgery. The drug can cause side effects such as nausea, vomiting, hair loss, and low blood cell counts, among others. It may also increase the risk of certain infections and bleeding complications.

As with all chemotherapy drugs, carmustine can have serious and potentially life-threatening side effects, and it should only be administered under the close supervision of a qualified healthcare professional. Patients receiving carmustine treatment should be closely monitored for signs of toxicity and other adverse reactions.

Blood cells are the formed elements in the blood, including red blood cells (erythrocytes), white blood cells (leukocytes), and platelets (thrombocytes). These cells are produced in the bone marrow and play crucial roles in the body's functions. Red blood cells are responsible for carrying oxygen to tissues and carbon dioxide away from them, while white blood cells are part of the immune system and help defend against infection and disease. Platelets are cell fragments that are essential for normal blood clotting.

The "Graft versus Leukemia (GvL) Effect" is a term used in the field of hematopoietic stem cell transplantation to describe a desirable outcome where the donor's immune cells (graft) recognize and attack the recipient's leukemia cells (host). This effect occurs when the donor's T-lymphocytes, natural killer cells, and other immune cells become activated against the recipient's malignant cells.

The GvL effect is often observed in patients who have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT), where the donor and recipient are not genetically identical. The genetic disparity between the donor and recipient creates an environment that allows for the recognition of host leukemia cells as foreign, triggering an immune response against them.

While the GvL effect can be beneficial in eliminating residual leukemia cells, it can also lead to complications such as graft-versus-host disease (GvHD), where the donor's immune cells attack the recipient's healthy tissues. Balancing the GvL effect and minimizing GvHD remains a significant challenge in allo-HSCT.

Cytarabine is a chemotherapeutic agent used in the treatment of various types of cancer, including leukemias and lymphomas. Its chemical name is cytosine arabinoside, and it works by interfering with the DNA synthesis of cancer cells, which ultimately leads to their death.

Cytarabine is often used in combination with other chemotherapy drugs and may be administered through various routes, such as intravenous (IV) or subcutaneous injection, or orally. The specific dosage and duration of treatment will depend on the type and stage of cancer being treated, as well as the patient's overall health status.

Like all chemotherapy drugs, cytarabine can cause a range of side effects, including nausea, vomiting, diarrhea, hair loss, and an increased risk of infection. It may also cause more serious side effects, such as damage to the liver, kidneys, or nervous system, and it is important for patients to be closely monitored during treatment to minimize these risks.

It's important to note that medical treatments should only be administered under the supervision of a qualified healthcare professional, and this information should not be used as a substitute for medical advice.

Hodgkin disease, also known as Hodgkin lymphoma, is a type of cancer that originates in the white blood cells called lymphocytes. It typically affects the lymphatic system, which is a network of vessels and glands spread throughout the body. The disease is characterized by the presence of a specific type of abnormal cell, known as a Reed-Sternberg cell, within the affected lymph nodes.

The symptoms of Hodgkin disease may include painless swelling of the lymph nodes in the neck, armpits, or groin; fever; night sweats; weight loss; and fatigue. The exact cause of Hodgkin disease is unknown, but it is thought to involve a combination of genetic, environmental, and infectious factors.

Hodgkin disease is typically treated with a combination of chemotherapy, radiation therapy, and/or immunotherapy, depending on the stage and extent of the disease. With appropriate treatment, the prognosis for Hodgkin disease is generally very good, with a high cure rate. However, long-term side effects of treatment may include an increased risk of secondary cancers and other health problems.

Acute myeloid leukemia (AML) is a type of cancer that originates in the bone marrow, the soft inner part of certain bones where new blood cells are made. In AML, the immature cells, called blasts, in the bone marrow fail to mature into normal blood cells. Instead, these blasts accumulate and interfere with the production of normal blood cells, leading to a shortage of red blood cells (anemia), platelets (thrombocytopenia), and normal white blood cells (leukopenia).

AML is called "acute" because it can progress quickly and become severe within days or weeks without treatment. It is a type of myeloid leukemia, which means that it affects the myeloid cells in the bone marrow. Myeloid cells are a type of white blood cell that includes monocytes and granulocytes, which help fight infection and defend the body against foreign invaders.

In AML, the blasts can build up in the bone marrow and spread to other parts of the body, including the blood, lymph nodes, liver, spleen, and brain. This can cause a variety of symptoms, such as fatigue, fever, frequent infections, easy bruising or bleeding, and weight loss.

AML is typically treated with a combination of chemotherapy, radiation therapy, and/or stem cell transplantation. The specific treatment plan will depend on several factors, including the patient's age, overall health, and the type and stage of the leukemia.

A platelet count is a laboratory test that measures the number of platelets, also known as thrombocytes, in a sample of blood. Platelets are small, colorless cell fragments that circulate in the blood and play a crucial role in blood clotting. They help to stop bleeding by sticking together to form a plug at the site of an injured blood vessel.

A normal platelet count ranges from 150,000 to 450,000 platelets per microliter (µL) of blood. A lower than normal platelet count is called thrombocytopenia, while a higher than normal platelet count is known as thrombocytosis.

Abnormal platelet counts can be a sign of various medical conditions, including bleeding disorders, infections, certain medications, and some types of cancer. It is important to consult with a healthcare provider if you have any concerns about your platelet count or if you experience symptoms such as easy bruising, prolonged bleeding, or excessive menstrual flow.

In the field of medicine, "time factors" refer to the duration of symptoms or time elapsed since the onset of a medical condition, which can have significant implications for diagnosis and treatment. Understanding time factors is crucial in determining the progression of a disease, evaluating the effectiveness of treatments, and making critical decisions regarding patient care.

For example, in stroke management, "time is brain," meaning that rapid intervention within a specific time frame (usually within 4.5 hours) is essential to administering tissue plasminogen activator (tPA), a clot-busting drug that can minimize brain damage and improve patient outcomes. Similarly, in trauma care, the "golden hour" concept emphasizes the importance of providing definitive care within the first 60 minutes after injury to increase survival rates and reduce morbidity.

Time factors also play a role in monitoring the progression of chronic conditions like diabetes or heart disease, where regular follow-ups and assessments help determine appropriate treatment adjustments and prevent complications. In infectious diseases, time factors are crucial for initiating antibiotic therapy and identifying potential outbreaks to control their spread.

Overall, "time factors" encompass the significance of recognizing and acting promptly in various medical scenarios to optimize patient outcomes and provide effective care.

Myelodysplastic syndromes (MDS) are a group of diverse bone marrow disorders characterized by dysplasia (abnormal development or maturation) of one or more types of blood cells or by ineffective hematopoiesis, resulting in cytopenias (lower than normal levels of one or more types of blood cells). MDS can be classified into various subtypes based on the number and type of cytopenias, the degree of dysplasia, the presence of ring sideroblasts, and cytogenetic abnormalities.

The condition primarily affects older adults, with a median age at diagnosis of around 70 years. MDS can evolve into acute myeloid leukemia (AML) in approximately 30-40% of cases. The pathophysiology of MDS involves genetic mutations and chromosomal abnormalities that lead to impaired differentiation and increased apoptosis of hematopoietic stem and progenitor cells, ultimately resulting in cytopenias and an increased risk of developing AML.

The diagnosis of MDS typically requires a bone marrow aspiration and biopsy, along with cytogenetic and molecular analyses to identify specific genetic mutations and chromosomal abnormalities. Treatment options for MDS depend on the subtype, severity of cytopenias, and individual patient factors. These may include supportive care measures, such as transfusions and growth factor therapy, or more aggressive treatments, such as chemotherapy and stem cell transplantation.

Cytomegalovirus (CMV) infections are caused by the human herpesvirus 5 (HHV-5), a type of herpesvirus. The infection can affect people of all ages, but it is more common in individuals with weakened immune systems, such as those with HIV/AIDS or who have undergone organ transplantation.

CMV can be spread through close contact with an infected person's saliva, urine, blood, tears, semen, or breast milk. It can also be spread through sexual contact or by sharing contaminated objects, such as toys, eating utensils, or drinking glasses. Once a person is infected with CMV, the virus remains in their body for life and can reactivate later, causing symptoms to recur.

Most people who are infected with CMV do not experience any symptoms, but some may develop a mononucleosis-like illness, characterized by fever, fatigue, swollen glands, and sore throat. In people with weakened immune systems, CMV infections can cause more severe symptoms, including pneumonia, gastrointestinal disease, retinitis, and encephalitis.

Congenital CMV infection occurs when a pregnant woman passes the virus to her fetus through the placenta. This can lead to serious complications, such as hearing loss, vision loss, developmental delays, and mental disability.

Diagnosis of CMV infections is typically made through blood tests or by detecting the virus in bodily fluids, such as urine or saliva. Treatment depends on the severity of the infection and the patient's overall health. Antiviral medications may be prescribed to help manage symptoms and prevent complications.

Aplastic anemia is a medical condition characterized by pancytopenia (a decrease in all three types of blood cells: red blood cells, white blood cells, and platelets) due to the failure of bone marrow to produce new cells. It is called "aplastic" because the bone marrow becomes hypocellular or "aplastic," meaning it contains few or no blood-forming stem cells.

The condition can be acquired or inherited, with acquired aplastic anemia being more common. Acquired aplastic anemia can result from exposure to toxic chemicals, radiation, drugs, viral infections, or autoimmune disorders. Inherited forms of the disease include Fanconi anemia and dyskeratosis congenita.

Symptoms of aplastic anemia may include fatigue, weakness, shortness of breath, pale skin, easy bruising or bleeding, frequent infections, and fever. Treatment options for aplastic anemia depend on the severity of the condition and its underlying cause. They may include blood transfusions, immunosuppressive therapy, and stem cell transplantation.

A "Blood Cell Count" is a medical laboratory test that measures the number of red blood cells (RBCs), white blood cells (WBCs), and platelets in a sample of blood. This test is often used as a part of a routine check-up or to help diagnose various medical conditions, such as anemia, infection, inflammation, and many others.

The RBC count measures the number of oxygen-carrying cells in the blood, while the WBC count measures the number of immune cells that help fight infections. The platelet count measures the number of cells involved in clotting. Abnormal results in any of these counts may indicate an underlying medical condition and further testing may be required for diagnosis and treatment.

Lymphoma is a type of cancer that originates from the white blood cells called lymphocytes, which are part of the immune system. These cells are found in various parts of the body such as the lymph nodes, spleen, bone marrow, and other organs. Lymphoma can be classified into two main types: Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).

HL is characterized by the presence of a specific type of abnormal lymphocyte called Reed-Sternberg cells, while NHL includes a diverse group of lymphomas that lack these cells. The symptoms of lymphoma may include swollen lymph nodes, fever, night sweats, weight loss, and fatigue.

The exact cause of lymphoma is not known, but it is believed to result from genetic mutations in the lymphocytes that lead to uncontrolled cell growth and division. Exposure to certain viruses, chemicals, and radiation may increase the risk of developing lymphoma. Treatment options for lymphoma depend on various factors such as the type and stage of the disease, age, and overall health of the patient. Common treatments include chemotherapy, radiation therapy, immunotherapy, and stem cell transplantation.

Cytophagocytosis is a medical term that refers to the process in which certain types of cells, particularly immune cells like macrophages, engulf and digest other smaller cells or particles. This process helps the body to eliminate foreign substances, cellular debris, and pathogens such as bacteria, viruses, and fungi.

During cytophagocytosis, the macrophage extends its pseudopodia (cytoplasmic extensions) to surround and engulf the target cell or particle, forming a vesicle called a phagosome. The phagosome then fuses with a lysosome, an organelle containing digestive enzymes, which breaks down the contents of the phagosome into smaller molecules that can be used by the macrophage for energy or eliminated as waste products.

Cytophagocytosis is an essential part of the immune system's defense mechanisms and plays a crucial role in maintaining tissue homeostasis and preventing infection and disease.

Liver transplantation is a surgical procedure in which a diseased or failing liver is replaced with a healthy one from a deceased donor or, less commonly, a portion of a liver from a living donor. The goal of the procedure is to restore normal liver function and improve the patient's overall health and quality of life.

Liver transplantation may be recommended for individuals with end-stage liver disease, acute liver failure, certain genetic liver disorders, or liver cancers that cannot be treated effectively with other therapies. The procedure involves complex surgery to remove the diseased liver and implant the new one, followed by a period of recovery and close medical monitoring to ensure proper function and minimize the risk of complications.

The success of liver transplantation has improved significantly in recent years due to advances in surgical techniques, immunosuppressive medications, and post-transplant care. However, it remains a major operation with significant risks and challenges, including the need for lifelong immunosuppression to prevent rejection of the new liver, as well as potential complications such as infection, bleeding, and organ failure.

Chronic myelogenous leukemia (CML), BCR-ABL positive is a specific subtype of leukemia that originates in the bone marrow and involves the excessive production of mature granulocytes, a type of white blood cell. It is characterized by the presence of the Philadelphia chromosome, which is formed by a genetic translocation between chromosomes 9 and 22, resulting in the formation of the BCR-ABL fusion gene. This gene encodes for an abnormal protein with increased tyrosine kinase activity, leading to uncontrolled cell growth and division. The presence of this genetic abnormality is used to confirm the diagnosis and guide treatment decisions.

Lymphocyte depletion is a medical term that refers to the reduction in the number of lymphocytes (a type of white blood cell) in the body. Lymphocytes play a crucial role in the immune system, as they help to fight off infections and diseases.

Lymphocyte depletion can occur due to various reasons, including certain medical treatments such as chemotherapy or radiation therapy, immune disorders, viral infections, or bone marrow transplantation. This reduction in lymphocytes can make a person more susceptible to infections and diseases, as their immune system is weakened.

There are different types of lymphocytes, including T cells, B cells, and natural killer (NK) cells, and lymphocyte depletion can affect one or all of these types. In some cases, lymphocyte depletion may be temporary and resolve on its own or with treatment. However, in other cases, it may be more prolonged and require medical intervention to manage the associated risks and complications.

Neoplasms are abnormal growths of cells or tissues in the body that serve no physiological function. They can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms are typically slow growing and do not spread to other parts of the body, while malignant neoplasms are aggressive, invasive, and can metastasize to distant sites.

Neoplasms occur when there is a dysregulation in the normal process of cell division and differentiation, leading to uncontrolled growth and accumulation of cells. This can result from genetic mutations or other factors such as viral infections, environmental exposures, or hormonal imbalances.

Neoplasms can develop in any organ or tissue of the body and can cause various symptoms depending on their size, location, and type. Treatment options for neoplasms include surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy, among others.

A fatal outcome is a term used in medical context to describe a situation where a disease, injury, or illness results in the death of an individual. It is the most severe and unfortunate possible outcome of any medical condition, and is often used as a measure of the severity and prognosis of various diseases and injuries. In clinical trials and research, fatal outcome may be used as an endpoint to evaluate the effectiveness and safety of different treatments or interventions.

Livedo reticularis is a cutaneous manifestation characterized by a bluish-purple, netlike pattern of discoloration on the skin. It is caused by the abnormal dilation and constriction of blood vessels near the skin's surface, leading to impaired circulation in the affected areas.

The condition can be idiopathic (primary) or secondary to various underlying disorders such as autoimmune diseases, vasculitis, hematologic disorders, infections, or medications that affect the blood vessels. In some cases, livedo reticularis may be a sign of an underlying medical condition requiring further evaluation and treatment.

It is essential to differentiate livedo reticularis from other related conditions like livedo racemosa, which presents with more irregular and diffuse patterns, and is typically associated with vasculitis or severe systemic disorders. Additionally, livedo reticularis should not be confused with cutis marmorata, a physiological response to cold temperatures that resolves upon warming the affected area.

Non-Langerhans cell histiocytosis (NLCH) is a group of rare disorders characterized by the abnormal proliferation and accumulation of histiocytes, which are immune cells that normally function to help fight infection. Unlike Langerhans cell histiocytosis (LCH), where the histiocytes involved are positive for the marker CD1a and the protein S-100, in NLCH, the histiocytes involved do not express these markers.

NLCH includes several distinct clinicopathological entities, such as juvenile xanthogranuloma, Erdheim-Chester disease, and Rosai-Dorfman disease. These conditions can affect various organs of the body, including the skin, bones, lungs, central nervous system, and others. The clinical manifestations, prognosis, and treatment options vary depending on the specific type of NLCH and the extent of organ involvement.

It is important to note that while some cases of NLCH may be self-limited or respond well to treatment, others can be aggressive and potentially life-threatening. Therefore, prompt and accurate diagnosis and management are crucial for optimizing patient outcomes.

A feasibility study is a preliminary investigation or analysis conducted to determine the viability of a proposed project, program, or product. In the medical field, feasibility studies are often conducted before implementing new treatments, procedures, equipment, or facilities. These studies help to assess the practicality and effectiveness of the proposed intervention, as well as its potential benefits and risks.

Feasibility studies in healthcare typically involve several steps:

1. Problem identification: Clearly define the problem that the proposed project, program, or product aims to address.
2. Objectives setting: Establish specific, measurable, achievable, relevant, and time-bound (SMART) objectives for the study.
3. Literature review: Conduct a thorough review of existing research and best practices related to the proposed intervention.
4. Methodology development: Design a methodology for data collection and analysis that will help answer the research questions and achieve the study's objectives.
5. Resource assessment: Evaluate the availability and adequacy of resources, including personnel, time, and finances, required to carry out the proposed intervention.
6. Risk assessment: Identify potential risks and challenges associated with the implementation of the proposed intervention and develop strategies to mitigate them.
7. Cost-benefit analysis: Estimate the costs and benefits of the proposed intervention, including direct and indirect costs, as well as short-term and long-term benefits.
8. Stakeholder engagement: Engage relevant stakeholders, such as patients, healthcare providers, administrators, and policymakers, to gather their input and support for the proposed intervention.
9. Decision-making: Based on the findings of the feasibility study, make an informed decision about whether or not to proceed with the proposed project, program, or product.

Feasibility studies are essential in healthcare as they help ensure that resources are allocated efficiently and effectively, and that interventions are evidence-based, safe, and beneficial for patients.

Follow-up studies are a type of longitudinal research that involve repeated observations or measurements of the same variables over a period of time, in order to understand their long-term effects or outcomes. In medical context, follow-up studies are often used to evaluate the safety and efficacy of medical treatments, interventions, or procedures.

In a typical follow-up study, a group of individuals (called a cohort) who have received a particular treatment or intervention are identified and then followed over time through periodic assessments or data collection. The data collected may include information on clinical outcomes, adverse events, changes in symptoms or functional status, and other relevant measures.

The results of follow-up studies can provide important insights into the long-term benefits and risks of medical interventions, as well as help to identify factors that may influence treatment effectiveness or patient outcomes. However, it is important to note that follow-up studies can be subject to various biases and limitations, such as loss to follow-up, recall bias, and changes in clinical practice over time, which must be carefully considered when interpreting the results.

Opportunistic infections (OIs) are infections that occur more frequently or are more severe in individuals with weakened immune systems, often due to a underlying condition such as HIV/AIDS, cancer, or organ transplantation. These infections are caused by microorganisms that do not normally cause disease in people with healthy immune function, but can take advantage of an opportunity to infect and cause damage when the body's defense mechanisms are compromised. Examples of opportunistic infections include Pneumocystis pneumonia, tuberculosis, candidiasis (thrush), and cytomegalovirus infection. Preventive measures, such as antimicrobial medications and vaccinations, play a crucial role in reducing the risk of opportunistic infections in individuals with weakened immune systems.

Hematologic diseases, also known as hematological disorders, refer to a group of conditions that affect the production, function, or destruction of blood cells or blood-related components, such as plasma. These diseases can affect erythrocytes (red blood cells), leukocytes (white blood cells), and platelets (thrombocytes), as well as clotting factors and hemoglobin.

Hematologic diseases can be broadly categorized into three main types:

1. Anemia: A condition characterized by a decrease in the total red blood cell count, hemoglobin, or hematocrit, leading to insufficient oxygen transport to tissues and organs. Examples include iron deficiency anemia, sickle cell anemia, and aplastic anemia.
2. Leukemia and other disorders of white blood cells: These conditions involve the abnormal production or function of leukocytes, which can lead to impaired immunity and increased susceptibility to infections. Examples include leukemias (acute lymphoblastic leukemia, chronic myeloid leukemia), lymphomas, and myelodysplastic syndromes.
3. Platelet and clotting disorders: These diseases affect the production or function of platelets and clotting factors, leading to abnormal bleeding or clotting tendencies. Examples include hemophilia, von Willebrand disease, thrombocytopenia, and disseminated intravascular coagulation (DIC).

Hematologic diseases can have various causes, including genetic defects, infections, autoimmune processes, environmental factors, or malignancies. Proper diagnosis and management of these conditions often require the expertise of hematologists, who specialize in diagnosing and treating disorders related to blood and its components.

Doxorubicin is a type of chemotherapy medication known as an anthracycline. It works by interfering with the DNA in cancer cells, which prevents them from growing and multiplying. Doxorubicin is used to treat a wide variety of cancers, including leukemia, lymphoma, breast cancer, lung cancer, ovarian cancer, and many others. It may be given alone or in combination with other chemotherapy drugs.

Doxorubicin is usually administered through a vein (intravenously) and can cause side effects such as nausea, vomiting, hair loss, mouth sores, and increased risk of infection. It can also cause damage to the heart muscle, which can lead to heart failure in some cases. For this reason, doctors may monitor patients' heart function closely while they are receiving doxorubicin treatment.

It is important for patients to discuss the potential risks and benefits of doxorubicin therapy with their healthcare provider before starting treatment.

Precursor Cell Lymphoblastic Leukemia-Lymphoma (previously known as Precursor T-lymphoblastic Leukemia/Lymphoma) is a type of cancer that affects the early stages of T-cell development. It is a subtype of acute lymphoblastic leukemia (ALL), which is characterized by the overproduction of immature white blood cells called lymphoblasts in the bone marrow, blood, and other organs.

In Precursor Cell Lymphoblastic Leukemia-Lymphoma, these abnormal lymphoblasts accumulate primarily in the lymphoid tissues such as the thymus and lymph nodes, leading to the enlargement of these organs. This subtype is more aggressive than other forms of ALL and has a higher risk of spreading to the central nervous system (CNS).

The medical definition of Precursor Cell Lymphoblastic Leukemia-Lymphoma includes:

1. A malignant neoplasm of immature T-cell precursors, also known as lymphoblasts.
2. Characterized by the proliferation and accumulation of these abnormal cells in the bone marrow, blood, and lymphoid tissues such as the thymus and lymph nodes.
3. Often associated with chromosomal abnormalities, genetic mutations, or aberrant gene expression that contribute to its aggressive behavior and poor prognosis.
4. Typically presents with symptoms related to bone marrow failure (anemia, neutropenia, thrombocytopenia), lymphadenopathy (swollen lymph nodes), hepatosplenomegaly (enlarged liver and spleen), and potential CNS involvement.
5. Diagnosed through a combination of clinical evaluation, imaging studies, and laboratory tests, including bone marrow aspiration and biopsy, immunophenotyping, cytogenetic analysis, and molecular genetic testing.
6. Treated with intensive multi-agent chemotherapy regimens, often combined with radiation therapy and/or stem cell transplantation to achieve remission and improve survival outcomes.

Cyclosporine is a medication that belongs to a class of drugs called immunosuppressants. It is primarily used to prevent the rejection of transplanted organs, such as kidneys, livers, and hearts. Cyclosporine works by suppressing the activity of the immune system, which helps to reduce the risk of the body attacking the transplanted organ.

In addition to its use in organ transplantation, cyclosporine may also be used to treat certain autoimmune diseases, such as rheumatoid arthritis and psoriasis. It does this by suppressing the overactive immune response that contributes to these conditions.

Cyclosporine is available in capsule, oral solution, and injectable forms. Common side effects of the medication include kidney problems, high blood pressure, tremors, headache, and nausea. Long-term use of cyclosporine can also increase the risk of certain types of cancer and infections.

It is important to note that cyclosporine should only be used under the close supervision of a healthcare provider, as it requires regular monitoring of blood levels and kidney function.

HLA (Human Leukocyte Antigen) antigens are a group of proteins found on the surface of cells in our body. They play a crucial role in the immune system's ability to differentiate between "self" and "non-self." HLA antigens are encoded by a group of genes located on chromosome 6, known as the major histocompatibility complex (MHC).

There are three types of HLA antigens: HLA class I, HLA class II, and HLA class III. HLA class I antigens are found on the surface of almost all cells in the body and help the immune system recognize and destroy virus-infected or cancerous cells. They consist of three components: HLA-A, HLA-B, and HLA-C.

HLA class II antigens are primarily found on the surface of immune cells, such as macrophages, B cells, and dendritic cells. They assist in the presentation of foreign particles (like bacteria and viruses) to CD4+ T cells, which then activate other parts of the immune system. HLA class II antigens include HLA-DP, HLA-DQ, and HLA-DR.

HLA class III antigens consist of various molecules involved in immune responses, such as cytokines and complement components. They are not directly related to antigen presentation.

The genetic diversity of HLA antigens is extensive, with thousands of variations or alleles. This diversity allows for a better ability to recognize and respond to a wide range of pathogens. However, this variation can also lead to compatibility issues in organ transplantation, as the recipient's immune system may recognize the donor's HLA antigens as foreign and attack the transplanted organ.

A blood donor is a person who voluntarily gives their own blood or blood components to be used for the benefit of another person in need. The blood donation process involves collecting the donor's blood, testing it for infectious diseases, and then storing it until it is needed by a patient. There are several types of blood donations, including:

1. Whole blood donation: This is the most common type of blood donation, where a donor gives one unit (about 450-500 milliliters) of whole blood. The blood is then separated into its components (red cells, plasma, and platelets) for transfusion to patients with different needs.
2. Double red cell donation: In this type of donation, the donor's blood is collected using a special machine that separates two units of red cells from the whole blood. The remaining plasma and platelets are returned to the donor during the donation process. This type of donation can be done every 112 days.
3. Platelet donation: A donor's blood is collected using a special machine that separates platelets from the whole blood. The red cells and plasma are then returned to the donor during the donation process. This type of donation can be done every seven days, up to 24 times a year.
4. Plasma donation: A donor's blood is collected using a special machine that separates plasma from the whole blood. The red cells and platelets are then returned to the donor during the donation process. This type of donation can be done every 28 days, up to 13 times a year.

Blood donors must meet certain eligibility criteria, such as being in good health, aged between 18 and 65 (in some countries, the upper age limit may vary), and weighing over 50 kg (110 lbs). Donors are also required to answer medical questionnaires and undergo a mini-physical examination before each donation. The frequency of blood donations varies depending on the type of donation and the donor's health status.

Bone marrow is the spongy tissue found inside certain bones in the body, such as the hips, thighs, and vertebrae. It is responsible for producing blood-forming cells, including red blood cells, white blood cells, and platelets. There are two types of bone marrow: red marrow, which is involved in blood cell production, and yellow marrow, which contains fatty tissue.

Red bone marrow contains hematopoietic stem cells, which can differentiate into various types of blood cells. These stem cells continuously divide and mature to produce new blood cells that are released into the circulation. Red blood cells carry oxygen throughout the body, white blood cells help fight infections, and platelets play a crucial role in blood clotting.

Bone marrow also serves as a site for immune cell development and maturation. It contains various types of immune cells, such as lymphocytes, macrophages, and dendritic cells, which help protect the body against infections and diseases.

Abnormalities in bone marrow function can lead to several medical conditions, including anemia, leukopenia, thrombocytopenia, and various types of cancer, such as leukemia and multiple myeloma. Bone marrow aspiration and biopsy are common diagnostic procedures used to evaluate bone marrow health and function.

Immunophenotyping is a medical laboratory technique used to identify and classify cells, usually in the context of hematologic (blood) disorders and malignancies (cancers), based on their surface or intracellular expression of various proteins and antigens. This technique utilizes specific antibodies tagged with fluorochromes, which bind to the target antigens on the cell surface or within the cells. The labeled cells are then analyzed using flow cytometry, allowing for the detection and quantification of multiple antigenic markers simultaneously.

Immunophenotyping helps in understanding the distribution of different cell types, their subsets, and activation status, which can be crucial in diagnosing various hematological disorders, immunodeficiencies, and distinguishing between different types of leukemias, lymphomas, and other malignancies. Additionally, it can also be used to monitor the progression of diseases, evaluate the effectiveness of treatments, and detect minimal residual disease (MRD) during follow-up care.

Immunosuppression is a state in which the immune system's ability to mount an immune response is reduced, compromised or inhibited. This can be caused by certain medications (such as those used to prevent rejection of transplanted organs), diseases (like HIV/AIDS), or genetic disorders. As a result, the body becomes more susceptible to infections and cancer development. It's important to note that immunosuppression should not be confused with immunity, which refers to the body's ability to resist and fight off infections and diseases.

Prospective studies, also known as longitudinal studies, are a type of cohort study in which data is collected forward in time, following a group of individuals who share a common characteristic or exposure over a period of time. The researchers clearly define the study population and exposure of interest at the beginning of the study and follow up with the participants to determine the outcomes that develop over time. This type of study design allows for the investigation of causal relationships between exposures and outcomes, as well as the identification of risk factors and the estimation of disease incidence rates. Prospective studies are particularly useful in epidemiology and medical research when studying diseases with long latency periods or rare outcomes.

Recombinant proteins are artificially created proteins produced through the use of recombinant DNA technology. This process involves combining DNA molecules from different sources to create a new set of genes that encode for a specific protein. The resulting recombinant protein can then be expressed, purified, and used for various applications in research, medicine, and industry.

Recombinant proteins are widely used in biomedical research to study protein function, structure, and interactions. They are also used in the development of diagnostic tests, vaccines, and therapeutic drugs. For example, recombinant insulin is a common treatment for diabetes, while recombinant human growth hormone is used to treat growth disorders.

The production of recombinant proteins typically involves the use of host cells, such as bacteria, yeast, or mammalian cells, which are engineered to express the desired protein. The host cells are transformed with a plasmid vector containing the gene of interest, along with regulatory elements that control its expression. Once the host cells are cultured and the protein is expressed, it can be purified using various chromatography techniques.

Overall, recombinant proteins have revolutionized many areas of biology and medicine, enabling researchers to study and manipulate proteins in ways that were previously impossible.

Mesenchymal Stem Cell Transplantation (MSCT) is a medical procedure that involves the transplantation of mesenchymal stem cells (MSCs), which are multipotent stromal cells that can differentiate into a variety of cell types, including bone, cartilage, fat, and muscle. These cells can be obtained from various sources, such as bone marrow, adipose tissue, umbilical cord blood, or dental pulp.

In MSCT, MSCs are typically harvested from the patient themselves (autologous transplantation) or from a donor (allogeneic transplantation). The cells are then processed and expanded in a laboratory setting before being injected into the patient's body, usually through an intravenous infusion.

MSCT is being investigated as a potential treatment for a wide range of medical conditions, including degenerative diseases, autoimmune disorders, and tissue injuries. The rationale behind this approach is that MSCs have the ability to migrate to sites of injury or inflammation, where they can help to modulate the immune response, reduce inflammation, and promote tissue repair and regeneration.

However, it's important to note that while MSCT holds promise as a therapeutic option, more research is needed to establish its safety and efficacy for specific medical conditions.

T-cell lymphoma is a type of cancer that affects the T-cells, which are a specific type of white blood cell responsible for immune function. These lymphomas develop from mature T-cells and can be classified into various subtypes based on their clinical and pathological features.

T-cell lymphomas can arise in many different organs, including the lymph nodes, skin, and other soft tissues. They often present with symptoms such as enlarged lymph nodes, fever, night sweats, and weight loss. The diagnosis of T-cell lymphoma typically involves a biopsy of the affected tissue, followed by immunophenotyping and genetic analysis to determine the specific subtype.

Treatment for T-cell lymphomas may include chemotherapy, radiation therapy, immunotherapy, or stem cell transplantation, depending on the stage and aggressiveness of the disease. The prognosis for T-cell lymphoma varies widely depending on the subtype and individual patient factors.

Bone marrow purging is a procedure that involves the removal of cancerous or damaged cells from bone marrow before it is transplanted into a patient. This process is often used in the treatment of blood cancers such as leukemia and lymphoma, as well as other diseases that affect the bone marrow.

The purging process typically involves collecting bone marrow from the patient or a donor, then treating it with chemicals or medications to eliminate any cancerous or damaged cells. The purged bone marrow is then transplanted back into the patient's body, where it can help to produce healthy new blood cells.

There are several methods that can be used for bone marrow purging, including physical separation techniques, chemical treatments, and immunological approaches using antibodies or other immune system components. The choice of method depends on several factors, including the type and stage of the disease being treated, as well as the patient's individual medical history and condition.

It is important to note that bone marrow purging is a complex procedure that carries some risks and potential complications, such as damage to healthy cells, delayed recovery, and increased risk of infection. As with any medical treatment, it should be carefully evaluated and discussed with a healthcare provider to determine whether it is appropriate for a given patient's situation.

I'm sorry for any confusion, but "pilot projects" is not a medical term per se. Instead, it is a general term used in various fields, including healthcare and medicine, to describe a small-scale initiative that is implemented on a temporary basis to evaluate its feasibility, effectiveness, or impact before deciding whether to expand or continue it.

In the context of healthcare, pilot projects might involve testing new treatment protocols, implementing innovative care models, or introducing technology solutions in a limited setting to assess their potential benefits and drawbacks. The results of these projects can help inform decisions about broader implementation and provide valuable insights for improving the quality and efficiency of healthcare services.

Prednisone is a synthetic glucocorticoid, which is a type of corticosteroid hormone. It is primarily used to reduce inflammation in various conditions such as asthma, allergies, arthritis, and autoimmune disorders. Prednisone works by mimicking the effects of natural hormones produced by the adrenal glands, suppressing the immune system's response and reducing the release of substances that cause inflammation.

It is available in oral tablet form and is typically prescribed to be taken at specific times during the day, depending on the condition being treated. Common side effects of prednisone include increased appetite, weight gain, mood changes, insomnia, and easy bruising. Long-term use or high doses can lead to more serious side effects such as osteoporosis, diabetes, cataracts, and increased susceptibility to infections.

Healthcare providers closely monitor patients taking prednisone for extended periods to minimize the risk of adverse effects. It is essential to follow the prescribed dosage regimen and not discontinue the medication abruptly without medical supervision, as this can lead to withdrawal symptoms or a rebound of the underlying condition.

Carboplatin is a chemotherapeutic agent used to treat various types of cancers, including ovarian, lung, and head and neck cancer. It is a platinum-containing compound that works by forming crosslinks in DNA, which leads to the death of rapidly dividing cells, such as cancer cells. Carboplatin is often used in combination with other chemotherapy drugs and is administered intravenously.

The medical definition of Carboplatin is:

"A platinum-containing antineoplastic agent that forms crosslinks with DNA, inducing cell cycle arrest and apoptosis. It is used to treat a variety of cancers, including ovarian, lung, and head and neck cancer."

Bone marrow diseases, also known as hematologic disorders, are conditions that affect the production and function of blood cells in the bone marrow. The bone marrow is the spongy tissue inside bones where all blood cells are produced. There are various types of bone marrow diseases, including:

1. Leukemia: A cancer of the blood-forming tissues, including the bone marrow. Leukemia causes the body to produce large numbers of abnormal white blood cells, which can crowd out healthy blood cells and impair their function.
2. Lymphoma: A cancer that starts in the lymphatic system, which is part of the immune system. Lymphoma can affect the bone marrow and cause an overproduction of abnormal white blood cells.
3. Multiple myeloma: A cancer of the plasma cells, a type of white blood cell found in the bone marrow. Multiple myeloma causes an overproduction of abnormal plasma cells, which can lead to bone pain, fractures, and other complications.
4. Aplastic anemia: A condition in which the bone marrow does not produce enough new blood cells. This can lead to symptoms such as fatigue, weakness, and an increased risk of infection.
5. Myelodysplastic syndromes (MDS): A group of disorders in which the bone marrow does not produce enough healthy blood cells. MDS can lead to anemia, infections, and bleeding.
6. Myeloproliferative neoplasms (MPNs): A group of disorders in which the bone marrow produces too many abnormal white or red blood cells, or platelets. MPNs can lead to symptoms such as fatigue, itching, and an increased risk of blood clots.

Treatment for bone marrow diseases depends on the specific condition and its severity. Treatment options may include chemotherapy, radiation therapy, stem cell transplantation, or targeted therapies that target specific genetic mutations.

CD (cluster of differentiation) antigens are cell-surface proteins that are expressed on leukocytes (white blood cells) and can be used to identify and distinguish different subsets of these cells. They are important markers in the field of immunology and hematology, and are commonly used to diagnose and monitor various diseases, including cancer, autoimmune disorders, and infectious diseases.

CD antigens are designated by numbers, such as CD4, CD8, CD19, etc., which refer to specific proteins found on the surface of different types of leukocytes. For example, CD4 is a protein found on the surface of helper T cells, while CD8 is found on cytotoxic T cells.

CD antigens can be used as targets for immunotherapy, such as monoclonal antibody therapy, in which antibodies are designed to bind to specific CD antigens and trigger an immune response against cancer cells or infected cells. They can also be used as markers to monitor the effectiveness of treatments and to detect minimal residual disease (MRD) after treatment.

It's important to note that not all CD antigens are exclusive to leukocytes, some can be found on other cell types as well, and their expression can vary depending on the activation state or differentiation stage of the cells.

Prognosis is a medical term that refers to the prediction of the likely outcome or course of a disease, including the chances of recovery or recurrence, based on the patient's symptoms, medical history, physical examination, and diagnostic tests. It is an important aspect of clinical decision-making and patient communication, as it helps doctors and patients make informed decisions about treatment options, set realistic expectations, and plan for future care.

Prognosis can be expressed in various ways, such as percentages, categories (e.g., good, fair, poor), or survival rates, depending on the nature of the disease and the available evidence. However, it is important to note that prognosis is not an exact science and may vary depending on individual factors, such as age, overall health status, and response to treatment. Therefore, it should be used as a guide rather than a definitive forecast.

Blood group incompatibility refers to a situation where the blood type of a donor and a recipient are not compatible, leading to an immune response and destruction of the donated red blood cells. This is because the recipient's immune system recognizes the donor's red blood cells as foreign due to the presence of incompatible antigens on their surface.

The most common type of blood group incompatibility occurs between individuals with different ABO blood types, such as when a person with type O blood receives type A, B, or AB blood. This can lead to agglutination and hemolysis of the donated red blood cells, causing potentially life-threatening complications such as hemolytic transfusion reaction.

Another type of blood group incompatibility occurs between Rh-negative mothers and their Rh-positive fetuses. If a mother's immune system is exposed to her fetus's Rh-positive red blood cells during pregnancy or childbirth, she may develop antibodies against them. This can lead to hemolytic disease of the newborn if the mother becomes pregnant with another Rh-positive fetus in the future.

To prevent these complications, it is essential to ensure that donated blood is compatible with the recipient's blood type before transfusion and that appropriate measures are taken during pregnancy and childbirth to prevent sensitization of Rh-negative mothers to Rh-positive red blood cells.

A residual neoplasm is a term used in pathology and oncology to describe the remaining abnormal tissue or cancer cells after a surgical procedure or treatment aimed at completely removing a tumor. This means that some cancer cells have been left behind and continue to persist in the body. The presence of residual neoplasm can increase the risk of recurrence or progression of the disease, as these remaining cells may continue to grow and divide.

Residual neoplasm is often assessed during follow-up appointments and monitoring, using imaging techniques like CT scans, MRIs, or PET scans, and sometimes through biopsies. The extent of residual neoplasm can influence the choice of further treatment options, such as additional surgery, radiation therapy, chemotherapy, or targeted therapies, to eliminate the remaining cancer cells and reduce the risk of recurrence.

Kidney transplantation is a surgical procedure where a healthy kidney from a deceased or living donor is implanted into a patient with end-stage renal disease (ESRD) or permanent kidney failure. The new kidney takes over the functions of filtering waste and excess fluids from the blood, producing urine, and maintaining the body's electrolyte balance.

The transplanted kidney is typically placed in the lower abdomen, with its blood vessels connected to the recipient's iliac artery and vein. The ureter of the new kidney is then attached to the recipient's bladder to ensure proper urine flow. Following the surgery, the patient will require lifelong immunosuppressive therapy to prevent rejection of the transplanted organ by their immune system.

Antineoplastic agents are a class of drugs used to treat malignant neoplasms or cancer. These agents work by inhibiting the growth and proliferation of cancer cells, either by killing them or preventing their division and replication. Antineoplastic agents can be classified based on their mechanism of action, such as alkylating agents, antimetabolites, topoisomerase inhibitors, mitotic inhibitors, and targeted therapy agents.

Alkylating agents work by adding alkyl groups to DNA, which can cause cross-linking of DNA strands and ultimately lead to cell death. Antimetabolites interfere with the metabolic processes necessary for DNA synthesis and replication, while topoisomerase inhibitors prevent the relaxation of supercoiled DNA during replication. Mitotic inhibitors disrupt the normal functioning of the mitotic spindle, which is essential for cell division. Targeted therapy agents are designed to target specific molecular abnormalities in cancer cells, such as mutated oncogenes or dysregulated signaling pathways.

It's important to note that antineoplastic agents can also affect normal cells and tissues, leading to various side effects such as nausea, vomiting, hair loss, and myelosuppression (suppression of bone marrow function). Therefore, the use of these drugs requires careful monitoring and management of their potential adverse effects.

Cell transplantation is the process of transferring living cells from one part of the body to another or from one individual to another. In medicine, cell transplantation is often used as a treatment for various diseases and conditions, including neurodegenerative disorders, diabetes, and certain types of cancer. The goal of cell transplantation is to replace damaged or dysfunctional cells with healthy ones, thereby restoring normal function to the affected area.

In the context of medical research, cell transplantation may involve the use of stem cells, which are immature cells that have the ability to develop into many different types of specialized cells. Stem cell transplantation has shown promise in the treatment of a variety of conditions, including spinal cord injuries, stroke, and heart disease.

It is important to note that cell transplantation carries certain risks, such as immune rejection and infection. As such, it is typically reserved for cases where other treatments have failed or are unlikely to be effective.

Transplantation Immunology is a branch of medicine that deals with the immune responses occurring between a transplanted organ or tissue and the recipient's body. It involves understanding and managing the immune system's reaction to foreign tissue, which can lead to rejection of the transplanted organ. This field also studies the use of immunosuppressive drugs to prevent rejection and the potential risks and side effects associated with their use. The main goal of transplantation immunology is to find ways to promote the acceptance of transplanted tissue while minimizing the risk of infection and other complications.

A leukocyte count, also known as a white blood cell (WBC) count, is a laboratory test that measures the number of leukocytes in a sample of blood. Leukocytes are a vital part of the body's immune system and help fight infection and inflammation. A high or low leukocyte count may indicate an underlying medical condition, such as an infection, inflammation, or a bone marrow disorder. The normal range for a leukocyte count in adults is typically between 4,500 and 11,000 cells per microliter (mcL) of blood. However, the normal range can vary slightly depending on the laboratory and the individual's age and sex.

Methotrexate is a medication used in the treatment of certain types of cancer and autoimmune diseases. It is an antimetabolite that inhibits the enzyme dihydrofolate reductase, which is necessary for the synthesis of purines and pyrimidines, essential components of DNA and RNA. By blocking this enzyme, methotrexate interferes with cell division and growth, making it effective in treating rapidly dividing cells such as cancer cells.

In addition to its use in cancer treatment, methotrexate is also used to manage autoimmune diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. In these conditions, methotrexate modulates the immune system and reduces inflammation.

It's important to note that methotrexate can have significant side effects and should be used under the close supervision of a healthcare provider. Regular monitoring of blood counts, liver function, and kidney function is necessary during treatment with methotrexate.

Embryonic stem cells are a type of pluripotent stem cell that are derived from the inner cell mass of a blastocyst, which is a very early-stage embryo. These cells have the ability to differentiate into any cell type in the body, making them a promising area of research for regenerative medicine and the study of human development and disease. Embryonic stem cells are typically obtained from surplus embryos created during in vitro fertilization (IVF) procedures, with the consent of the donors. The use of embryonic stem cells is a controversial issue due to ethical concerns surrounding the destruction of human embryos.

Lymphocyte subsets refer to distinct populations of white blood cells called lymphocytes, which are crucial components of the adaptive immune system. There are two main types of lymphocytes: T cells and B cells, and each type has several subsets based on their surface receptors, functions, and activation status.

1. T cell subsets: These include CD4+ T helper cells (Th cells), CD8+ cytotoxic T cells (Tc cells), regulatory T cells (Tregs), and memory T cells. Th cells are further divided into Th1, Th2, Th17, and Tfh cells based on their cytokine production profiles and functions.
* CD4+ T helper cells (Th cells) play a central role in orchestrating the immune response by producing various cytokines that activate other immune cells.
* CD8+ cytotoxic T cells (Tc cells) directly kill virus-infected or malignant cells upon recognition of specific antigens presented on their surface.
* Regulatory T cells (Tregs) suppress the activation and proliferation of other immune cells to maintain self-tolerance and prevent autoimmunity.
* Memory T cells are long-lived cells that remain in the body after an initial infection or immunization, providing rapid protection upon subsequent encounters with the same pathogen.
2. B cell subsets: These include naïve B cells, memory B cells, and plasma cells. Upon activation by antigens, B cells differentiate into antibody-secreting plasma cells that produce specific antibodies to neutralize or eliminate pathogens.
* Naïve B cells are resting cells that have not yet encountered their specific antigen.
* Memory B cells are long-lived cells generated after initial antigen exposure, which can quickly differentiate into antibody-secreting plasma cells upon re-exposure to the same antigen.
* Plasma cells are terminally differentiated B cells that secrete large amounts of specific antibodies.

Analyzing lymphocyte subsets is essential for understanding immune system function and dysfunction, as well as monitoring the effectiveness of immunotherapies and vaccinations.

T-lymphocytes, also known as T-cells, are a type of white blood cell that plays a key role in the adaptive immune system's response to infection. They are produced in the bone marrow and mature in the thymus gland. There are several different types of T-cells, including CD4+ helper T-cells, CD8+ cytotoxic T-cells, and regulatory T-cells (Tregs).

CD4+ helper T-cells assist in activating other immune cells, such as B-lymphocytes and macrophages. They also produce cytokines, which are signaling molecules that help coordinate the immune response. CD8+ cytotoxic T-cells directly kill infected cells by releasing toxic substances. Regulatory T-cells help maintain immune tolerance and prevent autoimmune diseases by suppressing the activity of other immune cells.

T-lymphocytes are important in the immune response to viral infections, cancer, and other diseases. Dysfunction or depletion of T-cells can lead to immunodeficiency and increased susceptibility to infections. On the other hand, an overactive T-cell response can contribute to autoimmune diseases and chronic inflammation.

Dexamethasone is a type of corticosteroid medication, which is a synthetic version of a natural hormone produced by the adrenal glands. It is often used to reduce inflammation and suppress the immune system in a variety of medical conditions, including allergies, asthma, rheumatoid arthritis, and certain skin conditions.

Dexamethasone works by binding to specific receptors in cells, which triggers a range of anti-inflammatory effects. These include reducing the production of chemicals that cause inflammation, suppressing the activity of immune cells, and stabilizing cell membranes.

In addition to its anti-inflammatory effects, dexamethasone can also be used to treat other medical conditions, such as certain types of cancer, brain swelling, and adrenal insufficiency. It is available in a variety of forms, including tablets, liquids, creams, and injectable solutions.

Like all medications, dexamethasone can have side effects, particularly if used for long periods of time or at high doses. These may include mood changes, increased appetite, weight gain, acne, thinning skin, easy bruising, and an increased risk of infections. It is important to follow the instructions of a healthcare provider when taking dexamethasone to minimize the risk of side effects.

The "Graft vs Tumor Effect" is a term used in the field of transplantation medicine, particularly in allogeneic hematopoietic stem cell transplantation (HSCT). It refers to the anti-tumor activity exhibited by donor immune cells (graft) against residual malignant cells (tumor) in the recipient's body.

After HSCT, the donor's immune system is reconstituted in the recipient's body. If the donor and recipient are not identical, there may be differences in their major and minor histocompatibility antigens, which can lead to a graft-versus-host disease (GVHD) where the donor's immune cells attack the recipient's tissues. However, these same donor immune cells can also recognize and target any residual tumor cells in the recipient's body, leading to a graft vs tumor effect.

This effect can contribute to the elimination of residual malignant cells and reduce the risk of relapse, particularly in hematological malignancies such as leukemia and lymphoma. However, it is important to balance this effect with the risk of GVHD, which can cause significant morbidity and mortality. Therefore, strategies such as donor selection, graft manipulation, and immunosuppressive therapy are used to optimize the graft vs tumor effect while minimizing GVHD.

Flow cytometry is a medical and research technique used to measure physical and chemical characteristics of cells or particles, one cell at a time, as they flow in a fluid stream through a beam of light. The properties measured include:

* Cell size (light scatter)
* Cell internal complexity (granularity, also light scatter)
* Presence or absence of specific proteins or other molecules on the cell surface or inside the cell (using fluorescent antibodies or other fluorescent probes)

The technique is widely used in cell counting, cell sorting, protein engineering, biomarker discovery and monitoring disease progression, particularly in hematology, immunology, and cancer research.

An acute disease is a medical condition that has a rapid onset, develops quickly, and tends to be short in duration. Acute diseases can range from minor illnesses such as a common cold or flu, to more severe conditions such as pneumonia, meningitis, or a heart attack. These types of diseases often have clear symptoms that are easy to identify, and they may require immediate medical attention or treatment.

Acute diseases are typically caused by an external agent or factor, such as a bacterial or viral infection, a toxin, or an injury. They can also be the result of a sudden worsening of an existing chronic condition. In general, acute diseases are distinct from chronic diseases, which are long-term medical conditions that develop slowly over time and may require ongoing management and treatment.

Examples of acute diseases include:

* Acute bronchitis: a sudden inflammation of the airways in the lungs, often caused by a viral infection.
* Appendicitis: an inflammation of the appendix that can cause severe pain and requires surgical removal.
* Gastroenteritis: an inflammation of the stomach and intestines, often caused by a viral or bacterial infection.
* Migraine headaches: intense headaches that can last for hours or days, and are often accompanied by nausea, vomiting, and sensitivity to light and sound.
* Myocardial infarction (heart attack): a sudden blockage of blood flow to the heart muscle, often caused by a buildup of plaque in the coronary arteries.
* Pneumonia: an infection of the lungs that can cause coughing, chest pain, and difficulty breathing.
* Sinusitis: an inflammation of the sinuses, often caused by a viral or bacterial infection.

It's important to note that while some acute diseases may resolve on their own with rest and supportive care, others may require medical intervention or treatment to prevent complications and promote recovery. If you are experiencing symptoms of an acute disease, it is always best to seek medical attention to ensure proper diagnosis and treatment.

I'm sorry for any confusion, but "siblings" is not a medical term. It is a term used in genealogy and sociology to refer to the brothers and sisters that someone has. Sibling relationships can have medical implications, such as when inherited genetic disorders are present in a family, but the term "siblings" itself does not have a specific medical definition.

A nuclear family, in medical and social sciences, refers to a family structure consisting of two married parents and their biological or adopted children living together in one household. It's the basic unit of a traditional family structure, typically comprising of a father (male parent), a mother (female parent) and their direct offspring. However, it's important to note that there are many different types of families and none is considered universally superior or normative. The concept of a nuclear family has evolved over time and varies across cultures and societies.

Cell separation is a process used to separate and isolate specific cell types from a heterogeneous mixture of cells. This can be accomplished through various physical or biological methods, depending on the characteristics of the cells of interest. Some common techniques for cell separation include:

1. Density gradient centrifugation: In this method, a sample containing a mixture of cells is layered onto a density gradient medium and then centrifuged. The cells are separated based on their size, density, and sedimentation rate, with denser cells settling closer to the bottom of the tube and less dense cells remaining near the top.

2. Magnetic-activated cell sorting (MACS): This technique uses magnetic beads coated with antibodies that bind to specific cell surface markers. The labeled cells are then passed through a column placed in a magnetic field, which retains the magnetically labeled cells while allowing unlabeled cells to flow through.

3. Fluorescence-activated cell sorting (FACS): In this method, cells are stained with fluorochrome-conjugated antibodies that recognize specific cell surface or intracellular markers. The stained cells are then passed through a laser beam, which excites the fluorophores and allows for the detection and sorting of individual cells based on their fluorescence profile.

4. Filtration: This simple method relies on the physical size differences between cells to separate them. Cells can be passed through filters with pore sizes that allow smaller cells to pass through while retaining larger cells.

5. Enzymatic digestion: In some cases, cells can be separated by enzymatically dissociating tissues into single-cell suspensions and then using various separation techniques to isolate specific cell types.

These methods are widely used in research and clinical settings for applications such as isolating immune cells, stem cells, or tumor cells from biological samples.

A lymphocyte transfusion is not a standard medical practice. However, the term "lymphocyte transfusion" generally refers to the infusion of lymphocytes, a type of white blood cell, from a donor to a recipient. This procedure is rarely performed and primarily used in research or experimental settings, such as in the context of adoptive immunotherapy for cancer treatment.

In adoptive immunotherapy, T lymphocytes (a subtype of lymphocytes) are collected from the patient or a donor, activated, expanded in the laboratory, and then reinfused into the patient to enhance their immune response against cancer cells. This is not a common procedure and should only be performed under the guidance of experienced medical professionals in specialized centers.

It's important to note that lymphocyte transfusions are different from stem cell or bone marrow transplants, which involve the infusion of hematopoietic stem cells to reconstitute the recipient's entire blood and immune system.

Mononuclear leukocytes are a type of white blood cells (leukocytes) that have a single, large nucleus. They include lymphocytes (B-cells, T-cells, and natural killer cells), monocytes, and dendritic cells. These cells play important roles in the body's immune system, including defending against infection and disease, and participating in immune responses and surveillance. Mononuclear leukocytes can be found in the bloodstream as well as in tissues throughout the body. They are involved in both innate and adaptive immunity, providing specific and nonspecific defense mechanisms to protect the body from harmful pathogens and other threats.

Bone marrow cells are the types of cells found within the bone marrow, which is the spongy tissue inside certain bones in the body. The main function of bone marrow is to produce blood cells. There are two types of bone marrow: red and yellow. Red bone marrow is where most blood cell production takes place, while yellow bone marrow serves as a fat storage site.

The three main types of bone marrow cells are:

1. Hematopoietic stem cells (HSCs): These are immature cells that can differentiate into any type of blood cell, including red blood cells, white blood cells, and platelets. They have the ability to self-renew, meaning they can divide and create more hematopoietic stem cells.
2. Red blood cell progenitors: These are immature cells that will develop into mature red blood cells, also known as erythrocytes. Red blood cells carry oxygen from the lungs to the body's tissues and carbon dioxide back to the lungs.
3. Myeloid and lymphoid white blood cell progenitors: These are immature cells that will develop into various types of white blood cells, which play a crucial role in the body's immune system by fighting infections and diseases. Myeloid progenitors give rise to granulocytes (neutrophils, eosinophils, and basophils), monocytes, and megakaryocytes (which eventually become platelets). Lymphoid progenitors differentiate into B cells, T cells, and natural killer (NK) cells.

Bone marrow cells are essential for maintaining a healthy blood cell count and immune system function. Abnormalities in bone marrow cells can lead to various medical conditions, such as anemia, leukopenia, leukocytosis, thrombocytopenia, or thrombocytosis, depending on the specific type of blood cell affected. Additionally, bone marrow cells are often used in transplantation procedures to treat patients with certain types of cancer, such as leukemia and lymphoma, or other hematologic disorders.

Adult stem cells, also known as somatic stem cells, are undifferentiated cells found in specialized tissues or organs throughout the body of a developed organism. Unlike embryonic stem cells, which are derived from blastocysts and have the ability to differentiate into any cell type in the body (pluripotency), adult stem cells are typically more limited in their differentiation potential, meaning they can only give rise to specific types of cells within the tissue or organ where they reside.

Adult stem cells serve to maintain and repair tissues by replenishing dying or damaged cells. They can divide and self-renew over time, producing one daughter cell that remains a stem cell and another that differentiates into a mature, functional cell type. The most well-known adult stem cells are hematopoietic stem cells, which give rise to all types of blood cells, and mesenchymal stem cells, which can differentiate into various connective tissue cells such as bone, cartilage, fat, and muscle.

The potential therapeutic use of adult stem cells has been explored in various medical fields, including regenerative medicine and cancer therapy. However, their limited differentiation capacity and the challenges associated with isolating and expanding them in culture have hindered their widespread application. Recent advances in stem cell research, such as the development of techniques to reprogram adult cells into induced pluripotent stem cells (iPSCs), have opened new avenues for studying and harnessing the therapeutic potential of these cells.

Epirubicin is an anthracycline antibiotic used in cancer chemotherapy. It works by interfering with the DNA in cancer cells and preventing them from dividing and growing. Epirubicin is often used to treat breast cancer, lung cancer, stomach cancer, and ovarian cancer.

Like other anthracyclines, epirubicin can cause side effects such as hair loss, nausea and vomiting, mouth sores, and increased risk of infection due to damage to the bone marrow. It can also cause heart problems, including congestive heart failure, especially when given in high doses or when combined with other chemotherapy drugs that can also harm the heart.

Epirubicin is usually given by injection into a vein (intravenously) and is typically administered in cycles, with breaks between treatment periods to allow the body to recover from any side effects. The dose and schedule of epirubicin may vary depending on the type and stage of cancer being treated, as well as other factors such as the patient's overall health and any other medical conditions they may have.

A platelet transfusion is the process of medically administering platelets, which are small blood cells that help your body form clots to stop bleeding. Platelet transfusions are often given to patients with low platelet counts or dysfunctional platelets due to various reasons such as chemotherapy, bone marrow transplantation, disseminated intravascular coagulation (DIC), and other medical conditions leading to increased consumption or destruction of platelets. This procedure helps to prevent or treat bleeding complications in these patients. It's important to note that platelet transfusions should be given under the supervision of a healthcare professional, taking into account the patient's clinical condition, platelet count, and potential risks associated with transfusion reactions.

Immunomagnetic separation (IMS) is a medical diagnostic technique that combines the specificity of antibodies with the magnetic properties of nanoparticles to isolate and concentrate target cells or molecules from a sample. This method is widely used in research and clinical laboratories for the detection and analysis of various biological components, including bacteria, viruses, parasites, and tumor cells.

The process involves the use of magnetic beads coated with specific antibodies that bind to the target cells or molecules. Once bound, an external magnetic field is applied to separate the labeled cells or molecules from the unbound components in the sample. The isolated targets can then be washed, concentrated, and further analyzed using various methods such as polymerase chain reaction (PCR), flow cytometry, or microscopy.

IMS offers several advantages over traditional separation techniques, including high specificity, gentle handling of cells, minimal sample manipulation, and the ability to process large volumes of samples. These features make IMS a valuable tool in various fields, such as immunology, microbiology, hematology, oncology, and molecular biology.

Fetal blood refers to the blood circulating in a fetus during pregnancy. It is essential for the growth and development of the fetus, as it carries oxygen and nutrients from the placenta to the developing tissues and organs. Fetal blood also removes waste products, such as carbon dioxide, from the fetal tissues and transports them to the placenta for elimination.

Fetal blood has several unique characteristics that distinguish it from adult blood. For example, fetal hemoglobin (HbF) is the primary type of hemoglobin found in fetal blood, whereas adults primarily have adult hemoglobin (HbA). Fetal hemoglobin has a higher affinity for oxygen than adult hemoglobin, which allows it to more efficiently extract oxygen from the maternal blood in the placenta.

Additionally, fetal blood contains a higher proportion of reticulocytes (immature red blood cells) and nucleated red blood cells compared to adult blood. These differences reflect the high turnover rate of red blood cells in the developing fetus and the need for rapid growth and development.

Examination of fetal blood can provide important information about the health and well-being of the fetus during pregnancy. For example, fetal blood sampling (also known as cordocentesis or percutaneous umbilical blood sampling) can be used to diagnose genetic disorders, infections, and other conditions that may affect fetal development. However, this procedure carries risks, including preterm labor, infection, and fetal loss, and is typically only performed when there is a significant risk of fetal compromise or when other diagnostic tests have been inconclusive.

"Unrelated donors" in the context of medicine, specifically in transplantation medicine, refer to individuals who are not genetically related to the recipient and are searched for in national or international registries. They are identified as having a similar human leukocyte antigen (HLA) type to the recipient, making them suitable to donate stem cells for bone marrow transplantation or solid organs such as kidneys, liver, heart, lungs, and pancreas.

The process of finding an unrelated donor is coordinated by transplant centers and registries, such as the National Marrow Donor Program (NMDP) in the United States or World Marrow Donor Association (WMDA) globally. The success of finding a suitable unrelated donor depends on various factors, including the recipient's HLA type, age, ethnicity, and medical urgency.

It is important to note that unrelated donors undergo rigorous screening processes to ensure their health and suitability for donation, as well as to minimize any potential risks to both the donor and the recipient.

Polymerase Chain Reaction (PCR) is a laboratory technique used to amplify specific regions of DNA. It enables the production of thousands to millions of copies of a particular DNA sequence in a rapid and efficient manner, making it an essential tool in various fields such as molecular biology, medical diagnostics, forensic science, and research.

The PCR process involves repeated cycles of heating and cooling to separate the DNA strands, allow primers (short sequences of single-stranded DNA) to attach to the target regions, and extend these primers using an enzyme called Taq polymerase, resulting in the exponential amplification of the desired DNA segment.

In a medical context, PCR is often used for detecting and quantifying specific pathogens (viruses, bacteria, fungi, or parasites) in clinical samples, identifying genetic mutations or polymorphisms associated with diseases, monitoring disease progression, and evaluating treatment effectiveness.

Cell differentiation is the process by which a less specialized cell, or stem cell, becomes a more specialized cell type with specific functions and structures. This process involves changes in gene expression, which are regulated by various intracellular signaling pathways and transcription factors. Differentiation results in the development of distinct cell types that make up tissues and organs in multicellular organisms. It is a crucial aspect of embryonic development, tissue repair, and maintenance of homeostasis in the body.

A chronic disease is a long-term medical condition that often progresses slowly over a period of years and requires ongoing management and care. These diseases are typically not fully curable, but symptoms can be managed to improve quality of life. Common chronic diseases include heart disease, stroke, cancer, diabetes, arthritis, and COPD (chronic obstructive pulmonary disease). They are often associated with advanced age, although they can also affect children and younger adults. Chronic diseases can have significant impacts on individuals' physical, emotional, and social well-being, as well as on healthcare systems and society at large.

Antilymphocyte serum (ALS) is a type of immune serum that contains antibodies against human lymphocytes. It is produced by immunizing animals, such as horses or rabbits, with human lymphocytes to stimulate an immune response and the production of anti-lymphocyte antibodies. The resulting serum is then collected and can be used as a therapeutic agent to suppress the activity of the immune system in certain medical conditions.

ALS is primarily used in the treatment of transplant rejection, particularly in organ transplantation, where it helps to prevent the recipient's immune system from attacking and rejecting the transplanted organ. It can also be used in the management of autoimmune diseases, such as rheumatoid arthritis and lupus, to suppress the overactive immune response that contributes to these conditions.

It is important to note that the use of ALS carries a risk of side effects, including allergic reactions, fever, and decreased white blood cell counts. Close monitoring and appropriate management of these potential adverse events are essential during treatment with ALS.

Breast neoplasms refer to abnormal growths in the breast tissue that can be benign or malignant. Benign breast neoplasms are non-cancerous tumors or growths, while malignant breast neoplasms are cancerous tumors that can invade surrounding tissues and spread to other parts of the body.

Breast neoplasms can arise from different types of cells in the breast, including milk ducts, milk sacs (lobules), or connective tissue. The most common type of breast cancer is ductal carcinoma, which starts in the milk ducts and can spread to other parts of the breast and nearby structures.

Breast neoplasms are usually detected through screening methods such as mammography, ultrasound, or MRI, or through self-examination or clinical examination. Treatment options for breast neoplasms depend on several factors, including the type and stage of the tumor, the patient's age and overall health, and personal preferences. Treatment may include surgery, radiation therapy, chemotherapy, hormone therapy, or targeted therapy.

In epidemiology, the incidence of a disease is defined as the number of new cases of that disease within a specific population over a certain period of time. It is typically expressed as a rate, with the number of new cases in the numerator and the size of the population at risk in the denominator. Incidence provides information about the risk of developing a disease during a given time period and can be used to compare disease rates between different populations or to monitor trends in disease occurrence over time.

Leukocyte transfusion, also known as white blood cell (WBC) transfusion, involves the intravenous administration of leukocytes (white blood cells) from a donor to a recipient. This procedure is typically used in patients with severe immunodeficiency or those undergoing bone marrow transplantation, where they are unable to produce sufficient white blood cells to fight off infections.

Leukocyte transfusions can help boost the recipient's immune system and provide them with temporary protection against infections. However, this procedure carries some risks, including febrile non-hemolytic transfusion reactions, allergic reactions, transmission of infectious diseases, and the potential for transfusion-associated graft-versus-host disease (TA-GVHD). Therefore, leukocyte transfusions are usually reserved for specific clinical situations where the benefits outweigh the risks.

Neutropenia is a condition characterized by an abnormally low concentration (less than 1500 cells/mm3) of neutrophils, a type of white blood cell that plays a crucial role in fighting off bacterial and fungal infections. Neutrophils are essential components of the innate immune system, and their main function is to engulf and destroy microorganisms that can cause harm to the body.

Neutropenia can be classified as mild, moderate, or severe based on the severity of the neutrophil count reduction:

* Mild neutropenia: Neutrophil count between 1000-1500 cells/mm3
* Moderate neutropenia: Neutrophil count between 500-1000 cells/mm3
* Severe neutropenia: Neutrophil count below 500 cells/mm3

Severe neutropenia significantly increases the risk of developing infections, as the body's ability to fight off microorganisms is severely compromised. Common causes of neutropenia include viral infections, certain medications (such as chemotherapy or antibiotics), autoimmune disorders, and congenital conditions affecting bone marrow function. Treatment for neutropenia typically involves addressing the underlying cause, administering granulocyte-colony stimulating factors to boost neutrophil production, and providing appropriate antimicrobial therapy to prevent or treat infections.

"Cells, cultured" is a medical term that refers to cells that have been removed from an organism and grown in controlled laboratory conditions outside of the body. This process is called cell culture and it allows scientists to study cells in a more controlled and accessible environment than they would have inside the body. Cultured cells can be derived from a variety of sources, including tissues, organs, or fluids from humans, animals, or cell lines that have been previously established in the laboratory.

Cell culture involves several steps, including isolation of the cells from the tissue, purification and characterization of the cells, and maintenance of the cells in appropriate growth conditions. The cells are typically grown in specialized media that contain nutrients, growth factors, and other components necessary for their survival and proliferation. Cultured cells can be used for a variety of purposes, including basic research, drug development and testing, and production of biological products such as vaccines and gene therapies.

It is important to note that cultured cells may behave differently than they do in the body, and results obtained from cell culture studies may not always translate directly to human physiology or disease. Therefore, it is essential to validate findings from cell culture experiments using additional models and ultimately in clinical trials involving human subjects.

Prochlorperazine is an antipsychotic drug, specifically a phenothiazine derivative. It works by blocking dopamine receptors in the brain, which helps to reduce psychotic symptoms such as hallucinations and delusions, and also has antiemetic (anti-nausea and vomiting) effects.

Prochlorperazine is used to treat various conditions, including:

* Schizophrenia and other psychotic disorders
* Nausea and vomiting, including motion sickness and postoperative nausea and vomiting
* Severe anxiety or agitation
* Tension headaches

The drug can be administered orally, intramuscularly, or rectally, depending on the formulation. Common side effects of prochlorperazine include drowsiness, dry mouth, blurred vision, and constipation. More serious side effects can include neurological symptoms such as tardive dyskinesia (involuntary movements), neuroleptic malignant syndrome (a life-threatening condition characterized by fever, muscle rigidity, and autonomic dysfunction), and seizures. Prochlorperazine should be used with caution in elderly patients, those with a history of seizures or cardiovascular disease, and those taking other medications that may interact with it.

Donor selection is the process of evaluating and choosing potential organ, tissue, or stem cell donors based on various medical and non-medical criteria to ensure the safety and efficacy of the transplantation. The goal of donor selection is to identify a compatible donor with minimal risk of rejection and transmission of infectious diseases while also considering ethical and legal considerations.

Medical criteria for donor selection may include:

1. Age: Donors are typically required to be within a certain age range, depending on the type of organ or tissue being donated.
2. Blood type and human leukocyte antigen (HLA) typing: Compatibility between the donor's and recipient's blood types and HLA markers is crucial to reduce the risk of rejection.
3. Medical history: Donors must undergo a thorough medical evaluation, including a review of their medical history, physical examination, and laboratory tests to assess their overall health and identify any potential risks or contraindications for donation.
4. Infectious disease screening: Donors are tested for various infectious diseases, such as HIV, hepatitis B and C, syphilis, and cytomegalovirus (CMV), among others, to ensure they do not transmit infections to the recipient.
5. Tissue typing: For organ transplants, tissue typing is performed to assess the compatibility of the donor's and recipient's major histocompatibility complex (MHC) antigens, which play a significant role in the immune response and rejection risk.

Non-medical criteria for donor selection may include:

1. Consent: Donors must provide informed consent for organ or tissue donation, and their next of kin or legal representative may be involved in the decision-making process for deceased donors.
2. Legal considerations: There are specific laws and regulations governing organ and tissue donation that must be followed, such as age restrictions, geographical proximity between the donor and recipient, and cultural or religious beliefs.
3. Ethical considerations: Donor selection should adhere to ethical principles, such as fairness, respect for autonomy, and non-maleficence, to ensure that the process is transparent, equitable, and free from coercion or exploitation.

A Colony-Forming Units (CFU) assay is a type of laboratory test used to measure the number of viable, or living, cells in a sample. It is commonly used to enumerate bacteria, yeast, and other microorganisms. The test involves placing a known volume of the sample onto a nutrient-agar plate, which provides a solid growth surface for the cells. The plate is then incubated under conditions that allow the cells to grow and form colonies. Each colony that forms on the plate represents a single viable cell from the original sample. By counting the number of colonies and multiplying by the known volume of the sample, the total number of viable cells in the sample can be calculated. This information is useful in a variety of applications, including monitoring microbial populations, assessing the effectiveness of disinfection procedures, and studying microbial growth and survival.

Life tables are statistical tools used in actuarial science, demography, and public health to estimate the mortality rate and survival rates of a population. They provide a data-driven representation of the probability that individuals of a certain age will die before their next birthday (the death rate) or live to a particular age (the survival rate).

Life tables are constructed using data on the number of deaths and the size of the population in specific age groups over a given period. These tables typically include several columns representing different variables, such as:

1. Age group or interval: The age range for which the data is being presented (e.g., 0-1 year, 1-5 years, 5-10 years, etc.).
2. Number of people in the population: The size of the population within each age group.
3. Number of deaths: The number of individuals who died during the study period within each age group.
4. Death rate: The probability that an individual in a given age group will die before their next birthday. It is calculated as the number of deaths divided by the size of the population for that age group.
5. Survival rate: The probability that an individual in a given age group will survive to a specific age or older. It is calculated using the death rates from earlier age groups.
6. Life expectancy: The average number of years a person is expected to live, based on their current age and mortality rates for each subsequent age group.

Life tables are essential in various fields, including insurance, pension planning, social security administration, and healthcare policy development. They help researchers and policymakers understand the health status and demographic trends of populations, allowing them to make informed decisions about resource allocation, program development, and public health interventions.

A lymphocyte count is a laboratory test that measures the number of white blood cells called lymphocytes in a sample of blood. Lymphocytes are a vital part of the immune system and help fight off infections and diseases. A normal lymphocyte count ranges from 1,000 to 4,800 cells per microliter (µL) of blood for adults.

An abnormal lymphocyte count can indicate an infection, immune disorder, or blood cancer. A low lymphocyte count is called lymphopenia, while a high lymphocyte count is called lymphocytosis. The cause of an abnormal lymphocyte count should be investigated through further testing and clinical evaluation.

Medical Definition:

"Risk factors" are any attribute, characteristic or exposure of an individual that increases the likelihood of developing a disease or injury. They can be divided into modifiable and non-modifiable risk factors. Modifiable risk factors are those that can be changed through lifestyle choices or medical treatment, while non-modifiable risk factors are inherent traits such as age, gender, or genetic predisposition. Examples of modifiable risk factors include smoking, alcohol consumption, physical inactivity, and unhealthy diet, while non-modifiable risk factors include age, sex, and family history. It is important to note that having a risk factor does not guarantee that a person will develop the disease, but rather indicates an increased susceptibility.

Fever, also known as pyrexia or febrile response, is a common medical sign characterized by an elevation in core body temperature above the normal range of 36.5-37.5°C (97.7-99.5°F) due to a dysregulation of the body's thermoregulatory system. It is often a response to an infection, inflammation, or other underlying medical conditions, and it serves as a part of the immune system's effort to combat the invading pathogens or to repair damaged tissues.

Fevers can be classified based on their magnitude:

* Low-grade fever: 37.5-38°C (99.5-100.4°F)
* Moderate fever: 38-39°C (100.4-102.2°F)
* High-grade or severe fever: above 39°C (102.2°F)

It is important to note that a single elevated temperature reading does not necessarily indicate the presence of a fever, as body temperature can fluctuate throughout the day and can be influenced by various factors such as physical activity, environmental conditions, and the menstrual cycle in females. The diagnosis of fever typically requires the confirmation of an elevated core body temperature on at least two occasions or a consistently high temperature over a period of time.

While fevers are generally considered beneficial in fighting off infections and promoting recovery, extremely high temperatures or prolonged febrile states may necessitate medical intervention to prevent potential complications such as dehydration, seizures, or damage to vital organs.

Heart transplantation is a surgical procedure where a diseased, damaged, or failing heart is removed and replaced with a healthy donor heart. This procedure is usually considered as a last resort for patients with end-stage heart failure or severe coronary artery disease who have not responded to other treatments. The donor heart typically comes from a brain-dead individual whose family has agreed to donate their loved one's organs for transplantation. Heart transplantation is a complex and highly specialized procedure that requires a multidisciplinary team of healthcare professionals, including cardiologists, cardiac surgeons, anesthesiologists, perfusionists, nurses, and other support staff. The success rates for heart transplantation have improved significantly over the past few decades, with many patients experiencing improved quality of life and increased survival rates. However, recipients of heart transplants require lifelong immunosuppressive therapy to prevent rejection of the donor heart, which can increase the risk of infections and other complications.

Pluripotent stem cells are a type of undifferentiated stem cell that have the ability to differentiate into any cell type of the three germ layers (endoderm, mesoderm, and ectoderm) of a developing embryo. These cells can give rise to all the cell types that make up the human body, with the exception of those that form the extra-embryonic tissues such as the placenta.

Pluripotent stem cells are characterized by their ability to self-renew, which means they can divide and produce more pluripotent stem cells, and differentiate, which means they can give rise to specialized cell types with specific functions. Pluripotent stem cells can be derived from embryos at the blastocyst stage of development or generated in the lab through a process called induced pluripotency, where adult cells are reprogrammed to have the properties of embryonic stem cells.

Pluripotent stem cells hold great promise for regenerative medicine and tissue engineering because they can be used to generate large numbers of specific cell types that can potentially replace or repair damaged or diseased tissues in the body. However, their use is still a subject of ethical debate due to concerns about the source of embryonic stem cells and the potential risks associated with their use in clinical applications.

Methylprednisolone is a synthetic glucocorticoid drug, which is a class of hormones that naturally occur in the body and are produced by the adrenal gland. It is often used to treat various medical conditions such as inflammation, allergies, and autoimmune disorders. Methylprednisolone works by reducing the activity of the immune system, which helps to reduce symptoms such as swelling, pain, and redness.

Methylprednisolone is available in several forms, including tablets, oral suspension, and injectable solutions. It may be used for short-term or long-term treatment, depending on the condition being treated. Common side effects of methylprednisolone include increased appetite, weight gain, insomnia, mood changes, and increased susceptibility to infections. Long-term use of methylprednisolone can lead to more serious side effects such as osteoporosis, cataracts, and adrenal suppression.

It is important to note that methylprednisolone should be used under the close supervision of a healthcare provider, as it can cause serious side effects if not used properly. The dosage and duration of treatment will depend on various factors such as the patient's age, weight, medical history, and the condition being treated.

Leukemia, myeloid is a type of cancer that originates in the bone marrow, where blood cells are produced. Myeloid leukemia affects the myeloid cells, which include red blood cells, platelets, and most types of white blood cells. In this condition, the bone marrow produces abnormal myeloid cells that do not mature properly and accumulate in the bone marrow and blood. These abnormal cells hinder the production of normal blood cells, leading to various symptoms such as anemia, fatigue, increased risk of infections, and easy bruising or bleeding.

There are several types of myeloid leukemias, including acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). AML progresses rapidly and requires immediate treatment, while CML tends to progress more slowly. The exact causes of myeloid leukemia are not fully understood, but risk factors include exposure to radiation or certain chemicals, smoking, genetic disorders, and a history of chemotherapy or other cancer treatments.

Hepatic Veno-Occlusive Disease (VOD), also known as Sinusoidal Obstruction Syndrome (SOS), is a medical condition characterized by the obstruction or blockage of the small veins (venules) in the liver. This results in the backup of blood in the liver, leading to swelling and damage to the liver cells.

The obstruction is usually caused by the injury and inflammation of the endothelial cells lining the venules, which can be triggered by various factors such as chemotherapy drugs, radiation therapy, bone marrow transplantation, or exposure to certain toxins. The damage to the liver can lead to symptoms such as fluid accumulation in the abdomen (ascites), enlarged liver, jaundice, and in severe cases, liver failure.

The diagnosis of VOD/SOS is typically made based on a combination of clinical signs, symptoms, and imaging studies, such as ultrasound or CT scan. In some cases, a liver biopsy may be necessary to confirm the diagnosis. Treatment for VOD/SOS is primarily supportive, with the goal of managing symptoms and preventing complications. This may include medications to reduce swelling, improve liver function, and prevent infection. In severe cases, liver transplantation may be considered as a last resort.

Stem Cell Factor (SCF), also known as Kit Ligand or Steel Factor, is a growth factor that plays a crucial role in the regulation of hematopoiesis, which is the process of producing various blood cells. It is a glycoprotein that binds to the c-Kit receptor found on hematopoietic stem cells and progenitor cells, promoting their survival, proliferation, and differentiation into mature blood cells.

SCF is involved in the development and function of several types of blood cells, including red blood cells, white blood cells, and platelets. It also plays a role in the maintenance and self-renewal of hematopoietic stem cells, which are essential for the continuous production of new blood cells throughout an individual's lifetime.

In addition to its role in hematopoiesis, SCF has been implicated in various other biological processes, such as melanogenesis, gametogenesis, and tissue repair and regeneration. Dysregulation of SCF signaling has been associated with several diseases, including certain types of cancer, bone marrow failure disorders, and autoimmune diseases.

Podophyllotoxin is a pharmaceutical agent derived from the podophyllum plant. It is an antimitotic compound that inhibits microtubule assembly, leading to cell cycle arrest and apoptosis. It is primarily used in topical form as a treatment for genital warts, caused by certain types of human papillomavirus (HPV). Podophyllotoxin works by interfering with the growth of the wart cells, eventually causing them to die off.

It's important to note that podophyllotoxin is a potent cytotoxic agent and should only be used under the supervision of a healthcare professional. It should not be taken orally or applied to open wounds, and it should be kept out of reach of children.

Chimerism is a medical term that refers to the presence of genetically distinct cell populations within an individual. This phenomenon can occur naturally or as a result of a medical procedure such as a stem cell transplant. In natural chimerism, an individual may have cells with different genetic compositions due to events that occurred during embryonic development, such as the fusion of two fertilized eggs (also known as "twinning") or the exchange of cells between twins in utero.

In the context of a stem cell transplant, chimerism can occur when a donor's stem cells engraft and begin to produce new blood cells in the recipient's body. This can result in the presence of both the recipient's own cells and the donor's cells in the recipient's body. The degree of chimerism can vary, with some individuals showing complete chimerism (where all blood cells are derived from the donor) or mixed chimerism (where both the recipient's and donor's cells coexist).

Monitoring chimerism levels is important in stem cell transplantation to assess the success of the procedure and to detect any potential signs of graft rejection or relapse of the original disease.

Lung transplantation is a surgical procedure where one or both diseased lungs are removed and replaced with healthy lungs from a deceased donor. It is typically considered as a treatment option for patients with end-stage lung diseases, such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, idiopathic pulmonary fibrosis, and alpha-1 antitrypsin deficiency, who have exhausted all other medical treatments and continue to suffer from severe respiratory failure.

The procedure involves several steps, including evaluating the patient's eligibility for transplantation, matching the donor's lung size and blood type with the recipient, and performing the surgery under general anesthesia. After the surgery, patients require close monitoring and lifelong immunosuppressive therapy to prevent rejection of the new lungs.

Lung transplantation can significantly improve the quality of life and survival rates for some patients with end-stage lung disease, but it is not without risks, including infection, bleeding, and rejection. Therefore, careful consideration and thorough evaluation are necessary before pursuing this treatment option.

A stem cell niche is a specific microenvironment in which stem cells reside, interact with surrounding cells and receive molecular signals that regulate their self-renewal, proliferation, differentiation, and survival. This specialized niche provides the necessary conditions for maintaining the undifferentiated state of stem cells and controlling their fate decisions. The components of a stem cell niche typically include various cell types (such as supporting cells, immune cells, and blood vessels), extracellular matrix proteins, signaling molecules, and physical factors like oxygen tension and mechanical stress. Together, these elements create a unique microenvironment that helps to preserve the functional integrity and potential of stem cells for tissue repair, regeneration, and homeostasis.

Neural stem cells (NSCs) are a type of undifferentiated cells found in the central nervous system, including the brain and spinal cord. They have the ability to self-renew and generate the main types of cells found in the nervous system, such as neurons, astrocytes, and oligodendrocytes. NSCs are capable of dividing symmetrically to increase their own population or asymmetrically to produce one stem cell and one differentiated cell. They play a crucial role in the development and maintenance of the nervous system, and have the potential to be used in regenerative medicine and therapies for neurological disorders and injuries.

Cryopreservation is a medical procedure that involves the preservation of cells, tissues, or organs by cooling them to very low temperatures, typically below -150°C. This is usually achieved using liquid nitrogen. The low temperature slows down or stops biological activity, including chemical reactions and cellular metabolism, which helps to prevent damage and decay.

The cells, tissues, or organs that are being cryopreserved must be treated with a cryoprotectant solution before cooling to prevent the formation of ice crystals, which can cause significant damage. Once cooled, the samples are stored in specialized containers or tanks until they are needed for use.

Cryopreservation is commonly used in assisted reproductive technologies, such as the preservation of sperm, eggs, and embryos for fertility treatments. It is also used in research, including the storage of cell lines and stem cells, and in clinical settings, such as the preservation of skin grafts and corneas for transplantation.

Tissue and organ harvesting is the surgical removal of healthy tissues or organs from a living or deceased donor for the purpose of transplantation into another person in need of a transplant. This procedure is performed with great care, adhering to strict medical standards and ethical guidelines, to ensure the safety and well-being of both the donor and the recipient.

In the case of living donors, the harvested tissue or organ is typically removed from a site that can be safely spared, such as a kidney, a portion of the liver, or a segment of the lung. The donor must undergo extensive medical evaluation to ensure they are physically and psychologically suitable for the procedure.

For deceased donors, tissue and organ harvesting is performed in a manner that respects their wishes and those of their family, as well as adheres to legal and ethical requirements. Organs and tissues must be recovered promptly after death to maintain their viability for transplantation.

Tissue and organ harvesting is an essential component of the transplant process, allowing individuals with terminal illnesses or severe injuries to receive life-saving or life-enhancing treatments. It is a complex and highly regulated medical practice that requires specialized training, expertise, and coordination among healthcare professionals, donor families, and recipients.

"Cell count" is a medical term that refers to the process of determining the number of cells present in a given volume or sample of fluid or tissue. This can be done through various laboratory methods, such as counting individual cells under a microscope using a specialized grid called a hemocytometer, or using automated cell counters that use light scattering and electrical impedance techniques to count and classify different types of cells.

Cell counts are used in a variety of medical contexts, including hematology (the study of blood and blood-forming tissues), microbiology (the study of microscopic organisms), and pathology (the study of diseases and their causes). For example, a complete blood count (CBC) is a routine laboratory test that includes a white blood cell (WBC) count, red blood cell (RBC) count, hemoglobin level, hematocrit value, and platelet count. Abnormal cell counts can indicate the presence of various medical conditions, such as infections, anemia, or leukemia.

Graft rejection is an immune response that occurs when transplanted tissue or organ (the graft) is recognized as foreign by the recipient's immune system, leading to the activation of immune cells to attack and destroy the graft. This results in the failure of the transplant and the need for additional medical intervention or another transplant. There are three types of graft rejection: hyperacute, acute, and chronic. Hyperacute rejection occurs immediately or soon after transplantation due to pre-existing antibodies against the graft. Acute rejection typically occurs within weeks to months post-transplant and is characterized by the infiltration of T-cells into the graft. Chronic rejection, which can occur months to years after transplantation, is a slow and progressive process characterized by fibrosis and tissue damage due to ongoing immune responses against the graft.

Mesenchymal Stromal Cells (MSCs) are a type of adult stem cells found in various tissues, including bone marrow, adipose tissue, and umbilical cord blood. They have the ability to differentiate into multiple cell types, such as osteoblasts, chondrocytes, and adipocytes, under specific conditions. MSCs also possess immunomodulatory properties, making them a promising tool in regenerative medicine and therapeutic strategies for various diseases, including autoimmune disorders and tissue injuries. It is important to note that the term "Mesenchymal Stem Cells" has been replaced by "Mesenchymal Stromal Cells" in the scientific community to better reflect their biological characteristics and potential functions.

Lymphocytes are a type of white blood cell that is an essential part of the immune system. They are responsible for recognizing and responding to potentially harmful substances such as viruses, bacteria, and other foreign invaders. There are two main types of lymphocytes: B-lymphocytes (B-cells) and T-lymphocytes (T-cells).

B-lymphocytes produce antibodies, which are proteins that help to neutralize or destroy foreign substances. When a B-cell encounters a foreign substance, it becomes activated and begins to divide and differentiate into plasma cells, which produce and secrete large amounts of antibodies. These antibodies bind to the foreign substance, marking it for destruction by other immune cells.

T-lymphocytes, on the other hand, are involved in cell-mediated immunity. They directly attack and destroy infected cells or cancerous cells. T-cells can also help to regulate the immune response by producing chemical signals that activate or inhibit other immune cells.

Lymphocytes are produced in the bone marrow and mature in either the bone marrow (B-cells) or the thymus gland (T-cells). They circulate throughout the body in the blood and lymphatic system, where they can be found in high concentrations in lymph nodes, the spleen, and other lymphoid organs.

Abnormalities in the number or function of lymphocytes can lead to a variety of immune-related disorders, including immunodeficiency diseases, autoimmune disorders, and cancer.

Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) is a type of cytokine, which is a small signaling protein involved in immune response and hematopoiesis (the formation of blood cells). GM-CSF's specific role is to stimulate the production, proliferation, and activation of granulocytes (a type of white blood cell that fights against infection) and macrophages (large white blood cells that eat foreign substances, bacteria, and dead or dying cells).

In medical terms, GM-CSF is often used in therapeutic settings to boost the production of white blood cells in patients undergoing chemotherapy or radiation treatment for cancer. This can help to reduce the risk of infection during these treatments. It can also be used to promote the growth and differentiation of stem cells in bone marrow transplant procedures.

Monoclonal antibodies are a type of antibody that are identical because they are produced by a single clone of cells. They are laboratory-produced molecules that act like human antibodies in the immune system. They can be designed to attach to specific proteins found on the surface of cancer cells, making them useful for targeting and treating cancer. Monoclonal antibodies can also be used as a therapy for other diseases, such as autoimmune disorders and inflammatory conditions.

Monoclonal antibodies are produced by fusing a single type of immune cell, called a B cell, with a tumor cell to create a hybrid cell, or hybridoma. This hybrid cell is then able to replicate indefinitely, producing a large number of identical copies of the original antibody. These antibodies can be further modified and engineered to enhance their ability to bind to specific targets, increase their stability, and improve their effectiveness as therapeutic agents.

Monoclonal antibodies have several mechanisms of action in cancer therapy. They can directly kill cancer cells by binding to them and triggering an immune response. They can also block the signals that promote cancer growth and survival. Additionally, monoclonal antibodies can be used to deliver drugs or radiation directly to cancer cells, increasing the effectiveness of these treatments while minimizing their side effects on healthy tissues.

Monoclonal antibodies have become an important tool in modern medicine, with several approved for use in cancer therapy and other diseases. They are continuing to be studied and developed as a promising approach to treating a wide range of medical conditions.

Cytomegalovirus (CMV) is a type of herpesvirus that can cause infection in humans. It is characterized by the enlargement of infected cells (cytomegaly) and is typically transmitted through close contact with an infected person, such as through saliva, urine, breast milk, or sexual contact.

CMV infection can also be acquired through organ transplantation, blood transfusions, or during pregnancy from mother to fetus. While many people infected with CMV experience no symptoms, it can cause serious complications in individuals with weakened immune systems, such as those undergoing cancer treatment or those who have HIV/AIDS.

In newborns, congenital CMV infection can lead to hearing loss, vision problems, and developmental delays. Pregnant women who become infected with CMV for the first time during pregnancy are at higher risk of transmitting the virus to their unborn child. There is no cure for CMV, but antiviral medications can help manage symptoms and reduce the risk of complications in severe cases.

An immunocompromised host refers to an individual who has a weakened or impaired immune system, making them more susceptible to infections and decreased ability to fight off pathogens. This condition can be congenital (present at birth) or acquired (developed during one's lifetime).

Acquired immunocompromised states may result from various factors such as medical treatments (e.g., chemotherapy, radiation therapy, immunosuppressive drugs), infections (e.g., HIV/AIDS), chronic diseases (e.g., diabetes, malnutrition, liver disease), or aging.

Immunocompromised hosts are at a higher risk for developing severe and life-threatening infections due to their reduced immune response. Therefore, they require special consideration when it comes to prevention, diagnosis, and treatment of infectious diseases.

Idarubicin is an anthracycline antibiotic used in the treatment of various types of cancer, including leukemia and lymphoma. It works by interfering with the DNA of cancer cells, which prevents them from dividing and growing. Idarubicin is often administered intravenously in a hospital or clinic setting. Common side effects include nausea, vomiting, hair loss, and an increased risk of infection due to lowered white blood cell counts. It can also cause damage to the heart muscle, so regular monitoring of cardiac function is necessary during treatment.

Organ transplantation is a surgical procedure where an organ or tissue from one person (donor) is removed and placed into another person (recipient) whose organ or tissue is not functioning properly or has been damaged beyond repair. The goal of this complex procedure is to replace the non-functioning organ with a healthy one, thereby improving the recipient's quality of life and overall survival.

Organs that can be transplanted include the heart, lungs, liver, kidneys, pancreas, and intestines. Tissues such as corneas, skin, heart valves, and bones can also be transplanted. The donor may be deceased or living, depending on the type of organ and the medical circumstances.

Organ transplantation is a significant and life-changing event for both the recipient and their families. It requires careful evaluation, matching, and coordination between the donor and recipient, as well as rigorous post-transplant care to ensure the success of the procedure and minimize the risk of rejection.

Neuroblastoma is defined as a type of cancer that develops from immature nerve cells found in the fetal or early postnatal period, called neuroblasts. It typically occurs in infants and young children, with around 90% of cases diagnosed before age five. The tumors often originate in the adrenal glands but can also arise in the neck, chest, abdomen, or spine. Neuroblastoma is characterized by its ability to spread (metastasize) to other parts of the body, including bones, bone marrow, lymph nodes, and skin. The severity and prognosis of neuroblastoma can vary widely, depending on factors such as the patient's age at diagnosis, stage of the disease, and specific genetic features of the tumor.

Induced Pluripotent Stem Cells (iPSCs) are a type of pluripotent stem cells that are generated from somatic cells, such as skin or blood cells, through the introduction of specific genes encoding transcription factors. These reprogrammed cells exhibit similar characteristics to embryonic stem cells, including the ability to differentiate into any cell type of the three germ layers (endoderm, mesoderm, and ectoderm). The discovery and development of iPSCs have opened up new possibilities in regenerative medicine, drug testing and development, and disease modeling, while avoiding ethical concerns associated with embryonic stem cells.

Acute Myelomonocytic Leukemia (AML-M4) is a subtype of acute myeloid leukemia, which is a type of cancer that affects the blood and bone marrow. In AML-M4, there is an overproduction of immature white blood cells called myeloblasts and monoblasts, which accumulate in the bone marrow and interfere with normal blood cell production.

These abnormal cells can also spread to other parts of the body, such as the skin, lymph nodes, and organs. Symptoms of AML-M4 may include fatigue, fever, frequent infections, easy bruising or bleeding, and shortness of breath. Treatment typically involves chemotherapy, radiation therapy, and/or stem cell transplantation.

It is important to note that a diagnosis of acute myelomonocytic leukemia should be made by a qualified healthcare professional based on a thorough medical evaluation, including a review of the patient's medical history, physical examination, and diagnostic test results.

Mitoxantrone is a synthetic antineoplastic anthracenedione drug, which means it is used to treat cancer. Its medical definition can be found in various authoritative sources such as the Merck Manual or Stedman's Medical Dictionary. Here's a brief version of the definition from MedlinePlus, a service of the US National Library of Medicine:

"Mitoxantrone is used to treat certain types of cancer (e.g., breast cancer, leukemia, non-Hodgkin's lymphoma). It works by slowing or stopping the growth of cancer cells. Mitoxantrone belongs to a class of drugs known as antitumor antibiotics."

Please note that this is a simplified definition meant for general information purposes and does not include all the details that might be present in a comprehensive medical definition. Always consult a healthcare professional or refer to authoritative resources for accurate, detailed, and up-to-date information.

'Cell lineage' is a term used in biology and medicine to describe the developmental history or relationship of a cell or group of cells to other cells, tracing back to the original progenitor or stem cell. It refers to the series of cell divisions and differentiation events that give rise to specific types of cells in an organism over time.

In simpler terms, cell lineage is like a family tree for cells, showing how they are related to each other through a chain of cell division and specialization events. This concept is important in understanding the development, growth, and maintenance of tissues and organs in living beings.

Circulating neoplastic cells (CNCs) are defined as malignant cancer cells that have detached from the primary tumor site and are found circulating in the peripheral blood. These cells have undergone genetic and epigenetic changes, leading to uncontrolled cell growth and division, and can form new tumors at distant sites in the body, a process known as metastasis.

The presence of CNCs has been shown to be a prognostic factor for poor outcomes in various types of cancer, including breast, colon, and prostate cancer. The detection and characterization of CNCs can provide valuable information about the tumor's biology, aggressiveness, and response to therapy, allowing for more personalized treatment approaches.

However, the detection of CNCs is challenging due to their rarity in the bloodstream, with only a few cells present among billions of normal blood cells. Therefore, highly sensitive methods such as flow cytometry, polymerase chain reaction (PCR), and next-generation sequencing are used for their identification and quantification.

A dose-response relationship in the context of drugs refers to the changes in the effects or symptoms that occur as the dose of a drug is increased or decreased. Generally, as the dose of a drug is increased, the severity or intensity of its effects also increases. Conversely, as the dose is decreased, the effects of the drug become less severe or may disappear altogether.

The dose-response relationship is an important concept in pharmacology and toxicology because it helps to establish the safe and effective dosage range for a drug. By understanding how changes in the dose of a drug affect its therapeutic and adverse effects, healthcare providers can optimize treatment plans for their patients while minimizing the risk of harm.

The dose-response relationship is typically depicted as a curve that shows the relationship between the dose of a drug and its effect. The shape of the curve may vary depending on the drug and the specific effect being measured. Some drugs may have a steep dose-response curve, meaning that small changes in the dose can result in large differences in the effect. Other drugs may have a more gradual dose-response curve, where larger changes in the dose are needed to produce significant effects.

In addition to helping establish safe and effective dosages, the dose-response relationship is also used to evaluate the potential therapeutic benefits and risks of new drugs during clinical trials. By systematically testing different doses of a drug in controlled studies, researchers can identify the optimal dosage range for the drug and assess its safety and efficacy.

Monoclonal murine-derived antibodies are a type of laboratory-produced antibody that is identical in structure, having been derived from a single clone of cells. These antibodies are created using mouse cells and are therefore composed entirely of mouse immune proteins. They are designed to bind specifically to a particular target protein or antigen, making them useful tools for research, diagnostic testing, and therapeutic applications.

Monoclonal antibodies offer several advantages over polyclonal antibodies (which are derived from multiple clones of cells and can recognize multiple epitopes on an antigen). Monoclonal antibodies have a consistent and uniform structure, making them more reliable for research and diagnostic purposes. They also have higher specificity and affinity for their target antigens, allowing for more sensitive detection and measurement.

However, there are some limitations to using monoclonal murine-derived antibodies in therapeutic applications. Because they are composed entirely of mouse proteins, they can elicit an immune response in humans, leading to the production of human anti-mouse antibodies (HAMA) that can neutralize their effectiveness. To overcome this limitation, researchers have developed chimeric and humanized monoclonal antibodies that incorporate human protein sequences, reducing the risk of an immune response.

Granulocytes are a type of white blood cell that plays a crucial role in the body's immune system. They are called granulocytes because they contain small granules in their cytoplasm, which are filled with various enzymes and proteins that help them fight off infections and destroy foreign substances.

There are three types of granulocytes: neutrophils, eosinophils, and basophils. Neutrophils are the most abundant type and are primarily responsible for fighting bacterial infections. Eosinophils play a role in defending against parasitic infections and regulating immune responses. Basophils are involved in inflammatory reactions and allergic responses.

Granulocytes are produced in the bone marrow and released into the bloodstream, where they circulate and patrol for any signs of infection or foreign substances. When they encounter a threat, they quickly move to the site of infection or injury and release their granules to destroy the invading organisms or substances.

Abnormal levels of granulocytes in the blood can indicate an underlying medical condition, such as an infection, inflammation, or a bone marrow disorder.

Ganciclovir is an antiviral medication used to prevent and treat cytomegalovirus (CMV) infections, particularly in individuals who have undergone organ transplants or have weakened immune systems due to conditions like HIV/AIDS. It works by inhibiting the replication of the virus, thereby reducing its ability to cause damage to the body's cells and tissues.

The medical definition of Ganciclovir is:

A synthetic nucleoside analogue with antiviral activity against herpesviruses, including cytomegalovirus (CMV). Ganciclovir is converted intracellularly to its active form, ganciclovir triphosphate, which inhibits viral DNA polymerase and subsequently prevents viral replication. It is primarily used for the prevention and treatment of CMV infections in immunocompromised patients, such as those who have undergone organ transplants or have HIV/AIDS. Ganciclovir is available in various formulations, including oral capsules, intravenous solution, and ocular implants.

Transplantation is a medical procedure where an organ or tissue is removed from one person (the donor) and placed into another person (the recipient) for the purpose of replacing the recipient's damaged or failing organ or tissue with a functioning one. The goal of transplantation is to restore normal function, improve quality of life, and extend lifespan in individuals with organ failure or severe tissue damage. Common types of transplants include kidney, liver, heart, lung, pancreas, small intestine, and bone marrow transplantations. The success of a transplant depends on various factors, including the compatibility between the donor and recipient, the health of both individuals, and the effectiveness of immunosuppressive therapy to prevent rejection of the transplanted organ or tissue.

Wiskott-Aldrich Syndrome (WAS) is a rare X-linked recessive primary immunodeficiency disorder characterized by the triad of microthrombocytopenia, eczema, and recurrent infections. It is caused by mutations in the WAS gene, which encodes the Wiskott-Aldrich syndrome protein (WASp), a key regulator of actin cytoskeleton reorganization in hematopoietic cells.

The clinical features of WAS include:

1. Microthrombocytopenia: This is characterized by small platelet size and low platelet count, leading to an increased risk of bleeding.
2. Eczema: This is a chronic inflammatory skin disorder that can cause itching, redness, and scaly patches on the skin.
3. Recurrent infections: Patients with WAS are susceptible to bacterial, viral, and fungal infections due to impaired immune function.

Other clinical manifestations of WAS may include autoimmune disorders, lymphoma, and inflammatory bowel disease. The severity of the disease can vary widely among patients, ranging from mild to severe. Treatment options for WAS include hematopoietic stem cell transplantation (HSCT), gene therapy, and supportive care measures such as antibiotics, immunoglobulin replacement therapy, and platelet transfusions.

Multipotent stem cells are a type of stem cell that have the ability to differentiate into multiple cell types, but are more limited than pluripotent stem cells. These stem cells are found in various tissues and organs throughout the body, including bone marrow, adipose tissue, and dental pulp. They can give rise to a number of different cell types within their own germ layer (endoderm, mesoderm, or ectoderm), but cannot cross germ layer boundaries. For example, multipotent stem cells found in bone marrow can differentiate into various blood cells such as red and white blood cells, but they cannot differentiate into nerve cells or liver cells. These stem cells play important roles in tissue repair and regeneration, and have potential therapeutic applications in regenerative medicine.

Blood preservation refers to the process of keeping blood viable and functional outside of the body for transfusion purposes. This is typically achieved through the addition of various chemical additives, such as anticoagulants and nutrients, to a storage solution in which the blood is contained. The preserved blood is then refrigerated or frozen until it is needed for transfusion.

The goal of blood preservation is to maintain the structural integrity and functional capacity of the red blood cells, white blood cells, and platelets, as well as the coagulation factors, in order to ensure that the transfused blood is safe and effective. Different storage conditions and additives are used for the preservation of different components of blood, depending on their specific requirements.

It's important to note that while blood preservation extends the shelf life of donated blood, it does not last indefinitely. The length of time that blood can be stored depends on several factors, including the type of blood component and the storage conditions. Regular testing is performed to ensure that the preserved blood remains safe and effective for transfusion.

The ABO blood-group system is a classification system used in blood transfusion medicine to determine the compatibility of donated blood with a recipient's blood. It is based on the presence or absence of two antigens, A and B, on the surface of red blood cells (RBCs), as well as the corresponding antibodies present in the plasma.

There are four main blood types in the ABO system:

1. Type A: These individuals have A antigens on their RBCs and anti-B antibodies in their plasma.
2. Type B: They have B antigens on their RBCs and anti-A antibodies in their plasma.
3. Type AB: They have both A and B antigens on their RBCs but no natural antibodies against either A or B antigens.
4. Type O: They do not have any A or B antigens on their RBCs, but they have both anti-A and anti-B antibodies in their plasma.

Transfusing blood from a donor with incompatible ABO antigens can lead to an immune response, causing the destruction of donated RBCs and potentially life-threatening complications such as acute hemolytic transfusion reaction. Therefore, it is crucial to match the ABO blood type between donors and recipients before performing a blood transfusion.

Islets of Langerhans transplantation is a surgical procedure that involves the transplantation of isolated islets from a deceased donor's pancreas into another person with type 1 diabetes. The islets of Langerhans are clusters of cells within the pancreas that produce hormones, including insulin, which regulates blood sugar levels.

In type 1 diabetes, the body's immune system mistakenly attacks and destroys these insulin-producing cells, leading to high blood sugar levels. Islet transplantation aims to replace the damaged islets with healthy ones from a donor, allowing the recipient's body to produce and regulate its own insulin again.

The procedure involves extracting the islets from the donor pancreas and infusing them into the recipient's liver through a small incision in the abdomen. Once inside the liver, the islets can sense glucose levels in the bloodstream and release insulin as needed to maintain normal blood sugar levels.

Islet transplantation has shown promising results in improving blood sugar control and reducing the risk of severe hypoglycemia (low blood sugar) in people with type 1 diabetes. However, it requires long-term immunosuppressive therapy to prevent rejection of the transplanted islets, which can have side effects and increase the risk of infections.

An erythrocyte transfusion, also known as a red blood cell (RBC) transfusion, is the process of transferring compatible red blood cells from a donor to a recipient. This procedure is typically performed to increase the recipient's oxygen-carrying capacity, usually in situations where there is significant blood loss, anemia, or impaired red blood cell production.

During the transfusion, the donor's red blood cells are collected, typed, and tested for compatibility with the recipient's blood to minimize the risk of a transfusion reaction. Once compatible units are identified, they are infused into the recipient's circulation through a sterile intravenous (IV) line. The recipient's body will eventually eliminate the donated red blood cells within 100-120 days as part of its normal turnover process.

Erythrocyte transfusions can be lifesaving in various clinical scenarios, such as trauma, surgery, severe anemia due to chronic diseases, and hematologic disorders. However, they should only be used when necessary, as there are potential risks associated with the procedure, including allergic reactions, transmission of infectious diseases, transfusion-related acute lung injury (TRALI), and iron overload in cases of multiple transfusions.

Heterocyclic compounds are organic compounds that contain at least one atom within the ring structure, other than carbon, such as nitrogen, oxygen, sulfur or phosphorus. These compounds make up a large class of naturally occurring and synthetic materials, including many drugs, pigments, vitamins, and antibiotics. The presence of the heteroatom in the ring can have significant effects on the physical and chemical properties of the compound, such as its reactivity, stability, and bonding characteristics. Examples of heterocyclic compounds include pyridine, pyrimidine, and furan.

A biological marker, often referred to as a biomarker, is a measurable indicator that reflects the presence or severity of a disease state, or a response to a therapeutic intervention. Biomarkers can be found in various materials such as blood, tissues, or bodily fluids, and they can take many forms, including molecular, histologic, radiographic, or physiological measurements.

In the context of medical research and clinical practice, biomarkers are used for a variety of purposes, such as:

1. Diagnosis: Biomarkers can help diagnose a disease by indicating the presence or absence of a particular condition. For example, prostate-specific antigen (PSA) is a biomarker used to detect prostate cancer.
2. Monitoring: Biomarkers can be used to monitor the progression or regression of a disease over time. For instance, hemoglobin A1c (HbA1c) levels are monitored in diabetes patients to assess long-term blood glucose control.
3. Predicting: Biomarkers can help predict the likelihood of developing a particular disease or the risk of a negative outcome. For example, the presence of certain genetic mutations can indicate an increased risk for breast cancer.
4. Response to treatment: Biomarkers can be used to evaluate the effectiveness of a specific treatment by measuring changes in the biomarker levels before and after the intervention. This is particularly useful in personalized medicine, where treatments are tailored to individual patients based on their unique biomarker profiles.

It's important to note that for a biomarker to be considered clinically valid and useful, it must undergo rigorous validation through well-designed studies, including demonstrating sensitivity, specificity, reproducibility, and clinical relevance.

Mesna is a medication used in the prevention and treatment of hemorrhagic cystitis (inflammation and bleeding of the bladder) caused by certain chemotherapy drugs, specifically ifosfamide and cyclophosphamide. Mesna works by neutralizing the toxic metabolites of these chemotherapy agents, which can cause bladder irritation and damage.

Mesna is administered intravenously (into a vein) along with ifosfamide or cyclophosphamide, and it may also be given as a separate infusion after the chemotherapy treatment. The dosage and timing of Mesna administration are determined by the healthcare provider based on the patient's weight, kidney function, and the dose of chemotherapy received.

It is important to note that Mesna does not have any direct anticancer effects and is used solely to manage the side effects of chemotherapy.

Natural Killer (NK) cells are a type of lymphocyte, which are large granular innate immune cells that play a crucial role in the host's defense against viral infections and malignant transformations. They do not require prior sensitization to target and destroy abnormal cells, such as virus-infected cells or tumor cells. NK cells recognize their targets through an array of germline-encoded activating and inhibitory receptors that detect the alterations in the cell surface molecules of potential targets. Upon activation, NK cells release cytotoxic granules containing perforins and granzymes to induce target cell apoptosis, and they also produce a variety of cytokines and chemokines to modulate immune responses. Overall, natural killer cells serve as a critical component of the innate immune system, providing rapid and effective responses against infected or malignant cells.

C57BL/6 (C57 Black 6) is an inbred strain of laboratory mouse that is widely used in biomedical research. The term "inbred" refers to a strain of animals where matings have been carried out between siblings or other closely related individuals for many generations, resulting in a population that is highly homozygous at most genetic loci.

The C57BL/6 strain was established in 1920 by crossing a female mouse from the dilute brown (DBA) strain with a male mouse from the black strain. The resulting offspring were then interbred for many generations to create the inbred C57BL/6 strain.

C57BL/6 mice are known for their robust health, longevity, and ease of handling, making them a popular choice for researchers. They have been used in a wide range of biomedical research areas, including studies of cancer, immunology, neuroscience, cardiovascular disease, and metabolism.

One of the most notable features of the C57BL/6 strain is its sensitivity to certain genetic modifications, such as the introduction of mutations that lead to obesity or impaired glucose tolerance. This has made it a valuable tool for studying the genetic basis of complex diseases and traits.

Overall, the C57BL/6 inbred mouse strain is an important model organism in biomedical research, providing a valuable resource for understanding the genetic and molecular mechanisms underlying human health and disease.

Fetal stem cells are a type of stem cell that are derived from fetal tissue, which is tissue obtained from an elective abortion or a spontaneous miscarriage. These stem cells have the ability to differentiate into various cell types, including neurons, cardiac muscle cells, and hepatocytes (liver cells). Fetal stem cells are unique in that they have a greater capacity for self-renewal and can generate a larger number of differentiated cells compared to adult stem cells. They also have the potential to be less immunogenic than other types of stem cells, making them a promising candidate for cell-based therapies and regenerative medicine. However, the use of fetal stem cells is a subject of ethical debate due to their source.

In the context of healthcare, "safety" refers to the freedom from harm or injury that is intentionally designed into a process, system, or environment. It involves the prevention of adverse events or injuries, as well as the reduction of risk and the mitigation of harm when accidents do occur. Safety in healthcare aims to protect patients, healthcare workers, and other stakeholders from potential harm associated with medical care, treatments, or procedures. This is achieved through evidence-based practices, guidelines, protocols, training, and continuous quality improvement efforts.

Cytokines are a broad and diverse category of small signaling proteins that are secreted by various cells, including immune cells, in response to different stimuli. They play crucial roles in regulating the immune response, inflammation, hematopoiesis, and cellular communication.

Cytokines mediate their effects by binding to specific receptors on the surface of target cells, which triggers intracellular signaling pathways that ultimately result in changes in gene expression, cell behavior, and function. Some key functions of cytokines include:

1. Regulating the activation, differentiation, and proliferation of immune cells such as T cells, B cells, natural killer (NK) cells, and macrophages.
2. Coordinating the inflammatory response by recruiting immune cells to sites of infection or tissue damage and modulating their effector functions.
3. Regulating hematopoiesis, the process of blood cell formation in the bone marrow, by controlling the proliferation, differentiation, and survival of hematopoietic stem and progenitor cells.
4. Modulating the development and function of the nervous system, including neuroinflammation, neuroprotection, and neuroregeneration.

Cytokines can be classified into several categories based on their structure, function, or cellular origin. Some common types of cytokines include interleukins (ILs), interferons (IFNs), tumor necrosis factors (TNFs), chemokines, colony-stimulating factors (CSFs), and transforming growth factors (TGFs). Dysregulation of cytokine production and signaling has been implicated in various pathological conditions, such as autoimmune diseases, chronic inflammation, cancer, and neurodegenerative disorders.

Heterologous transplantation is a type of transplantation where an organ or tissue is transferred from one species to another. This is in contrast to allogeneic transplantation, where the donor and recipient are of the same species, or autologous transplantation, where the donor and recipient are the same individual.

In heterologous transplantation, the immune systems of the donor and recipient are significantly different, which can lead to a strong immune response against the transplanted organ or tissue. This is known as a graft-versus-host disease (GVHD), where the immune cells in the transplanted tissue attack the recipient's body.

Heterologous transplantation is not commonly performed in clinical medicine due to the high risk of rejection and GVHD. However, it may be used in research settings to study the biology of transplantation and to develop new therapies for transplant rejection.

Cell culture is a technique used in scientific research to grow and maintain cells from plants, animals, or humans in a controlled environment outside of their original organism. This environment typically consists of a sterile container called a cell culture flask or plate, and a nutrient-rich liquid medium that provides the necessary components for the cells' growth and survival, such as amino acids, vitamins, minerals, and hormones.

There are several different types of cell culture techniques used in research, including:

1. Adherent cell culture: In this technique, cells are grown on a flat surface, such as the bottom of a tissue culture dish or flask. The cells attach to the surface and spread out, forming a monolayer that can be observed and manipulated under a microscope.
2. Suspension cell culture: In suspension culture, cells are grown in liquid medium without any attachment to a solid surface. These cells remain suspended in the medium and can be agitated or mixed to ensure even distribution of nutrients.
3. Organoid culture: Organoids are three-dimensional structures that resemble miniature organs and are grown from stem cells or other progenitor cells. They can be used to study organ development, disease processes, and drug responses.
4. Co-culture: In co-culture, two or more different types of cells are grown together in the same culture dish or flask. This technique is used to study cell-cell interactions and communication.
5. Conditioned medium culture: In this technique, cells are grown in a medium that has been conditioned by previous cultures of other cells. The conditioned medium contains factors secreted by the previous cells that can influence the growth and behavior of the new cells.

Cell culture techniques are widely used in biomedical research to study cellular processes, develop drugs, test toxicity, and investigate disease mechanisms. However, it is important to note that cell cultures may not always accurately represent the behavior of cells in a living organism, and results from cell culture experiments should be validated using other methods.

Lymphoproliferative disorders (LPDs) are a group of diseases characterized by the excessive proliferation of lymphoid cells, which are crucial components of the immune system. These disorders can arise from both B-cells and T-cells, leading to various clinical manifestations ranging from benign to malignant conditions.

LPDs can be broadly classified into reactive and neoplastic categories:

1. Reactive Lymphoproliferative Disorders: These are typically triggered by infections, autoimmune diseases, or immunodeficiency states. They involve an exaggerated response of the immune system leading to the excessive proliferation of lymphoid cells. Examples include:
* Infectious mononucleosis (IM) caused by Epstein-Barr virus (EBV)
* Lymph node enlargement due to various infections or autoimmune disorders
* Post-transplant lymphoproliferative disorder (PTLD), which occurs in the context of immunosuppression following organ transplantation
2. Neoplastic Lymphoproliferative Disorders: These are malignant conditions characterized by uncontrolled growth and accumulation of abnormal lymphoid cells, leading to the formation of tumors. They can be further classified into Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Examples include:
* Hodgkin lymphoma (HL): Classical HL and nodular lymphocyte-predominant HL
* Non-Hodgkin lymphoma (NHL): Various subtypes, such as diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and Burkitt lymphoma

It is important to note that the distinction between reactive and neoplastic LPDs can sometimes be challenging, requiring careful clinical, histopathological, immunophenotypic, and molecular evaluations. Proper diagnosis and classification of LPDs are crucial for determining appropriate treatment strategies and predicting patient outcomes.

A "Drug Administration Schedule" refers to the plan for when and how a medication should be given to a patient. It includes details such as the dose, frequency (how often it should be taken), route (how it should be administered, such as orally, intravenously, etc.), and duration (how long it should be taken) of the medication. This schedule is often created and prescribed by healthcare professionals, such as doctors or pharmacists, to ensure that the medication is taken safely and effectively. It may also include instructions for missed doses or changes in the dosage.

A living donor is a person who voluntarily donates an organ or part of an organ to another person while they are still alive. This can include donations such as a kidney, liver lobe, lung, or portion of the pancreas or intestines. The donor and recipient typically undergo medical evaluation and compatibility testing to ensure the best possible outcome for the transplantation procedure. Living donation is regulated by laws and ethical guidelines to ensure that donors are fully informed and making a voluntary decision.

Viral activation, also known as viral reactivation or virus reactivation, refers to the process in which a latent or dormant virus becomes active and starts to replicate within a host cell. This can occur when the immune system is weakened or compromised, allowing the virus to evade the body's natural defenses and cause disease.

In some cases, viral activation can be triggered by certain environmental factors, such as stress, exposure to UV light, or infection with another virus. Once activated, the virus can cause symptoms similar to those seen during the initial infection, or it may lead to new symptoms depending on the specific virus and the host's immune response.

Examples of viruses that can remain dormant in the body and be reactivated include herpes simplex virus (HSV), varicella-zoster virus (VZV), cytomegalovirus (CMV), and Epstein-Barr virus (EBV). It is important to note that not all viruses can be reactivated, and some may remain dormant in the body indefinitely without causing any harm.

Local neoplasm recurrence is the return or regrowth of a tumor in the same location where it was originally removed or treated. This means that cancer cells have survived the initial treatment and started to grow again in the same area. It's essential to monitor and detect any local recurrence as early as possible, as it can affect the prognosis and may require additional treatment.

Cell survival refers to the ability of a cell to continue living and functioning normally, despite being exposed to potentially harmful conditions or treatments. This can include exposure to toxins, radiation, chemotherapeutic drugs, or other stressors that can damage cells or interfere with their normal processes.

In scientific research, measures of cell survival are often used to evaluate the effectiveness of various therapies or treatments. For example, researchers may expose cells to a particular drug or treatment and then measure the percentage of cells that survive to assess its potential therapeutic value. Similarly, in toxicology studies, measures of cell survival can help to determine the safety of various chemicals or substances.

It's important to note that cell survival is not the same as cell proliferation, which refers to the ability of cells to divide and multiply. While some treatments may promote cell survival, they may also inhibit cell proliferation, making them useful for treating diseases such as cancer. Conversely, other treatments may be designed to specifically target and kill cancer cells, even if it means sacrificing some healthy cells in the process.

Cell proliferation is the process by which cells increase in number, typically through the process of cell division. In the context of biology and medicine, it refers to the reproduction of cells that makes up living tissue, allowing growth, maintenance, and repair. It involves several stages including the transition from a phase of quiescence (G0 phase) to an active phase (G1 phase), DNA replication in the S phase, and mitosis or M phase, where the cell divides into two daughter cells.

Abnormal or uncontrolled cell proliferation is a characteristic feature of many diseases, including cancer, where deregulated cell cycle control leads to excessive and unregulated growth of cells, forming tumors that can invade surrounding tissues and metastasize to distant sites in the body.

A matched-pair analysis is a type of statistical analysis used in epidemiological or clinical research to reduce or control confounding and increase the power of a study. In this approach, pairs of subjects are created who are similar to each other with respect to certain covariates or potential confounders, such as age, sex, race, or disease severity. One member of the pair is then exposed to the factor of interest (e.g., a treatment or risk factor), while the other member is not. By comparing outcomes between the exposed and non-exposed members of each pair, researchers can better isolate the effects of the exposure from the influence of confounding variables.

This technique is particularly useful in observational studies where random assignment to exposure groups is not possible or ethical. However, it's important to note that matching on too many variables or selecting inappropriate matching criteria can actually reduce the generalizability and power of the study. Therefore, careful consideration should be given when designing a matched-pair analysis.

Pancreas transplantation is a surgical procedure that involves implanting a healthy pancreas from a deceased donor into a recipient with diabetes. The primary goal of this procedure is to restore the recipient's insulin production and eliminate the need for insulin injections, thereby improving their quality of life and reducing the risk of long-term complications associated with diabetes.

There are three main types of pancreas transplantation:

1. Simultaneous pancreas-kidney (SPK) transplantation: This is the most common type of pancreas transplant, performed simultaneously with a kidney transplant in patients with diabetes and end-stage renal disease (ESRD). The new pancreas not only restores insulin production but also helps prevent further kidney damage.
2. Pancreas after kidney (PAK) transplantation: In this procedure, a patient receives a kidney transplant first, followed by a pancreas transplant at a later time. This is typically performed in patients who have already undergone a successful kidney transplant and wish to improve their diabetes management.
3. Pancreas transplantation alone (PTA): In rare cases, a pancreas transplant may be performed without a concurrent kidney transplant. This is usually considered for patients with brittle diabetes who experience severe hypoglycemic episodes despite optimal medical management and lifestyle modifications.

The success of pancreas transplantation has significantly improved over the years, thanks to advancements in surgical techniques, immunosuppressive medications, and post-transplant care. However, it is essential to weigh the benefits against the risks, such as potential complications related to surgery, infection, rejection, and long-term use of immunosuppressive drugs. Ultimately, the decision to undergo pancreas transplantation should be made in consultation with a multidisciplinary team of healthcare professionals, considering each patient's unique medical history and personal circumstances.

Central venous catheterization is a medical procedure in which a flexible tube called a catheter is inserted into a large vein in the body, usually in the neck (internal jugular vein), chest (subclavian vein), or groin (femoral vein). The catheter is threaded through the vein until it reaches a central location, such as the superior vena cava or the right atrium of the heart.

Central venous catheterization may be performed for several reasons, including:

1. To administer medications, fluids, or nutritional support directly into the bloodstream.
2. To monitor central venous pressure (CVP), which can help assess a patient's volume status and cardiac function.
3. To draw blood samples for laboratory tests.
4. To deliver chemotherapy drugs or other medications that may be harmful to peripheral veins.
5. To provide access for hemodialysis or other long-term therapies.

The procedure requires careful attention to sterile technique to minimize the risk of infection, and it is usually performed under local anesthesia with sedation or general anesthesia. Complications of central venous catheterization may include bleeding, infection, pneumothorax (collapsed lung), arterial puncture, and catheter-related bloodstream infections (CRBSI).

Ewing sarcoma is a type of cancer that originates in bones or the soft tissues surrounding them, such as muscles and tendons. It primarily affects children and adolescents, although it can occur in adults as well. The disease is characterized by small, round tumor cells that typically grow quickly and are prone to metastasize (spread) to other parts of the body, most commonly the lungs, bones, and bone marrow.

Ewing sarcoma is caused by a genetic abnormality, specifically a chromosomal translocation that results in the fusion of two genes, EWSR1 and FLI1. This gene fusion leads to the formation of an abnormal protein that disrupts normal cell growth and division processes, ultimately resulting in cancer.

Symptoms of Ewing sarcoma can vary depending on the location and size of the tumor but may include pain or swelling in the affected area, fever, fatigue, and weight loss. Diagnosis typically involves imaging studies such as X-rays, CT scans, or MRI scans to locate the tumor, followed by a biopsy to confirm the presence of cancer cells. Treatment may involve surgery, radiation therapy, chemotherapy, or a combination of these approaches, depending on the stage and location of the disease.

Multivariate analysis is a statistical method used to examine the relationship between multiple independent variables and a dependent variable. It allows for the simultaneous examination of the effects of two or more independent variables on an outcome, while controlling for the effects of other variables in the model. This technique can be used to identify patterns, associations, and interactions among multiple variables, and is commonly used in medical research to understand complex health outcomes and disease processes. Examples of multivariate analysis methods include multiple regression, factor analysis, cluster analysis, and discriminant analysis.

Thrombocytopenia is a medical condition characterized by an abnormally low platelet count (thrombocytes) in the blood. Platelets are small cell fragments that play a crucial role in blood clotting, helping to stop bleeding when a blood vessel is damaged. A healthy adult typically has a platelet count between 150,000 and 450,000 platelets per microliter of blood. Thrombocytopenia is usually diagnosed when the platelet count falls below 150,000 platelets/µL.

Thrombocytopenia can be classified into three main categories based on its underlying cause:

1. Immune thrombocytopenia (ITP): An autoimmune disorder where the immune system mistakenly attacks and destroys its own platelets, leading to a decreased platelet count. ITP can be further divided into primary or secondary forms, depending on whether it occurs alone or as a result of another medical condition or medication.
2. Decreased production: Thrombocytopenia can occur when there is insufficient production of platelets in the bone marrow due to various causes, such as viral infections, chemotherapy, radiation therapy, leukemia, aplastic anemia, or vitamin B12 or folate deficiency.
3. Increased destruction or consumption: Thrombocytopenia can also result from increased platelet destruction or consumption due to conditions like disseminated intravascular coagulation (DIC), thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), or severe bacterial infections.

Symptoms of thrombocytopenia may include easy bruising, prolonged bleeding from cuts, spontaneous nosebleeds, bleeding gums, blood in urine or stools, and skin rashes like petechiae (small red or purple spots) or purpura (larger patches). The severity of symptoms can vary depending on the degree of thrombocytopenia and the presence of any underlying conditions. Treatment for thrombocytopenia depends on the cause and may include medications, transfusions, or addressing the underlying condition.

CD3 antigens are a group of proteins found on the surface of T-cells, which are a type of white blood cell that plays a central role in the immune response. The CD3 antigens are composed of several different subunits (ε, δ, γ, and α) that associate to form the CD3 complex, which is involved in T-cell activation and signal transduction.

The CD3 complex is associated with the T-cell receptor (TCR), which recognizes and binds to specific antigens presented by antigen-presenting cells. When the TCR binds to an antigen, it triggers a series of intracellular signaling events that lead to T-cell activation and the initiation of an immune response.

CD3 antigens are important targets for immunotherapy in some diseases, such as certain types of cancer. For example, monoclonal antibodies that target CD3 have been developed to activate T-cells and enhance their ability to recognize and destroy tumor cells. However, CD3-targeted therapies can also cause side effects, such as cytokine release syndrome, which can be serious or life-threatening in some cases.

A "second primary neoplasm" is a distinct, new cancer or malignancy that develops in a person who has already had a previous cancer. It is not a recurrence or metastasis of the original tumor, but rather an independent cancer that arises in a different location or organ system. The development of second primary neoplasms can be influenced by various factors such as genetic predisposition, environmental exposures, and previous treatments like chemotherapy or radiation therapy.

It is important to note that the definition of "second primary neoplasm" may vary slightly depending on the specific source or context. In general medical usage, it refers to a new, separate cancer; however, in some research or clinical settings, there might be more precise criteria for defining and diagnosing second primary neoplasms.

Lymphocyte activation is the process by which B-cells and T-cells (types of lymphocytes) become activated to perform effector functions in an immune response. This process involves the recognition of specific antigens presented on the surface of antigen-presenting cells, such as dendritic cells or macrophages.

The activation of B-cells leads to their differentiation into plasma cells that produce antibodies, while the activation of T-cells results in the production of cytotoxic T-cells (CD8+ T-cells) that can directly kill infected cells or helper T-cells (CD4+ T-cells) that assist other immune cells.

Lymphocyte activation involves a series of intracellular signaling events, including the binding of co-stimulatory molecules and the release of cytokines, which ultimately result in the expression of genes involved in cell proliferation, differentiation, and effector functions. The activation process is tightly regulated to prevent excessive or inappropriate immune responses that can lead to autoimmunity or chronic inflammation.

Severe Combined Immunodeficiency (SCID) is a group of rare genetic disorders characterized by deficient or absent immune responses. It results from mutations in different genes involved in the development and function of T lymphocytes, B lymphocytes, or both, leading to a severe impairment in cell-mediated and humoral immunity.

Infants with SCID are extremely vulnerable to infections, which can be life-threatening. Common symptoms include chronic diarrhea, failure to thrive, recurrent pneumonia, and persistent candidiasis (thrush). If left untreated, it can lead to severe disability or death within the first two years of life. Treatment typically involves bone marrow transplantation or gene therapy to restore immune function.

SCID mice is an acronym for Severe Combined Immunodeficiency mice. These are genetically modified mice that lack a functional immune system due to the mutation or knockout of several key genes required for immunity. This makes them ideal for studying the human immune system, infectious diseases, and cancer, as well as testing new therapies and treatments in a controlled environment without the risk of interference from the mouse's own immune system. SCID mice are often used in xenotransplantation studies, where human cells or tissues are transplanted into the mouse to study their behavior and interactions with the human immune system.

Neutrophils are a type of white blood cell that are part of the immune system's response to infection. They are produced in the bone marrow and released into the bloodstream where they circulate and are able to move quickly to sites of infection or inflammation in the body. Neutrophils are capable of engulfing and destroying bacteria, viruses, and other foreign substances through a process called phagocytosis. They are also involved in the release of inflammatory mediators, which can contribute to tissue damage in some cases. Neutrophils are characterized by the presence of granules in their cytoplasm, which contain enzymes and other proteins that help them carry out their immune functions.

Stomatitis is a medical term that refers to inflammation of the mucous membrane of any of the soft tissues in the mouth, including the lips, gums, tongue, palate, and cheek lining. It can cause discomfort, pain, and sores or lesions in the mouth. Stomatitis may result from a variety of causes, such as infection, injury, allergic reaction, or systemic diseases. Treatment depends on the underlying cause and may include medications, mouth rinses, or changes in oral hygiene practices.

Transplantation tolerance, also known as immunological tolerance or transplant tolerance, is a state in which the immune system of a transplant recipient does not mount an immune response against the transplanted organ or tissue. This is an important goal in transplantation medicine to prevent graft rejection and reduce the need for long-term immunosuppressive therapy, which can have significant side effects.

Transplantation tolerance can be achieved through various mechanisms, including the deletion or regulation of donor-reactive T cells, the induction of regulatory T cells (Tregs) that suppress immune responses against the graft, and the modulation of innate immune responses. The development of strategies to induce transplantation tolerance is an active area of research in transplantation medicine.

Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a laboratory technique used in molecular biology to amplify and detect specific DNA sequences. This technique is particularly useful for the detection and quantification of RNA viruses, as well as for the analysis of gene expression.

The process involves two main steps: reverse transcription and polymerase chain reaction (PCR). In the first step, reverse transcriptase enzyme is used to convert RNA into complementary DNA (cDNA) by reading the template provided by the RNA molecule. This cDNA then serves as a template for the PCR amplification step.

In the second step, the PCR reaction uses two primers that flank the target DNA sequence and a thermostable polymerase enzyme to repeatedly copy the targeted cDNA sequence. The reaction mixture is heated and cooled in cycles, allowing the primers to anneal to the template, and the polymerase to extend the new strand. This results in exponential amplification of the target DNA sequence, making it possible to detect even small amounts of RNA or cDNA.

RT-PCR is a sensitive and specific technique that has many applications in medical research and diagnostics, including the detection of viruses such as HIV, hepatitis C virus, and SARS-CoV-2 (the virus that causes COVID-19). It can also be used to study gene expression, identify genetic mutations, and diagnose genetic disorders.

Regeneration in a medical context refers to the process of renewal, restoration, and growth that replaces damaged or missing cells, tissues, organs, or even whole limbs in some organisms. This complex biological process involves various cellular and molecular mechanisms, such as cell proliferation, differentiation, and migration, which work together to restore the structural and functional integrity of the affected area.

In human medicine, regeneration has attracted significant interest due to its potential therapeutic applications in treating various conditions, including degenerative diseases, trauma, and congenital disorders. Researchers are actively studying the underlying mechanisms of regeneration in various model organisms to develop novel strategies for promoting tissue repair and regeneration in humans.

Examples of regeneration in human medicine include liver regeneration after partial hepatectomy, where the remaining liver lobes can grow back to their original size within weeks, and skin wound healing, where keratinocytes migrate and proliferate to close the wound and restore the epidermal layer. However, the regenerative capacity of humans is limited compared to some other organisms, such as planarians and axolotls, which can regenerate entire body parts or even their central nervous system.

Cisplatin is a chemotherapeutic agent used to treat various types of cancers, including testicular, ovarian, bladder, head and neck, lung, and cervical cancers. It is an inorganic platinum compound that contains a central platinum atom surrounded by two chloride atoms and two ammonia molecules in a cis configuration.

Cisplatin works by forming crosslinks between DNA strands, which disrupts the structure of DNA and prevents cancer cells from replicating. This ultimately leads to cell death and slows down or stops the growth of tumors. However, cisplatin can also cause damage to normal cells, leading to side effects such as nausea, vomiting, hearing loss, and kidney damage. Therefore, it is essential to monitor patients closely during treatment and manage any adverse effects promptly.

Tacrolimus is an immunosuppressant drug that is primarily used to prevent the rejection of transplanted organs. It works by inhibiting the activity of T-cells, which are a type of white blood cell that plays a central role in the body's immune response. By suppressing the activity of these cells, tacrolimus helps to reduce the risk of an immune response being mounted against the transplanted organ.

Tacrolimus is often used in combination with other immunosuppressive drugs, such as corticosteroids and mycophenolate mofetil, to provide a comprehensive approach to preventing organ rejection. It is available in various forms, including capsules, oral solution, and intravenous injection.

The drug was first approved for use in the United States in 1994 and has since become a widely used immunosuppressant in transplant medicine. Tacrolimus is also being studied as a potential treatment for a variety of other conditions, including autoimmune diseases and cancer.

Minor histocompatibility antigens (miHA) are proteins that exist in cells which can stimulate an immune response, particularly in the context of transplantation. Unlike major histocompatibility complex (MHC) antigens, which are highly polymorphic and well-known to trigger strong immune responses, miHA are generally less variable and may not be as immediately apparent to the immune system.

Minor histocompatibility antigens can arise from differences in genetic sequences that code for proteins outside of the MHC region. These differences can result in the production of altered or unique peptides that can be presented on the surface of cells via MHC molecules, where they may be recognized as foreign by the immune system.

In the context of transplantation, the recipient's immune system may recognize and attack donor tissues expressing these miHA, leading to graft rejection or graft-versus-host disease (GVHD). This is particularly relevant in hematopoietic stem cell transplantation (HSCT), where the transferred stem cells can differentiate into various cell types, including immune cells that may recognize and attack the recipient's tissues.

Understanding miHA and their role in transplant rejection has led to the development of strategies to minimize graft rejection and GVHD, such as T-cell depletion or targeted therapies against specific miHA.

Stem cell research is a branch of medical science that focuses on the study and application of stem cells, which are undifferentiated or unspecialized cells with the ability to differentiate into various specialized cell types in the body. These cells have the potential to regenerate and repair damaged tissues and organs, making them a promising area of research for the development of new treatments for a wide range of diseases and conditions, including cancer, neurodegenerative disorders, diabetes, heart disease, and more.

Stem cell research involves several key areas, such as:

1. Isolation and culture: Scientists isolate stem cells from various sources, such as embryos, umbilical cord blood, or adult tissues, and grow them in a lab to study their properties and behaviors.
2. Differentiation: Researchers induce stem cells to differentiate into specific cell types, such as heart cells, brain cells, or pancreatic cells, by exposing them to various growth factors and other chemical signals.
3. Genetic modification: Scientists may modify the genes of stem cells to enhance their therapeutic potential or to study the effects of genetic mutations on cell behavior and development.
4. Transplantation: In some cases, researchers transplant stem cells into animal models or human patients to investigate their ability to repair damaged tissues and organs.
5. Ethical considerations: Stem cell research raises several ethical concerns related to the use of embryonic stem cells, which are derived from human embryos. These concerns have led to ongoing debates about the limits and regulations surrounding this area of research.

Overall, stem cell research holds great promise for the development of new medical treatments and therapies, but it also requires careful consideration of ethical issues and rigorous scientific investigation to ensure its safety and effectiveness.

Interleukin-2 (IL-2) is a type of cytokine, which are signaling molecules that mediate and regulate immunity, inflammation, and hematopoiesis. Specifically, IL-2 is a growth factor for T cells, a type of white blood cell that plays a central role in the immune response. It is primarily produced by CD4+ T cells (also known as T helper cells) and stimulates the proliferation and differentiation of activated T cells, including effector T cells and regulatory T cells. IL-2 also has roles in the activation and function of other immune cells, such as B cells, natural killer cells, and dendritic cells. Dysregulation of IL-2 production or signaling can contribute to various pathological conditions, including autoimmune diseases, chronic infections, and cancer.

B-lymphocytes, also known as B-cells, are a type of white blood cell that plays a key role in the immune system's response to infection. They are responsible for producing antibodies, which are proteins that help to neutralize or destroy pathogens such as bacteria and viruses.

When a B-lymphocyte encounters a pathogen, it becomes activated and begins to divide and differentiate into plasma cells, which produce and secrete large amounts of antibodies specific to the antigens on the surface of the pathogen. These antibodies bind to the pathogen, marking it for destruction by other immune cells such as neutrophils and macrophages.

B-lymphocytes also have a role in presenting antigens to T-lymphocytes, another type of white blood cell involved in the immune response. This helps to stimulate the activation and proliferation of T-lymphocytes, which can then go on to destroy infected cells or help to coordinate the overall immune response.

Overall, B-lymphocytes are an essential part of the adaptive immune system, providing long-lasting immunity to previously encountered pathogens and helping to protect against future infections.

Bleomycin is a type of chemotherapeutic agent used to treat various types of cancer, including squamous cell carcinoma, testicular cancer, and lymphomas. It works by causing DNA damage in rapidly dividing cells, which can inhibit the growth and proliferation of cancer cells.

Bleomycin is an antibiotic derived from Streptomyces verticillus and is often administered intravenously or intramuscularly. While it can be effective in treating certain types of cancer, it can also have serious side effects, including lung toxicity, which can lead to pulmonary fibrosis and respiratory failure. Therefore, bleomycin should only be used under the close supervision of a healthcare professional who is experienced in administering chemotherapy drugs.

Testicular neoplasms are abnormal growths or tumors in the testicle that can be benign (non-cancerous) or malignant (cancerous). They are a type of genitourinary cancer, which affects the reproductive and urinary systems. Testicular neoplasms can occur in men of any age but are most commonly found in young adults between the ages of 15 and 40.

Testicular neoplasms can be classified into two main categories: germ cell tumors and non-germ cell tumors. Germ cell tumors, which arise from the cells that give rise to sperm, are further divided into seminomas and non-seminomas. Seminomas are typically slow-growing and have a good prognosis, while non-seminomas tend to grow more quickly and can spread to other parts of the body.

Non-germ cell tumors are less common than germ cell tumors and include Leydig cell tumors, Sertoli cell tumors, and lymphomas. These tumors can have a variety of clinical behaviors, ranging from benign to malignant.

Testicular neoplasms often present as a painless mass or swelling in the testicle. Other symptoms may include a feeling of heaviness or discomfort in the scrotum, a dull ache in the lower abdomen or groin, and breast enlargement (gynecomastia).

Diagnosis typically involves a physical examination, imaging studies such as ultrasound or CT scan, and blood tests to detect tumor markers. Treatment options depend on the type and stage of the neoplasm but may include surgery, radiation therapy, chemotherapy, or a combination of these modalities. Regular self-examinations of the testicles are recommended for early detection and improved outcomes.

"Age factors" refer to the effects, changes, or differences that age can have on various aspects of health, disease, and medical care. These factors can encompass a wide range of issues, including:

1. Physiological changes: As people age, their bodies undergo numerous physical changes that can affect how they respond to medications, illnesses, and medical procedures. For example, older adults may be more sensitive to certain drugs or have weaker immune systems, making them more susceptible to infections.
2. Chronic conditions: Age is a significant risk factor for many chronic diseases, such as heart disease, diabetes, cancer, and arthritis. As a result, age-related medical issues are common and can impact treatment decisions and outcomes.
3. Cognitive decline: Aging can also lead to cognitive changes, including memory loss and decreased decision-making abilities. These changes can affect a person's ability to understand and comply with medical instructions, leading to potential complications in their care.
4. Functional limitations: Older adults may experience physical limitations that impact their mobility, strength, and balance, increasing the risk of falls and other injuries. These limitations can also make it more challenging for them to perform daily activities, such as bathing, dressing, or cooking.
5. Social determinants: Age-related factors, such as social isolation, poverty, and lack of access to transportation, can impact a person's ability to obtain necessary medical care and affect their overall health outcomes.

Understanding age factors is critical for healthcare providers to deliver high-quality, patient-centered care that addresses the unique needs and challenges of older adults. By taking these factors into account, healthcare providers can develop personalized treatment plans that consider a person's age, physical condition, cognitive abilities, and social circumstances.

Pancytopenia is a medical condition characterized by a reduction in the number of all three types of blood cells in the peripheral blood: red blood cells (anemia), white blood cells (leukopenia), and platelets (thrombocytopenia). This condition can be caused by various underlying diseases, including bone marrow disorders, viral infections, exposure to toxic substances or radiation, vitamin deficiencies, and certain medications. Symptoms of pancytopenia may include fatigue, weakness, increased susceptibility to infections, and easy bruising or bleeding.

In the context of medicine, risk is the probability or likelihood of an adverse health effect or the occurrence of a negative event related to treatment or exposure to certain hazards. It is usually expressed as a ratio or percentage and can be influenced by various factors such as age, gender, lifestyle, genetics, and environmental conditions. Risk assessment involves identifying, quantifying, and prioritizing risks to make informed decisions about prevention, mitigation, or treatment strategies.

Fetal tissue transplantation is a medical procedure that involves the surgical implantation of tissue from developing fetuses into patients for therapeutic purposes. The tissue used in these procedures typically comes from elective abortions, and can include tissues such as neural cells, liver cells, pancreatic islets, and heart valves.

The rationale behind fetal tissue transplantation is that the developing fetus has a high capacity for cell growth and regeneration, making its tissues an attractive source of cells for transplantation. Additionally, because fetal tissue is often less mature than adult tissue, it may be less likely to trigger an immune response in the recipient, reducing the risk of rejection.

Fetal tissue transplantation has been explored as a potential treatment for a variety of conditions, including Parkinson's disease, diabetes, and heart disease. However, the use of fetal tissue in medical research and therapy remains controversial due to ethical concerns surrounding the sourcing of the tissue.

Neoplasms, germ cell and embryonal are types of tumors that originate from the abnormal growth of cells. Here's a brief medical definition for each:

1. Neoplasms: Neoplasms refer to abnormal tissue growths or masses, which can be benign (non-cancerous) or malignant (cancerous). They result from uncontrolled cell division and may invade surrounding tissues or spread to other parts of the body through a process called metastasis.
2. Germ Cell Tumors: These are rare tumors that develop from the germ cells, which give rise to sperm and eggs in the reproductive organs (ovaries and testes). They can be benign or malignant and may occur in both children and adults. Germ cell tumors can also arise outside of the reproductive organs, a condition known as extragonadal germ cell tumors.
3. Embryonal Tumors: These are a type of malignant neoplasm that primarily affects infants and young children. They develop from embryonic cells, which are immature cells present during fetal development. Embryonal tumors can occur in various organs, including the brain (medulloblastomas), nervous system (primitive neuroectodermal tumors or PNETs), and other areas like the kidneys and liver.

It is essential to note that these conditions require professional medical evaluation and treatment by healthcare professionals with expertise in oncology and related fields.

Peripheral nerves are nerve fibers that transmit signals between the central nervous system (CNS, consisting of the brain and spinal cord) and the rest of the body. These nerves convey motor, sensory, and autonomic information, enabling us to move, feel, and respond to changes in our environment. They form a complex network that extends from the CNS to muscles, glands, skin, and internal organs, allowing for coordinated responses and functions throughout the body. Damage or injury to peripheral nerves can result in various neurological symptoms, such as numbness, weakness, or pain, depending on the type and severity of the damage.

A chimera, in the context of medicine and biology, is a single organism that is composed of cells with different genetics. This can occur naturally in some situations, such as when fraternal twins do not fully separate in utero and end up sharing some organs or tissues. The term "chimera" can also refer to an organism that contains cells from two different species, which can happen in certain types of genetic research or medical treatments. For example, a patient's cells might be genetically modified in a lab and then introduced into their body to treat a disease; if some of these modified cells mix with the patient's original cells, the result could be a chimera.

It's worth noting that the term "chimera" comes from Greek mythology, where it referred to a fire-breathing monster that was part lion, part goat, and part snake. In modern scientific usage, the term has a specific technical meaning related to genetics and organisms, but it may still evoke images of fantastical creatures for some people.

Animal disease models are specialized animals, typically rodents such as mice or rats, that have been genetically engineered or exposed to certain conditions to develop symptoms and physiological changes similar to those seen in human diseases. These models are used in medical research to study the pathophysiology of diseases, identify potential therapeutic targets, test drug efficacy and safety, and understand disease mechanisms.

The genetic modifications can include knockout or knock-in mutations, transgenic expression of specific genes, or RNA interference techniques. The animals may also be exposed to environmental factors such as chemicals, radiation, or infectious agents to induce the disease state.

Examples of animal disease models include:

1. Mouse models of cancer: Genetically engineered mice that develop various types of tumors, allowing researchers to study cancer initiation, progression, and metastasis.
2. Alzheimer's disease models: Transgenic mice expressing mutant human genes associated with Alzheimer's disease, which exhibit amyloid plaque formation and cognitive decline.
3. Diabetes models: Obese and diabetic mouse strains like the NOD (non-obese diabetic) or db/db mice, used to study the development of type 1 and type 2 diabetes, respectively.
4. Cardiovascular disease models: Atherosclerosis-prone mice, such as ApoE-deficient or LDLR-deficient mice, that develop plaque buildup in their arteries when fed a high-fat diet.
5. Inflammatory bowel disease models: Mice with genetic mutations affecting intestinal barrier function and immune response, such as IL-10 knockout or SAMP1/YitFc mice, which develop colitis.

Animal disease models are essential tools in preclinical research, but it is important to recognize their limitations. Differences between species can affect the translatability of results from animal studies to human patients. Therefore, researchers must carefully consider the choice of model and interpret findings cautiously when applying them to human diseases.

Follicular lymphoma is a specific type of low-grade or indolent non-Hodgkin lymphoma (NHL). It develops from the B-lymphocytes, a type of white blood cell found in the lymphatic system. This lymphoma is characterized by the presence of abnormal follicles or nodules in the lymph nodes and other organs. The neoplastic cells in this subtype exhibit a distinct growth pattern that resembles normal follicular centers, hence the name "follicular lymphoma."

The majority of cases involve a translocation between chromosomes 14 and 18 [t(14;18)], leading to an overexpression of the BCL-2 gene. This genetic alteration contributes to the cancer cells' resistance to programmed cell death, allowing them to accumulate in the body.

Follicular lymphoma is typically slow-growing and may not cause symptoms for a long time. Common manifestations include painless swelling of lymph nodes, fatigue, weight loss, and night sweats. Treatment options depend on various factors such as the stage of the disease, patient's age, and overall health. Watchful waiting, chemotherapy, immunotherapy, targeted therapy, radiation therapy, or a combination of these approaches may be used to manage follicular lymphoma.

Messenger RNA (mRNA) is a type of RNA (ribonucleic acid) that carries genetic information copied from DNA in the form of a series of three-base code "words," each of which specifies a particular amino acid. This information is used by the cell's machinery to construct proteins, a process known as translation. After being transcribed from DNA, mRNA travels out of the nucleus to the ribosomes in the cytoplasm where protein synthesis occurs. Once the protein has been synthesized, the mRNA may be degraded and recycled. Post-transcriptional modifications can also occur to mRNA, such as alternative splicing and addition of a 5' cap and a poly(A) tail, which can affect its stability, localization, and translation efficiency.

'Antibodies, Neoplasm' is a medical term that refers to abnormal antibodies produced by neoplastic cells, which are cells that have undergone uncontrolled division and form a tumor or malignancy. These antibodies can be produced in large quantities and may have altered structures or functions compared to normal antibodies.

Neoplastic antibodies can arise from various types of malignancies, including leukemias, lymphomas, and multiple myeloma. In some cases, these abnormal antibodies can interfere with the normal functioning of the immune system and contribute to the progression of the disease.

In addition, neoplastic antibodies can also be used as tumor markers for diagnostic purposes. For example, certain types of monoclonal gammopathy, such as multiple myeloma, are characterized by the overproduction of a single type of immunoglobulin, which can be detected in the blood or urine and used to monitor the disease.

Overall, 'Antibodies, Neoplasm' is a term that encompasses a wide range of abnormal antibodies produced by neoplastic cells, which can have significant implications for both the diagnosis and treatment of malignancies.

CD4-positive T-lymphocytes, also known as CD4+ T cells or helper T cells, are a type of white blood cell that plays a crucial role in the immune response. They express the CD4 receptor on their surface and help coordinate the immune system's response to infectious agents such as viruses and bacteria.

CD4+ T cells recognize and bind to specific antigens presented by antigen-presenting cells, such as dendritic cells or macrophages. Once activated, they can differentiate into various subsets of effector cells, including Th1, Th2, Th17, and Treg cells, each with distinct functions in the immune response.

CD4+ T cells are particularly important in the immune response to HIV (human immunodeficiency virus), which targets and destroys these cells, leading to a weakened immune system and increased susceptibility to opportunistic infections. The number of CD4+ T cells is often used as a marker of disease progression in HIV infection, with lower counts indicating more advanced disease.

Cell-and tissue-based therapy is a type of medical treatment that involves the use of living cells or tissues to repair, replace, or regenerate damaged or diseased cells or tissues in the body. This can include the transplantation of stem cells, which are immature cells that have the ability to develop into different types of cells, as well as the use of fully differentiated cells or tissues that have specific functions in the body.

Cell-and tissue-based therapies may be used to treat a wide variety of medical conditions, including degenerative diseases, injuries, and congenital defects. Some examples of cell-and tissue-based therapies include:

* Bone marrow transplantation: This involves the transplantation of blood-forming stem cells from the bone marrow of a healthy donor to a patient in need of new blood cells due to disease or treatment with chemotherapy or radiation.
* Corneal transplantation: This involves the transplantation of healthy corneal tissue from a deceased donor to a patient with damaged or diseased corneas.
* Articular cartilage repair: This involves the use of cells or tissues to repair damaged articular cartilage, which is the smooth, white tissue that covers the ends of bones where they come together to form joints.

Cell-and tissue-based therapies are a rapidly evolving field of medicine, and researchers are continually exploring new ways to use these treatments to improve patient outcomes. However, it is important to note that cell-and tissue-based therapies also carry some risks, including the possibility of rejection or infection, and they should only be performed by qualified medical professionals in appropriate settings.

Immunohistochemistry (IHC) is a technique used in pathology and laboratory medicine to identify specific proteins or antigens in tissue sections. It combines the principles of immunology and histology to detect the presence and location of these target molecules within cells and tissues. This technique utilizes antibodies that are specific to the protein or antigen of interest, which are then tagged with a detection system such as a chromogen or fluorophore. The stained tissue sections can be examined under a microscope, allowing for the visualization and analysis of the distribution and expression patterns of the target molecule in the context of the tissue architecture. Immunohistochemistry is widely used in diagnostic pathology to help identify various diseases, including cancer, infectious diseases, and immune-mediated disorders.

A phenotype is the physical or biochemical expression of an organism's genes, or the observable traits and characteristics resulting from the interaction of its genetic constitution (genotype) with environmental factors. These characteristics can include appearance, development, behavior, and resistance to disease, among others. Phenotypes can vary widely, even among individuals with identical genotypes, due to differences in environmental influences, gene expression, and genetic interactions.

Coculture techniques refer to a type of experimental setup in which two or more different types of cells or organisms are grown and studied together in a shared culture medium. This method allows researchers to examine the interactions between different cell types or species under controlled conditions, and to study how these interactions may influence various biological processes such as growth, gene expression, metabolism, and signal transduction.

Coculture techniques can be used to investigate a wide range of biological phenomena, including the effects of host-microbe interactions on human health and disease, the impact of different cell types on tissue development and homeostasis, and the role of microbial communities in shaping ecosystems. These techniques can also be used to test the efficacy and safety of new drugs or therapies by examining their effects on cells grown in coculture with other relevant cell types.

There are several different ways to establish cocultures, depending on the specific research question and experimental goals. Some common methods include:

1. Mixed cultures: In this approach, two or more cell types are simply mixed together in a culture dish or flask and allowed to grow and interact freely.
2. Cell-layer cultures: Here, one cell type is grown on a porous membrane or other support structure, while the second cell type is grown on top of it, forming a layered coculture.
3. Conditioned media cultures: In this case, one cell type is grown to confluence and its culture medium is collected and then used to grow a second cell type. This allows the second cell type to be exposed to any factors secreted by the first cell type into the medium.
4. Microfluidic cocultures: These involve growing cells in microfabricated channels or chambers, which allow for precise control over the spatial arrangement and flow of nutrients, waste products, and signaling molecules between different cell types.

Overall, coculture techniques provide a powerful tool for studying complex biological systems and gaining insights into the mechanisms that underlie various physiological and pathological processes.

Spermatogonia are a type of diploid germ cells found in the seminiferous tubules of the testis. They are the stem cells responsible for sperm production (spermatogenesis) in males. There are two types of spermatogonia: A-dark (Ad) and A-pale (Ap). The Ad spermatogonia function as reserve stem cells, while the Ap spermatogonia serve as the progenitor cells that divide to produce type B spermatogonia. Type B spermatogonia then differentiate into primary spermatocytes, which undergo meiosis to form haploid spermatozoa.

Combination drug therapy is a treatment approach that involves the use of multiple medications with different mechanisms of action to achieve better therapeutic outcomes. This approach is often used in the management of complex medical conditions such as cancer, HIV/AIDS, and cardiovascular diseases. The goal of combination drug therapy is to improve efficacy, reduce the risk of drug resistance, decrease the likelihood of adverse effects, and enhance the overall quality of life for patients.

In combining drugs, healthcare providers aim to target various pathways involved in the disease process, which may help to:

1. Increase the effectiveness of treatment by attacking the disease from multiple angles.
2. Decrease the dosage of individual medications, reducing the risk and severity of side effects.
3. Slow down or prevent the development of drug resistance, a common problem in chronic diseases like HIV/AIDS and cancer.
4. Improve patient compliance by simplifying dosing schedules and reducing pill burden.

Examples of combination drug therapy include:

1. Antiretroviral therapy (ART) for HIV treatment, which typically involves three or more drugs from different classes to suppress viral replication and prevent the development of drug resistance.
2. Chemotherapy regimens for cancer treatment, where multiple cytotoxic agents are used to target various stages of the cell cycle and reduce the likelihood of tumor cells developing resistance.
3. Cardiovascular disease management, which may involve combining medications such as angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, diuretics, and statins to control blood pressure, heart rate, fluid balance, and cholesterol levels.
4. Treatment of tuberculosis, which often involves a combination of several antibiotics to target different aspects of the bacterial life cycle and prevent the development of drug-resistant strains.

When prescribing combination drug therapy, healthcare providers must carefully consider factors such as potential drug interactions, dosing schedules, adverse effects, and contraindications to ensure safe and effective treatment. Regular monitoring of patients is essential to assess treatment response, manage side effects, and adjust the treatment plan as needed.

Neoplastic stem cells, also known as cancer stem cells (CSCs), are a subpopulation of cells within a tumor that are capable of self-renewal and generating the heterogeneous lineages of cells that comprise the tumor. These cells are believed to be responsible for the initiation, maintenance, and progression of cancer, as well as its recurrence and resistance to therapy.

CSCs share some similarities with normal stem cells, such as their ability to divide asymmetrically and give rise to differentiated progeny. However, they also have distinct characteristics that distinguish them from their normal counterparts, including aberrant gene expression, altered signaling pathways, and increased resistance to apoptosis (programmed cell death).

The existence of CSCs has important implications for cancer diagnosis, treatment, and prevention. Targeting these cells specifically may be necessary to achieve durable remissions and prevent relapse, as they are thought to survive conventional therapies that target the bulk of the tumor. Further research is needed to better understand the biology of CSCs and develop effective strategies for their elimination.

Monocytes are a type of white blood cell that are part of the immune system. They are large cells with a round or oval shape and a nucleus that is typically indented or horseshoe-shaped. Monocytes are produced in the bone marrow and then circulate in the bloodstream, where they can differentiate into other types of immune cells such as macrophages and dendritic cells.

Monocytes play an important role in the body's defense against infection and tissue damage. They are able to engulf and digest foreign particles, microorganisms, and dead or damaged cells, which helps to clear them from the body. Monocytes also produce cytokines, which are signaling molecules that help to coordinate the immune response.

Elevated levels of monocytes in the bloodstream can be a sign of an ongoing infection, inflammation, or other medical conditions such as cancer or autoimmune disorders.

Interleukin-3 (IL-3) is a type of cytokine, which is a small signaling protein that modulates the immune response, cell growth, and differentiation. IL-3 is primarily produced by activated T cells and mast cells. It plays an essential role in the survival, proliferation, and differentiation of hematopoietic stem cells, which give rise to all blood cell types. Specifically, IL-3 supports the development of myeloid lineage cells, including basophils, eosinophils, mast cells, megakaryocytes, and erythroid progenitors.

IL-3 binds to its receptor, the interleukin-3 receptor (IL-3R), which consists of two subunits: CD123 (the alpha chain) and CD131 (the beta chain). The binding of IL-3 to its receptor triggers a signaling cascade within the cell that ultimately leads to changes in gene expression, promoting cell growth and differentiation. Dysregulation of IL-3 production or signaling has been implicated in several hematological disorders, such as leukemia and myelodysplastic syndromes.

Inbred NOD (Nonobese Diabetic) mice are a strain of laboratory mice that are genetically predisposed to develop autoimmune diabetes. This strain was originally developed in Japan and has been widely used as an animal model for studying type 1 diabetes and its complications.

NOD mice typically develop diabetes spontaneously at around 12-14 weeks of age, although the onset and severity of the disease can vary between individual mice. The disease is caused by a breakdown in immune tolerance, leading to an autoimmune attack on the insulin-producing beta cells of the pancreas.

Inbred NOD mice are highly valuable for research purposes because they exhibit many of the same genetic and immunological features as human patients with type 1 diabetes. By studying these mice, researchers can gain insights into the underlying mechanisms of the disease and develop new treatments and therapies.

Heterotopic transplantation is a type of organ or tissue transplant where the graft is placed in a different location from where it normally resides while still maintaining its original site. This is often done to supplement the function of the existing organ rather than replacing it. A common example of heterotopic transplantation is a heart transplant, where the donor's heart is placed in a new location in the recipient's body, while the recipient's own heart remains in place but is typically nonfunctional. This allows for the possibility of returning the function of the recipient's heart if the transplanted organ fails.

In heterotopic kidney transplantation, the donor kidney is placed in a different location, usually in the lower abdomen, while the recipient's own kidneys are left in place. This approach can be beneficial for recipients with poor renal function or other medical conditions that make traditional kidney transplantation too risky.

Heterotopic transplantation is also used in liver transplantation, where a portion of the donor liver is placed in a different location, typically in the recipient's abdomen, while the recipient's own liver remains in place. This approach can be useful for recipients with acute liver failure or other conditions that make traditional liver transplantation too risky.

One advantage of heterotopic transplantation is that it allows for the possibility of returning the function of the recipient's organ if the transplanted organ fails, as well as reducing the risk of rejection and improving overall outcomes for the recipient. However, this approach also has some disadvantages, such as increased complexity of the surgical procedure, potential for complications related to the placement of the graft, and the need for ongoing immunosuppression therapy to prevent rejection.

Postoperative complications refer to any unfavorable condition or event that occurs during the recovery period after a surgical procedure. These complications can vary in severity and may include, but are not limited to:

1. Infection: This can occur at the site of the incision or inside the body, such as pneumonia or urinary tract infection.
2. Bleeding: Excessive bleeding (hemorrhage) can lead to a drop in blood pressure and may require further surgical intervention.
3. Blood clots: These can form in the deep veins of the legs (deep vein thrombosis) and can potentially travel to the lungs (pulmonary embolism).
4. Wound dehiscence: This is when the surgical wound opens up, which can lead to infection and further complications.
5. Pulmonary issues: These include atelectasis (collapsed lung), pneumonia, or respiratory failure.
6. Cardiovascular problems: These include abnormal heart rhythms (arrhythmias), heart attack, or stroke.
7. Renal failure: This can occur due to various reasons such as dehydration, blood loss, or the use of certain medications.
8. Pain management issues: Inadequate pain control can lead to increased stress, anxiety, and decreased mobility.
9. Nausea and vomiting: These can be caused by anesthesia, opioid pain medication, or other factors.
10. Delirium: This is a state of confusion and disorientation that can occur in the elderly or those with certain medical conditions.

Prompt identification and management of these complications are crucial to ensure the best possible outcome for the patient.

Cell division is the process by which a single eukaryotic cell (a cell with a true nucleus) divides into two identical daughter cells. This complex process involves several stages, including replication of DNA, separation of chromosomes, and division of the cytoplasm. There are two main types of cell division: mitosis and meiosis.

Mitosis is the type of cell division that results in two genetically identical daughter cells. It is a fundamental process for growth, development, and tissue repair in multicellular organisms. The stages of mitosis include prophase, prometaphase, metaphase, anaphase, and telophase, followed by cytokinesis, which divides the cytoplasm.

Meiosis, on the other hand, is a type of cell division that occurs in the gonads (ovaries and testes) during the production of gametes (sex cells). Meiosis results in four genetically unique daughter cells, each with half the number of chromosomes as the parent cell. This process is essential for sexual reproduction and genetic diversity. The stages of meiosis include meiosis I and meiosis II, which are further divided into prophase, prometaphase, metaphase, anaphase, and telophase.

In summary, cell division is the process by which a single cell divides into two daughter cells, either through mitosis or meiosis. This process is critical for growth, development, tissue repair, and sexual reproduction in multicellular organisms.

CD8-positive T-lymphocytes, also known as CD8+ T cells or cytotoxic T cells, are a type of white blood cell that plays a crucial role in the adaptive immune system. They are named after the CD8 molecule found on their surface, which is a protein involved in cell signaling and recognition.

CD8+ T cells are primarily responsible for identifying and destroying virus-infected cells or cancerous cells. When activated, they release cytotoxic granules that contain enzymes capable of inducing apoptosis (programmed cell death) in the target cells. They also produce cytokines such as interferon-gamma, which can help coordinate the immune response and activate other immune cells.

CD8+ T cells are generated in the thymus gland and are a type of T cell, which is a lymphocyte that matures in the thymus and plays a central role in cell-mediated immunity. They recognize and respond to specific antigens presented on the surface of infected or cancerous cells in conjunction with major histocompatibility complex (MHC) class I molecules.

Overall, CD8+ T cells are an essential component of the immune system's defense against viral infections and cancer.

A plant stem is not typically defined in a medical context, but rather in the field of botany. However, I can certainly provide a general biological definition for you.

In plants, stems are organs that serve primarily as support structures, holding leaves, flowers, and fruits aloft where they can receive sunlight and exchange gases. They also act as conduits, transporting water, nutrients, and sugars made during photosynthesis between the roots and shoots of a plant.

The stem is usually composed of three main tissue systems: dermal, vascular, and ground. The dermal tissue system forms the outermost layer(s) of the stem, providing protection and sometimes participating in gas exchange. The vascular tissue system contains the xylem (which transports water and nutrients upward) and phloem (which transports sugars and other organic compounds downward). The ground tissue system, located between the dermal and vascular tissues, is responsible for food storage and support.

While not a direct medical definition, understanding the structure and function of plant stems can be relevant in fields such as nutrition, agriculture, and environmental science, which have implications for human health.

Sensitivity and specificity are statistical measures used to describe the performance of a diagnostic test or screening tool in identifying true positive and true negative results.

* Sensitivity refers to the proportion of people who have a particular condition (true positives) who are correctly identified by the test. It is also known as the "true positive rate" or "recall." A highly sensitive test will identify most or all of the people with the condition, but may also produce more false positives.
* Specificity refers to the proportion of people who do not have a particular condition (true negatives) who are correctly identified by the test. It is also known as the "true negative rate." A highly specific test will identify most or all of the people without the condition, but may also produce more false negatives.

In medical testing, both sensitivity and specificity are important considerations when evaluating a diagnostic test. High sensitivity is desirable for screening tests that aim to identify as many cases of a condition as possible, while high specificity is desirable for confirmatory tests that aim to rule out the condition in people who do not have it.

It's worth noting that sensitivity and specificity are often influenced by factors such as the prevalence of the condition in the population being tested, the threshold used to define a positive result, and the reliability and validity of the test itself. Therefore, it's important to consider these factors when interpreting the results of a diagnostic test.

An allograft is a type of transplant in which tissue or an organ is transferred from one individual to another, within the same species. The donor and recipient are genetically different, so the recipient's immune system may recognize the donated tissue or organ as foreign and mount an immune response against it. To minimize the risk of rejection, recipients typically receive immunosuppressive drugs to dampen their immune response.

Allografts can be used in a variety of medical contexts, including reconstructive surgery, orthopedic surgery, and organ transplantation. Examples of allografts include heart valves, tendons, ligaments, corneas, skin, and whole organs such as kidneys, livers, and hearts.

It's worth noting that allografts are distinguished from autografts, which involve transplanting tissue or an organ from one part of the body to another in the same individual, and xenografts, which involve transplanting tissue or organs between different species.

Autologous blood transfusion is a medical procedure in which a patient receives their own blood that has been collected and stored prior to surgery or a medical treatment that may cause significant blood loss. The blood is drawn from the patient, typically in the days or weeks leading up to the scheduled procedure, and then stored until it is needed during or after the surgery.

The primary advantage of autologous blood transfusion is that it eliminates the risk of transfusion reactions, infectious disease transmission, and immunomodulation associated with allogeneic (donor) blood transfusions. However, not all patients are candidates for this type of transfusion due to various factors such as medical conditions, low hemoglobin levels, or insufficient time to collect and store the blood before the procedure.

Autologous blood transfusion can be performed using several methods, including preoperative blood donation, acute normovolemic hemodilution, intraoperative cell salvage, and postoperative blood collection. The choice of method depends on various factors, such as the patient's medical condition, the type and extent of surgery, and the availability of resources.

In summary, autologous blood transfusion is a safe and effective way to reduce the need for allogeneic blood transfusions during or after surgical procedures, but it may not be suitable for all patients.

Peripheral blood stem cell transplantation (PBSCT), also called "Peripheral stem cell support", is a method of replacing blood- ... "Peripheral blood stem cells for allogeneic transplantation: a review". Stem Cells. 19 (2): 108-17. doi:10.1634/stemcells.19-2- ... "Stem Cell Transplant (Peripheral Blood, Bone Marrow, and Cord Blood Transplants)". Retrieved 4 March 2012. "Peripheral Blood ... "Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation". 2005-09-09. Welte, K; Gabrilove, J; Bronchud, MH; ...
"Human intrathecal transplantation of peripheral blood stem cells in amyotrophic lateral sclerosis". J Hematother Stem Cell Res ... approach focused on gene therapy and stem cells and ALS TDI was the first to publish on the safety of the use of stem cells in ...
"Detection of Mucor velutinosus in a blood culture after autologous peripheral blood stem cell transplantation: a pediatric case ...
Twenty-five years of peripheral blood stem cell transplantation Blood., Martin Körbling, Freireich EJ., 2011 Jun 16; 117 (24): ... ISBN 9780865422537 Blood stem cells., Martin Körbling, In: Clinical Bone Marrow and Blood Stem Cell Transplantation (2nd ... Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells., Martin Körbling, Katz RL, ... ISBN 9780521622882 History of blood stem cell transplants, Martin Körbling (together with Fliedner TM), In: Blood stem cell ...
16 December 2013 Why Perform a Stem Cell Transplant? Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation ... Mesenchymal stem cell Ovarian stem cell Partial cloning Plant stem cell Stem cell controversy Stem cell marker Stem cell laws ... mesenchymal stem cell, adipose-derived stem cell, endothelial stem cell, dental pulp stem cell, etc.). Muse cells (multi- ... "Reprogramming of human peripheral blood cells to induced pluripotent stem cells". Cell Stem Cell. 7 (1): 20-24. doi:10.1016/j. ...
16 December 2013 Why Perform a Stem Cell Transplant? Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation ... Fetal tissue implant Induced pluripotent stem cell Induced stem cells Stem cell chip Stem cell therapy for macular degeneration ... "Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry". Cell Stem Cell. 19 (2): 154-157. doi:10.1016/j.stem. ... and such research involves adult stem cells, amniotic stem cells, and induced pluripotent stem cells. On 23 January 2009, the ...
December 2006). "Long-term follow-up of autologous peripheral blood stem cell transplantation in the treatment of a patient ... Cells are usually CD34 positive. Median survival is about nine months.[citation needed] Autologous stem cell transplantation ... Clinically patients present with reduction in the count of all blood cells (pancytopenia), a very few blasts in the peripheral ... blood and no or little spleen enlargement (splenomegaly). ...
Transplantation of stem cells are taken from the bone marrow, peripheral blood or umbilical cord of healthy, matched donors. ... Hematopoietic stem cells give rise to blood cells. Differentiation and proliferation of hematopoietic stem cells require a lot ... Stem cells are taken from an affected child's blood or bone marrow. Then in laboratory conditions the stem cells are ... Hematopoietic stem cell transplantation (HSCT) involves intravenous infusion of stem cells to those who have either a damaged ...
... surgery followed by post-operative injections of autologous peripheral blood progenitor cells (PBPC) in combination with ... red blood cells, platelets, and nucleated cells. The adult stem cell fraction is present in the nucleated cells of the marrow. ... As a result, many researchers have focused on adult stem cells, or stem cells isolated from adult humans that can be ... meaning they are cells that have the ability to develop into more than one type of specialized cell. Mesenchymal stem cells ...
January 2009). "Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a ... diverse group of aggressive lymphomas that develop from mature-stage white blood cells called T-cells and natural killer cells ... Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), is a subtype of peripheral T-cell lymphoma. Peripheral T-cell ... July 2007). "Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from ...
OLOLRMC Cancer Center is Baton Rouge area's only peripheral blood stem cell transplantation program, and only high-dose ... The hospital also manages a blood-donating service. OLOLRMC was the first hospital in the world to use an integrated radiology ...
Intensive or high-dose chemotherapy with autologous bone marrow transplantation or peripheral blood stem cell rescue has not ... By nature, these tumors invade diffusely throughout the brain stem, growing between normal nerve cells. Aggressive surgery ... Hall WA, Doolittle ND, Daman M, Bruns PK, Muldoon L, Fortin D, Neuwelt EA (May 2006). "Osmotic blood-brain barrier disruption ... DMG is believed to be caused by genetic mutations that cause epigenetic changes in cells of the developing nervous system, ...
... irradiated accident victim in China with HLA-mismatched peripheral blood stem cell transplantation and mesenchymal stem cells ... cite journal}}: Cite journal requires ,journal= (help) "Infusion of HLA-mismatched peripheral blood stem cells improves the ... At the end of 2012, at the invitation of Blood, Ai became a member on its editorial board. "HLA-Mismatched Stem-Cell ... "The radiation protection and therapy effects of mesenchymal stem cells in mice with acute radiation injury". The British ...
... attempted to restore some functionality to Ouchi's immune system by administering peripheral blood stem cell transplantation, ... After receiving the transplant from his sister, Ouchi initially experienced increased white blood cell counts temporarily but ... to boost stem cell count). Despite his seven month battle, he was unable to fight radiation-exacerbated infections and internal ... and white blood cell counts began to decrease. Numerous other interventions were conducted in an attempt to arrest further ...
Tichelli André; Rovó Alicia (2013). "Fertility Issues Following Hematopoietic Stem Cell Transplantation". Expert Rev Hematol. 6 ... 2001). "Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey". Lancet. 358 (9278): ... Tichelli André; Rovó Alicia (2013). "Fertility Issues Following Hematopoietic Stem Cell Transplantation". Expert Rev Hematol. 6 ... a special type of cell division specific to germ cells, produces egg cells in women. During meiosis, accurate segregation of ...
"Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation". ... Mar 2019). "Peripheral blood stem cell for haploidentical transplantation with post-transplant high dose cyclophosphamide: ... Jun 2018). "Five year follow-up after autologous peripheral blood hematopoietic stem cell transplantation for refractory, ... or non-myeloablative stem cell transplantation (NST) was pioneered by Slavin for safer stem cell transplantation for the ...
... the previous year and had been expected to undergo a bone marrow transplantation and peripheral blood stem cell transplantation ... What I'd rather talk about is how we can solicit blood donations to replace the supply that I have consumed in the hospital. - ...
... and horse antithymocyte globulin conditioning regimen for allogeneic peripheral blood stem cell transplantation performed in ...
... and allogeneic peripheral blood stem cell transplant". Bone Marrow Transplant. 40 (6): 573-8. doi:10.1038/sj.bmt.1705771. PMID ... The number of pregnancies observed after hematopoietic stem cell transplantation involving such a procedure is lower than 2%. ... Tichelli André, Rovó Alicia (2013). "Fertility Issues Following Hematopoietic Stem Cell Transplantation". Expert Rev Hematol. 6 ... 2001). "Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey". Lancet. 358 (9278): ...
Cycles are repeated every 14 days for 3 cycles, then high-dose chemotherapy with autologous stem-cell transplantation follows ( ... A Highly Effective Cytoreduction and Peripheral-Blood Progenitor-Cell Mobilization Regimen for Transplant-Eligible Patients ... ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell ... In case of CD20-positive B cell lymphoid malignancies the ICE regimen is often combined today with rituximab. This regimen is ...
... peripheral blood stem cells collected by apheresis, and umbilical cord stem cells. By 2016, this has grown to over 13,000 stem ... On January 13, 2011, City of Hope performed its 10,000th hematopoietic stem cell transplantation, which includes transplants of ... contract to facilitate stem cell research from laboratory to clinical study; focus on development and manufacture of stem cell ... Joy, Darrin S. (2009-12-14). "City of Hope receives $17 million for islet and stem cell informatics". City of Hope - Hope News ...
Pavletic's research also includes pioneering work on the use of peripheral blood cells in allogeneic stem cell transplantation ... From 1999 until 2002 he was the Director of the Allogeneic Stem Cell Transplantation program at the University of Nebraska. ... the most common late effect in cancer survivors who underwent allogeneic stem cell transplantations as a form of treatment. ... Pavletic's main area of research is in the field of hematopoietic stem cell transplantation for hematologic malignancies, ...
... of Chronic Graft Versus Host Disease and Relapse Associated with T-Cell Depleted Peripheral Blood Stem Cell Transplantation for ... "Overview of T-cell depletion in haploidentical stem cell transplantation". Blood Transfusion. 10 (3): 264-272. doi:10.2450/ ... Or-Geva, N; Reisner, Y (March 2016). "The evolution of T-cell depletion in haploidentical stem-cell transplantation". British ... Booth, Claire (2013). "The Current Role of T Cell Depletion in Paediatric Stem Cell Transplantation". British Journal of ...
It involves collecting some of the patient's own peripheral blood stem cells, giving low-intensity chemotherapy to eliminate ... "Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II ... 2019). "Metformin Restores CNS Remyelination Capacity by Rejuvenating Aged Stem Cells". Cell Stem Cell. 25 (4): 473-485.e8. doi ... Lymphocyte subpopulations in peripheral blood is a promising tool to select RRMS candidate for fingolimod treatment. Gadolinium ...
"Peripheral blood stem cells for allogeneic transplantation: a review". Stem Cells. 19 (2): 108-17. doi:10.1634/stemcells.19-2- ... Hematopoietic stem cell transplantation (HSCT) is the transplantation of blood stem cells derived from the bone marrow (that is ... most hematopoietic stem cell transplantation procedures are now performed using stem cells collected from the peripheral blood ... Stem cell transplantation was pioneered using bone-marrow-derived stem cells by a team at the Fred Hutchinson Cancer Research ...
"Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from ... The T-cells of umbilical cord blood (UCB) have an inherent immunological immaturity, and the use of UCB stem cells in unrelated ... GvHD is commonly associated with bone marrow transplants and stem cell transplants. White blood cells of the donor's immune ... "Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood?". Blood. 101 (11): 4233-44. doi:10.1182/ ...
"Peripheral blood stem cells for allogeneic transplantation: a review". Stem Cells. 19 (2): 108-117. doi:10.1634/stemcells.19-2- ... Peripheral blood stem cells are now the most common source of stem cells for HSCT. They are collected from the blood through a ... Hematopoietic stem-cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived ... The red blood cells are returned to the donor. The peripheral stem cell yield is boosted with daily subcutaneous injections of ...
... radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell ... followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma". Ann. Oncol ... To this end, lymphoid leukemias can also be divided by the type of cells affected: B-cell leukemia T-cell leukemia NK-cell ... T cells, B cells and NK cells are nearly impossible to distinguish under a microscope, therefore one must use a flow cytometer ...
... stem cell transplantation and mesenchymal stem cells 2013 Haploidentical nonmyeloablative allogeneic peripheral blood stem cell ... blood stem cell transplantation 2005 Establishment of a rhesus haploidentical hematopoietic stem cell and mesenchymal stem cell ... stem cell transplantation 2003 The clinical research of nonmyeloablative allogeneic peripheral blood hematopoietic stem cells ... stem cell transplantation 2007 Effects of mesenchymal stem cells on cell cycle and apoptosis of hematopoietic tissue cells in ...
The cells employed are allogeneic peripheral blood stem cells. Matched HLA between donor and recipient is not necessary. The ... which will be reinitiated by donor's stem cells soon after transplantation, and will play a role as recipient-versus-tumor (RVT ... Donor's stem cells, which have been processed, will also accelerate functional recovery of recipient's hematopoietic stem cells ... mismatched allogeneic peripheral blood stem cells following a reduced-intensity chemotherapy or targeted therapy. The term " ...
Successful stem cell transplantation for patients with severe combined immunodeficiency (SCID) from matched family donors ... Multilineage hematopoietic engraftment after allogeneic peripheral blood stem cell transplantation without conditioning in SCID ... Successful stem cell transplantation for patients with severe combined immunodeficiency (SCID) from matched family donors ... They received megadoses of stem cells (18-23 x 10(6)CD34/kg). In contrast to the expected mixed chimerism that usually occurs ...
... to assess the incidence and analyze reasons which cause prolongation of hospital stay in patients engrafted after peripheral ... blood stem cell transplantation (PBSCT), we performed this retrospective analysis. One hundred patients (receiving 123 ... Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A ... Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation ...
Peripheral blood stem cell transplantation (PBSCT), also called "Peripheral stem cell support", is a method of replacing blood- ... "Peripheral blood stem cells for allogeneic transplantation: a review". Stem Cells. 19 (2): 108-17. doi:10.1634/stemcells.19-2- ... "Stem Cell Transplant (Peripheral Blood, Bone Marrow, and Cord Blood Transplants)". Retrieved 4 March 2012. "Peripheral Blood ... "Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation". 2005-09-09. Welte, K; Gabrilove, J; Bronchud, MH; ...
... of single-dose 6 mg pegfilgrastim in mobilizing peripheral blood stem cells in allogeneic hematopoietic cell transplantation ... Effectiveness of single-dose 6 mg pegfilgrastim in mobilizing peripheral blood stem cells ... A single injection of 12 mg pegfilgrastim was used to mobilize peripheral blood progenitor cells (PBPCs) from healthy donors in ... was effective and safe for mobilizing CD34+ cells in donors for allogeneic hematopoietic stem cell transplantation. We ...
The patient then underwent high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation (auto-PBSCT ... The patient then underwent high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation (auto-PBSCT ... The patient then underwent high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation (auto-PBSCT ... The patient then underwent high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation (auto-PBSCT ...
Renal cell carcinoma (see the image below) is the most common type of kidney cancer in adults. It accounts for approximately 3 ... Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N ... Nonmyeloablative allogeneic stem cell transplantation. Nonmyeloablative allogeneic stem cell transplantation can induce ... followed by an infusion of peripheral blood stem cells from a human leukocyte antigen (HLA) - identical sibling or a sibling ...
title = "Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from ... T1 - Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from ... Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from ... Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from ...
Dive into the research topics of High-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary ... T1 - High-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary breast cancer refractory to ... High-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary breast cancer refractory to ... High-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary breast cancer refractory to ...
Cell Surgical Network is an international team of physicians committed to advancing personal cell therapy for their patients. ... Clinical outcome of autologous peripheral blood stem cell transplantation in opticospinal and conventional forms of secondary ... Clinical outcome of autologous peripheral blood stem cell transplantation in opticospinal and conventional forms of secondary ... Clinical outcome of autologous peripheral blood stem cell transplantation in opticospinal and conventional forms of secondary ...
Mobilized peripheral blood stem cells compared with bone marrow for related reduced-intensity transplantation in acute myeloid ... Mobilized peripheral blood stem cells compared with bone marrow for related reduced-intensity transplantation in acute myeloid ... Mobilized peripheral blood stem cells compared with bone marrow for related reduced-intensity transplantation in acute myeloid ... T1 - Mobilized peripheral blood stem cells compared with bone marrow for related reduced-intensity transplantation in acute ...
Fetal Blood. Humans. Recurrence. Graft vs Host Disease. Leukemia, Myeloid, Acute. Peripheral Blood Stem Cell Transplantation ... Comparison of Outcomes after Unrelated Double-Unit Cord Blood and Haploidentical Peripheral Blood Stem Cell Transplantation in ... Unmanipulated haploidentical hematopoietic stem cell transplantation (HCT) with post-transplantation cyclophosphamide as graft- ... Unmanipulated haploidentical hematopoietic stem cell transplantation (HCT) with post-transplantation cyclophosphamide as graft- ...
Streptococcus viridans bacteremia following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 1998 ... Predictors of viridans streptococcal shock syndrome in bacteremic children with cancer and stem-cell transplant recipients. J ... Clinical significance of viridans streptococci isolated from blood cultures. J Clin Microbiol. 1982;15:725-7 .PubMedGoogle ... Viridans streptococci isolated by culture from blood of cancer patients: clinical and microbiologic analysis of 50 cases. J ...
Cell Enumeration Kit and ISHAGE protocol help in flow cytometry-based enumeration of CD34+ counts for stem cell transplantation ... Bone marrow versus peripheral blood for stem cell transplantation. Hematopoietic stem cells (HSC) from the bone marrow can be ... Transplantation of hematopoietic stem cells from the peripheral blood. J Cell Mol Med. 2005;9(1):37-50. doi: 10.1111/j.1582- ... Stem cell transplantation is performed after high-dose chemotherapy (HDC) to restore a cancer patients blood and immune cell ...
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem ... non-Hodgkins lymphoma patients after retrieval therapy which includes peripheral blood. stem cell transplantation (PBSCT) in ... A Pilot Study of Peripheral Blood Stem Cell Transplantation (PBSCT) After Preparative Therapy Consisting of Cyclophosphamide, ... A Pilot Study of Peripheral Blood Stem Cell Transplantation (PBSCT) After Preparative Therapy Consisting of Cyclophosphamide, ...
Stem cell transplantation for malignant lymphoma. *Peripheral blood stem cell mobilization for autologous stem cell ... MemberBlood and Marrow Transplant Program, William J von Liebig Transplant Center ...
Stem Cell Transplantation in minutes with SmartDraw. SmartDraw includes 1000s of professional healthcare and anatomy chart ... Stem Cell Transplantation. donor. stem cells from. peripheral blood. Allogeneic stem cell transplantation. Stem Cell come form ... Bone marrow transplantation. Umbilical cord blood transplantation. Autologous stem cell transplantation. Syngeneic stem cell ... Leukemia - Stem Cell Transplantation. Create healthcare diagrams like this example called Leukemia - Stem Cell Transplantation ...
Pseudomembranous Tracheobronchitis Caused by Aspergillus in a Patient after Peripheral Blood Stem Cell Transplantation. L P Koh ... A Unique Pair of Monozygotic Twins with Concordant Clear Cell Renal Cell Carcinoma: A Case Report. Min-Han Tan, Jasmine Yang, ... Squamous Cell Carcinoma arising in a Cutaneous Epidermal Cyst-A Case Report. T H Wong, A K M Khoo, P H Tan, B H Ong ... Liver Transplantation in a Child With Severe Hypercholesterolaemia in Alagille Syndrome. S C Quek, M Aw, S H Quak, K ...
... bone marrow transplantation or peripheral blood stem cell transplantation.. *Patients receiving granulocyte components, ... Red Blood Cells. Red blood cells (RBCs), also known as packed red blood cells (pRBCs), are prepared from whole blood by ... Red blood cells do not provide viable platelets, nor do they provide clinically significant amounts of coagulation factors. In ... The volume of one unit of RBCs contains approximately 200mL red blood cells, 100 mL of an additive solution, and ~30mL plasma, ...
There is a paucity of data examining the tolerance and outcome of hematopoietic stem cell transplantation (HSCT) for relapse ... three received matched related peripheral blood stem cells and four receivedmatched unrelated marrow (n = 3) or peripheral ... Five patients received autologous HSCT: threemarrow and two peripheral blood stem cells. Among seven allogeneic transplants, ... Hematopoietic Stem Cell Transplantation in Lymphoma Patients Receiving Prior Therapy With Tositumomab/Iodine-131 Tositumomab. ...
HCMV infection of humanized mice after transplantation of G-CSF-mobilized peripheral blood stem cells from HCMV-seropositive ... Blood. 2011 Jan 6;117(1):352-61. (doi: 10.1182/blood-2010-06-291245.) [PMID: 20930069, PMCID: PMC3037756] Epub 2010 Oct 7. ... Retrieval of human cytomegalovirus glycoprotein B from cell surface is not required for virus envelopment in astrocytoma cells ... Biol Blood Marrow Transplant. 2014 Jan;20(1):132-5. (doi: 10.1016/j.bbmt.2013.10.019.) [PMID: 24161922, PMCID: PMC3922710] Epub ...
UDENYCA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. ... UDENYCA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation ... Increased white blood cell count (leukocytosis). Your healthcare provider will check your blood during treatment with UDENYCA. ... Sickle cell crises. You may have a serious sickle cell crisis, which could lead to death, if you have a sickle cell disorder ...
First described in 1848, MM is characterized by a proliferation of malignant plasma cells and a subsequent overabundance of ... Clinicians treat many patients with high-dose therapy and peripheral blood or bone marrow stem cell transplantation. ... A Phase II trial of autologous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the ... Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood ...
Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation ... Swiss Blood Stem Cell Transplantation Group), Haematopoietic stem cell transplantation: activity in Switzerland compared with ... for the Swiss Blood Stem Cell Transplantation Group (SBST), Haematopoietic cell transplantation in Switzerland, changes and ... a report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation registry 1997-2016 ...
Heterologous Transplantation (Xenotransplantation) 5. Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell ... 04/01/2012 - "Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French ... 10/01/2006 - "To study the possible relationship between whole-blood hydroxychloroquine (HCQ) concentrations and clinical ...
Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing- ... DOI for Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of ... of Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of ... DOI for Cerebrospinal fluid cytokines after autologous haematopoietic stem cell transplantation and intrathecal rituximab ...
... is not approved for use for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. ... Increased white blood cell count (leukocytosis). Your healthcare provider will check your blood during treatment. ... Sickle cell crises. You may have a serious sickle cell crisis, which could lead to death, if you have a sickle cell disorder ... G-CSF stimulates your bone marrow to produce a type of white blood cell, called neutrophils. Neutrophils are important for ...
FYLNETRA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation ... FYLNETRA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation ... Increased white blood cell count (leukocytosis). Your healthcare provider will check your blood during treatment with FYLNETRA. ... Sickle cell crises. You may have a serious sickle cell crisis, which could lead to death, if you have a sickle cell disorder ...
... cells_in_mice_using_natural_killer_nk_cells_from_umbilical_cord_blood ... However, in 1988, researchers found cord blood to be another source for stem cell transplantation. These immature stem cells ... Historical transplants used a matched donors peripheral blood or bone marrow to transplant to a patient. ... Stem Cell Research. Breakthrough in treating leukemia, lymphoma with umbilical cord blood stem cells. December 9, 2013 06:56 PM ...
Guidelines for Preventing Transmission of Human Immunodeficiency Virus Through Transplantation of Human Tissue and Organs ... Peripheral blood stem cells are being used for autologous transplantation and, in the future, may be useful for allogeneic use ... Furthermore, cord blood stem cells are being used for both related- and unrelated-donor allogeneic transplantation.. Current ... In addition to HIV transmission through blood and blood products, reports of HIV infection following transplantation have ...
  • The patient then underwent high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation (auto-PBSCT). (elsevierpure.com)
  • Clinical outcome of autologous peripheral blood stem cell transplantation in opticospinal and conventional forms of secondary progressive multiple sclerosis in a Chinese population. (cellsurgicalnetwork.com)
  • To evaluate clinical outcomes of autologous peripheral blood stem cell transplantation (APBCST) between opticospinal multiple sclerosis (OSMS) and conventional multiple sclerosis (CMS) during disease progressive stage in a Chinese population. (cellsurgicalnetwork.com)
  • Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. (smw.ch)
  • Thereafter, the patient received autologous peripheral blood stem cell transplantation with high-dose chemotherapy (combination of ifosphamide, carboplatin and etoposide) as pretreatment. (karger.com)
  • Reduction in late mortality among patients with Multiple Myeloma treated with Autologous Peripheral Blood Stem Cell Transplantation - a BMTSS Report. (stembook.org)
  • High-dose melphalan followed by autologous peripheral blood stem cell transplantation may also be used. (merckmanuals.com)
  • Effectiveness of single-dose 6 mg pegfilgrastim in mobilizing peripheral blood stem cells in allogeneic hematopoietic cell transplantation donors. (bvsalud.org)
  • The specific medications administered depend on the choice of therapy and whether it is supportive care only, immunosuppressive therapy, or hematopoietic cell transplantation. (medscape.com)
  • Monocyte subpopulation recovery as predictors of hematopoietic cell transplantation outcomes. (stembook.org)
  • Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic cell transplantation program (Part I): Minimum requirements and beyond. (stembook.org)
  • Central venous catheter placement is required before the administration of hematopoietic cell transplantation. (medscape.com)
  • Full hematopoietic engraftment was reported in one case after bone marrow transplantation without conditioning for a SCID patient. (nih.gov)
  • Bone Marrow Transplantation (2000) 26, 877-880. (nature.com)
  • Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. (nature.com)
  • Immature hematopoietic stem cells in the circulating blood that are similar to those in the bone marrow are collected by apheresis from a donor (PBSC collection). (wikipedia.org)
  • The administered hematopoietic stem cells then migrate to the recipient's bone marrow, through a process known as stem cell homing, where the transplanted cells override the previous bone marrow. (wikipedia.org)
  • This allows the bone marrow to recover, proliferate and continue producing healthy blood cells. (wikipedia.org)
  • Cells from the patient's sister's bone marrow were administered, and in the following weeks successfully began dividing and differentiating into white blood cells. (wikipedia.org)
  • Bone marrow transplantation , 51 (12), 1599-1601. (johnshopkins.edu)
  • Bone marrow transplantation , 37 (10), 929-935. (elsevierpure.com)
  • Bone marrow transplantation , 45 , S21-S22. (amsterdamumc.org)
  • This study compared outcomes after dUCBT and haplo-HCT using peripheral blood stem cells (PBSCs) in adult patients with AML in complete remission (CR) who underwent transplantation in European Society for Blood and Marrow Transplantation (EBMT)-affiliated centers. (unisr.it)
  • 2 HSCs are primarily found in bone marrow niches, but a small fraction of HSCs can also be found in the peripheral blood. (bdbiosciences.com)
  • 3 Following exogenous stimulation, such as chemotherapy or using growth factors such as granulocyte colony stimulating factor (G-CSF) and filgrastim, the number of HSCs in the peripheral blood increases, either becoming on par or even exceeding the number in the bone marrow. (bdbiosciences.com)
  • CD34, a transmembrane phosphoglycoprotein, is present on immature hematopoietic precursor cells and all hematopoietic colony-forming cells in bone marrow and blood, including unipotent and pluripotent progenitor cells. (bdbiosciences.com)
  • Flow cytometric enumeration of CD34+ HSCs and progenitor cells is an established method for the evaluation of bone marrow and stem cell grafts. (bdbiosciences.com)
  • Characterize the time to recovery of normal bone marrow function after transplantation in these patients. (knowcancer.com)
  • OUTLINE: Patients receive 2 courses of reinduction chemotherapy followed by bone marrow biopsy and aspirate prior to peripheral blood stem cell (PBSC) harvest. (knowcancer.com)
  • Among seven allogeneic transplants,three received matched related peripheral blood stem cells and four receivedmatched unrelated marrow (n = 3) or peripheral blood (n = 1) stem cells.Allogeneic recipients received tacrolimus and methotrexate for graft-vs-hostdisease prophylaxis. (cancernetwork.com)
  • Patients undergoing fludarabine therapy (purine analog) , bone marrow transplantation or peripheral blood stem cell transplantation. (utmb.edu)
  • Multiple myeloma (MM) is a plasma cell malignancy in which monoclonal plasma cells proliferate in bone marrow, resulting in an overabundance of monoclonal paraprotein (M protein), destruction of bone, and displacement of other hematopoietic cell lines. (medscape.com)
  • Bone marrow aspirate demonstrating plasma cells of multiple myeloma. (medscape.com)
  • National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines also recommend the use of serum free light chain assay and plasma cell fluorescence in situ hybridization (FISH) on bone marrow: del 13, del 17p13, t(4;14), t(11;14), t(14;16), t(14;20), 1q21 amplification, 1p deletion as part of the initial diagnostic workup. (medscape.com)
  • Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. (smw.ch)
  • The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. (smw.ch)
  • Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. (smw.ch)
  • High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. (smw.ch)
  • The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. (smw.ch)
  • High-dose chemotherapy with autologous bone marrow transplantation: 11 years' experience in Zurich. (smw.ch)
  • Historical transplants used a matched donor's peripheral blood or bone marrow to transplant to a patient. (biologynews.net)
  • G-CSF stimulates your bone marrow to produce a type of white blood cell, called neutrophils. (drugs.com)
  • Atkinson K, Meyers J, Storb R, Prentice RL, Thomas ED . Varicella-zoster virus infection after marrow transplantation for aplastic anemia or leukemia. (nature.com)
  • Infection with varicella-zoster virus after marrow transplantation. (nature.com)
  • Han CS, Miller W, Haake R, Weisdorf D . Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications. (nature.com)
  • Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. (nature.com)
  • Aplastic anemia is a syndrome of bone marrow failure characterized by peripheral pancytopenia and marrow hypoplasia (see the image below). (medscape.com)
  • Low-power view of hematoxylin-eosin-stained bone marrow showing hypocellularity, with increased adipose tissue and decreased hematopoietic cells in the marrow space. (medscape.com)
  • The clinical presentation of patients with aplastic anemia includes signs and symptoms related to the decrease in bone marrow production of hematopoietic cells. (medscape.com)
  • The theoretical basis for marrow failure includes primary defects in or damage to the stem cell or the marrow microenvironment. (medscape.com)
  • External insults (eg, infections, radiation, drugs) may disrupt stem cell homeostasis in marrow environment, leading to altered growth. (medscape.com)
  • 1 This includes human cells for transplantation such as haematopoietic stem cells from bone marrow, peripheral blood or cord blood. (who.int)
  • Patients who undergo bone marrow transplantation are generally immunosuppressed with a dose of cyclophosphamide which is usually calculated based on the patient's weight. (slideshare.net)
  • She underwent hematopoietic stem cell transplantation which uses stem cells derived from bone marrow, peripheral blood, or umbilical cord blood. (turnto23.com)
  • Late-occurring Venous Thromboembolism in Allogeneic Blood or Marrow Transplant Survivors - a BMTSS-HiGHS2 Risk Model. (stembook.org)
  • Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. (stembook.org)
  • Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow allografts have improved Long-term Overall and Graft-versus-Host Disease, Relapse-Free Survival. (stembook.org)
  • Infections following Transplantation of Bone Marrow or Peripheral-Blood Stem Cells from Unrelated Donors. (stembook.org)
  • Diagnosis typically requires demonstration of M-protein (sometimes present in urine and not serum but rarely absent entirely) and/or light-chain proteinuria, and excessive plasma cells in the bone marrow. (merckmanuals.com)
  • A bone marrow transplant is when stem cells are removed from the bone marrow for transplant. (differencebetween.net)
  • These substances include, for instance, granulocyte- colony-stimulating factor (G-CSF), which is added so that the donors own bone marrow will make and produce more stem cells that will end up in the bloodstream. (differencebetween.net)
  • Further benefits are that the platelets and neutrophil cells (one of the white blood cells) are more easily able to recover if this method is used compared with the bone marrow procedure. (differencebetween.net)
  • There are some disadvantages to obtaining stem cells from blood rather than from bone marrow. (differencebetween.net)
  • A bone marrow transplant is when stem cells are removed from a donor's bone marrow for transplant into a patient. (differencebetween.net)
  • This is necessary because it is a rather painful process in which a needle is inserted directly into the marrow cavity of the bone and stem cells withdrawn. (differencebetween.net)
  • The advantage is that granulocyte- colony-stimulating factor (G-CSF) does not have to be given to the donor since the procedure involves going to the source of the stem cells, which is the bone marrow. (differencebetween.net)
  • A bone marrow transplant is when stem cells are harvested directly from the bone marrow. (differencebetween.net)
  • Bone marrow transplants involve cells that are taken out of the bone marrow. (differencebetween.net)
  • The study involved targeted mutational analysis of samples obtained before stem cell transplant from 1,514 MDS patients enrolled at the Center for International Blood and Marrow Transplant Research Repository between 2005 and 2014. (ascopost.com)
  • A transplantation of stem cells, from umbilical cord blood or from a peripheral stem cell or bone marrow donor, is appropriate for some boys with the disease, such as those with early symptoms and MRI abnormalities. (sunjournal.com)
  • For the purposes of this document, HSCT is defined of the CDC, the Infectious Diseases Society of America, as any transplantation of blood or marrow-derived he- and the American Society of Blood and Marrow Trans- matopoietic stem cells, regardless of transplant type plantation," which was published in the Morbidity and (allogeneic or autologous) or cell source (bone marrow, Mortality Weekly Report [1]. (cdc.gov)
  • Peripheral blood has largely replaced bone marrow as a source of stem cells, especially in autologous hematopoietic stem cell transplantation, because stem cell harvest is easier and neutrophil and platelet counts recover faster. (msdmanuals.com)
  • Low power, H and E showing a hypocellular bone marrow with increased adipose tissue and decreased hematopoietic cells in the marrow space. (medscape.com)
  • BLAISE, D. Healthy sibling donor anxiety and pain during bone marrow or peripheral blood stem cell harvesting for allogeneic transplantation: results of a randomized study. (bvsalud.org)
  • Bone marrow contains stem cells, which are immature cells that become blood cells. (medlineplus.gov)
  • People with life-threatening cancers, such as leukemia , lymphoma , and myeloma can be treated with a bone marrow transplant or, sometimes, a stem cell transplant. (medlineplus.gov)
  • Bone marrow donation can be done either by collecting a donor's bone marrow surgically, or by removing stem cells from a donor's blood. (medlineplus.gov)
  • First, the donor is given 5 days of shots to help stem cells move from the bone marrow into the blood. (medlineplus.gov)
  • 15]. The percentage of bone common of which are trisomy 8, mono- marrow blast cells for estimation of the Myelodysplastic syndrome (MDS) is somy 7 and 5q- [11]. (who.int)
  • Unmanipulated haploidentical hematopoietic stem cell transplantation (HCT) with post-transplantation cyclophosphamide as graft-versus-host disease (GVHD) prophylaxis (haplo-PTCY) and unrelated double-unit umbilical cord blood transplantation (dUCBT) are feasible options for treating patients with high-risk acute myelogenous leukemia (AML). (unisr.it)
  • Researchers from The University of Texas M. D. Anderson Cancer Center have found a therapy that effectively kills human leukemia cells in mice using natural killer (NK) cells from umbilical cord blood. (biologynews.net)
  • This is when stem cells that are obtained from the bloodstream or umbilical cord of a donor are used for transplant into a patient. (differencebetween.net)
  • Umbilical cord blood stem cells are only used for transplant into children since there are not enough cells present to be of any use for transplant into an adult patient. (differencebetween.net)
  • A stem cell transplant is when stem cells are harvested from the bloodstream or the umbilical cord. (differencebetween.net)
  • Stem cell transplants involve cells that are taken out of the blood or umbilical cord. (differencebetween.net)
  • peripheral blood, or placental/umbilical cord blood). (cdc.gov)
  • Umbilical cord hematopoietic stem cell transplantation has been restricted mainly to children because there are too few stem cells in umbilical cord blood for an adult. (msdmanuals.com)
  • The technique for umbilical cord hematopoietic stem cell transplantation is still in its infancy, but it is gaining interest. (msdmanuals.com)
  • For umbilical cord blood harvest, the cord is clamped after delivery of the baby, and blood is drawn from the cord with a needle and collected in a sterile bag. (msdmanuals.com)
  • The purpose of this study was to determine if 6 mg of pegfilgrastim was effective and safe for mobilizing CD34+ cells in donors for allogeneic hematopoietic stem cell transplantation . (bvsalud.org)
  • The safety profile of venetoclax following allogeneic hematopoietic stem cell transplantation in patients with chronic lymphocytic leukemia appears to be comparable with other reports in clinical trials. (cancernetwork.com)
  • Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis. (stembook.org)
  • In a study reported in The New England Journal of Medicine , R. Coleman Lindsley, MD, PhD , of Dana-Farber Cancer Institute, and colleagues found that a number of mutations present in patients with myelodysplastic syndromes (MDS) were associated with poorer clinical outcome after allogeneic hematopoietic stem cell transplantation. (ascopost.com)
  • Genetic profiling revealed that molecular subgroups of patients undergoing allogeneic hematopoietic stem-cell transplantation for MDS may inform prognostic stratification and the selection of conditioning regimen. (ascopost.com)
  • Allogeneic hematopoietic stem cell transplantation is limited mainly by lack of histocompatible donors. (msdmanuals.com)
  • Graft-versus-host disease is a common side effect of patients receiving stem cell transplants, which results when the T cells in the transplanted blood react against the patient's own cells. (biologynews.net)
  • Zweidler-McKay also predicts this type of transplant could be used for adults who have already had a transplant or for those adult and pediatric patients who aren't candidates for other stem cell transplants due to blood counts or illness. (biologynews.net)
  • This study will assess the safety and effectiveness of certain cord blood transplants. (nih.gov)
  • The study will help researchers learn the best methods for collecting, storing, and using cord blood in transplants. (nih.gov)
  • The number of human tissue transplants is increasing in both developed and developing countries, but global data on this form of transplantation are less complete. (who.int)
  • Access to transplantation is limited in low- and many medium-income countries, where the rate of transplants remains far below that of richer nations. (who.int)
  • Cord blood and haploidentical (half-matched) transplants are used to treat an increasing number of patients. (bmtinfonet.org)
  • Successful stem cell transplantation for patients with severe combined immunodeficiency (SCID) from matched family donors without conditioning results in engraftment of T lymphocytes. (nih.gov)
  • A single injection of 12 mg pegfilgrastim was used to mobilize peripheral blood progenitor cells (PBPCs) from healthy donors in some studies. (bvsalud.org)
  • The 73.3% of donors mobilized with pegfilgrastim yielded >4 × 106 cells /kg CD34+ cells in a single apheresis procedure when compared to the 33.3% of donors mobilized with G-CSF (P (bvsalud.org)
  • Exclusion of prospective blood donors based on their acknowledged risk behaviors for human immunodeficiency virus (HIV) infection began in 1983 (1). (cdc.gov)
  • In 1985, when tests for HIV antibody became available, screening prospective donors of blood, organs, and other tissues also began (2,3). (cdc.gov)
  • This study is investigating a new method for collecting blood stem cells from donors to see if it reduces transplant complications, such as rejection, in patients who have blood diseases. (nih.gov)
  • T cell preparation: Patients and donors undergo apheresis to obtain peripheral blood mononuclear cells (PBMCs), which are expanded in culture. (knowcancer.com)
  • Organ Transplantation.2 These Guiding Principles - whose emphases include voluntary donation, noncommercialization, genetic relation of recipients to donors and a preference for cadavers over living donors as sources - have considerably influenced professional codes, national, state and provincial legislation, and the policies of intergovernmental organizations. (who.int)
  • He remains in complete remission 2 years after transplantation. (elsevierpure.com)
  • Estimate the failure-free survival rate in a cohort of relapsed Hodgkin's lymphoma and non-Hodgkin's lymphoma patients after retrieval therapy which includes peripheral blood stem cell transplantation (PBSCT) in patients who achieve a complete remission or partial remission. (knowcancer.com)
  • Forty-two female patients (median age of 46 years) with breast cancer refractory to neoadjuvant chemotherapy received HDCT (cyclophosphamide, carmustine and thiotepa) supported by an autologous peripheral blood stem cells transplant. (elsevierpure.com)
  • For example, in developing and developed countries alike, kidney transplantation not only yields survival rates and quality-of-life that are far superior to those obtained with other treatments for end-stage renal disease, such as haemodialysis, but is also less costly in the long run. (who.int)
  • The aim of the academic journal is to provide a platform for researchers, scientists, physicians, and other health professionals to find latest research information in the areas of stem cell research, transplantations such as stem cell transplantation, transplantation immunology, kidney transplantation and its treatment. (slideshare.net)
  • 30,000 patients with blood-related malignancies receive HDC, which, if the response is satisfactory, could subsequently be followed by hematopoietic stem cell transplantation (HSCT). (bdbiosciences.com)
  • There is a paucity of data examining the tolerance and outcome of hematopoietic stem cell transplantation (HSCT) for relapse after tositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • There is a paucity of data examining the tolerance andoutcome of hematopoietic stem cell transplantation (HSCT) for relapse aftertositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • Five patients received autologous HSCT: threemarrow and two peripheral blood stem cells. (cancernetwork.com)
  • Opportunistic infections (OIs) are defined as any in- the infusion of hematopoietic stem cells from a donor fections that occur with increased frequency or severity into a patient who has received chemotherapy, which in HSCT patients. (cdc.gov)
  • are basically 3 phases of immune recovery for HSCT patients, The purposes of the guidelines are (1) to summarize the beginning at day 0, the day of transplantation. (cdc.gov)
  • The Hematopoietic stem cell transplantation (HSCT) is used in children as a definitive treatment for various oncological, immune deficiencies, hemoglobinopathy, and malignancies diseases that involve the hematological system, congenital metabolism disorders, among others. (bvsalud.org)
  • This is a quantitative, retrospective, observational, descriptive and analytical quantitative approach approaching the medical records of children and adolescents submitted to HSCT in a referral hospital service for this type of transplantation in the state of Rio Grande do Sul North (RN). (bvsalud.org)
  • The allogeneic HSCT was the most frequently performed (57.14%) and the most used source of Hematopoietic progenitor cells (HPC) was the peripheral blood (54.29%) and 5.71% of these patients developed the Graft versus Host Disease (GVHD), of which one was affected by acute GVHD and another by chronic GVHD. (bvsalud.org)
  • The profile of the clinical variables presented by the children and adolescents of this study shows that the most prevalent diagnosis was ALL, the most frequent toxicities were gastrointestinal, cardiac, respiratory and hematological, the most common HSCT was allogeneic peripheral blood and the greatest cause of mortality was sepsis. (bvsalud.org)
  • Hematopoietic stem cell transplantation not responded to other therapeutic modalities, with (HSCT) is used in children as a definitive treatment an increase in survival after transplantation, for different oncological, immune deficiencies, contributing to its use (YEILIPEK, 2014). (bvsalud.org)
  • Peripheral blood stem cells were obtained by leukapheresis after mobilization with granulocyte colony-stimulating factor. (cellsurgicalnetwork.com)
  • This pharmacologically induced egress of HSCs into peripheral blood, called mobilization, is utilized as the preferred strategy for generating HSCs for transplantation. (bdbiosciences.com)
  • Quantitating the CD34+ cell population can also be useful during mobilization as well as for determining the optimal timing of apheresis sessions to make sure that enough CD34+ cells have been harvested. (bdbiosciences.com)
  • UDENYCA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. (drugs.com)
  • The stem cell mobilization result was poor. (cdc.gov)
  • Before apheresis, the donor's blood count showed mild thrombocytopenia after G-CSF mobilization. (cdc.gov)
  • High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. (smw.ch)
  • LOS ANGELES (AP) - Selma Blair says she's in remission from multiple sclerosis as a result of undergoing stem cell transplantation. (turnto23.com)
  • In order to assess the incidence and analyze reasons which cause prolongation of hospital stay in patients engrafted after peripheral blood stem cell transplantation (PBSCT), we performed this retrospective analysis. (nature.com)
  • Peripheral blood stem cell transplantation (PBSCT), also called "Peripheral stem cell support", is a method of replacing blood-forming stem cells. (wikipedia.org)
  • Studies suggest that PBSCT has a better outcome in terms of the number of hematopoietic stem cell (CD34+ cells) yield. (wikipedia.org)
  • Since allogeneic PBSCT involves transformation of blood between different individuals, this naturally carries more complications than autologous PBSCT. (wikipedia.org)
  • If the total blood volume of the donor is less than that of the recipient (such as when a child is donating to an adult), multiple PBSCT sessions may be required for adequate collection. (wikipedia.org)
  • Determine the feasibility and efficacy of a reduced-intensity conditioning regimen comprising alemtuzumab, fludarabine, melphalan, and thiotepa followed by allogeneic peripheral blood stem cell transplantation (PBSCT) in patients with hematologic malignancies. (knowcancer.com)
  • Determine the safety of LMB-2 immunotoxin-treated, selectively-depleted donor T cells, administered after allogeneic PBSCT, in these patients. (knowcancer.com)
  • ABSTRACT This study examined haematopoietic stem cells of 19 high-risk cases of myelodysplastic syndrome (MDS) for apoptotic and anti-apoptotic signals and cellular proliferation and correlated these with clinical and cytogenetic subtypes, particularly trisomy 8. (who.int)
  • The essence of MDS is damage of In the current work we examined All our patients were of the high-risk colony-forming units [4], but the defect haematopoietic stem cells of high-risk group and none of them was eligible of the haematopoietic stem cells is not MDS cases for apoptotic and anti-apop- for stem cell transplantation. (who.int)
  • The apheresis procedure typically lasts for 4-6 hours, depending on the blood volume of the donor. (wikipedia.org)
  • The stem cells are then separated from the other blood cells by the process of apheresis, and then they are given to the patient through a catheter placed into a vein. (differencebetween.net)
  • Cord blood is a promising source of natural killer cells because the NK cells have enhanced sensitivity to stimulation, decreased potential to cause graft-versus-host disease and are available from cord banks throughout the country and world," says Zweidler-McKay. (biologynews.net)
  • Granulocyte colony stimulating factor (GCSF) are naturally occurring glycoproteins that stimulate white blood cell proliferation. (wikipedia.org)
  • Patients receiving granulocyte components, components that are HLA matched, or directed donations (from blood relatives) . (utmb.edu)
  • In the case of a stem cell transplant, granulocyte- colony-stimulating factor has to be given to the donor a few days before the procedure. (differencebetween.net)
  • Stem cell transplantation is performed after high-dose chemotherapy (HDC) to restore a cancer patient's blood and immune cell production capacity. (bdbiosciences.com)
  • High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma. (smw.ch)
  • Varicella zoster virus infection associated with high-dose chemotherapy and autologous stem-cell rescue. (nature.com)
  • Stem cells can be destroyed through cancer treatments such as chemotherapy or radiation, as well as any blood-related diseases, such as leukemia, lymphoma, neuroblastoma and multiple myeloma. (wikipedia.org)
  • Investigators will assess LP-284 as a treatment for those with B-cell non-Hodgkin lymphoma in a phase 1 trial. (cancernetwork.com)
  • OBJECTIVE: To assess the prognostic value of various parameters including positron emission tomography / computed tomography (PET/CT) and identify risk factors for survival of patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) treated with autologous stem cell transplantation (ASCT). (smw.ch)
  • Of the NHL patients, 59 (44%) had diffuse large B-cell lymphoma (DLBCL). (smw.ch)
  • Other risk factors for survival were primary refractory disease, initial lymphoma stage, number of previous chemotherapy lines, and high amounts of blood product transfusions. (smw.ch)
  • Stem cell transplant can be used to treat conditions such as multiple myeloma, and other cancers such as certain kinds of lymphoma and leukemia. (differencebetween.net)
  • These immature stem cells were easier to match to patients, especially those from non-Caucasian ethnicities, and could be stored for use as needed. (biologynews.net)
  • Because cord blood contains immature stem cells, HLA matching appears less crucial than for the other types of hematopoietic stem cell transplantation. (msdmanuals.com)
  • Globally, it is estimated that 120 000 corneal transplantations and 18 000 transplantations of allogeneic haematopoietic progenitor cells took place in the year 2000. (who.int)
  • 2 Evaluation of harvest adequacy requires the use of reliable progenitor cell assays and this is usually achieved by CD34 cell counting using flow cytometry. (bdbiosciences.com)
  • Flow cytometric applications for CD34+ cell identification and enumeration provide a rapid, quantitative and reproducible method to evaluate the progenitor cell population. (bdbiosciences.com)
  • Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience. (smw.ch)
  • Multiple myeloma is a cancer of plasma cells that produce monoclonal immunoglobulin and invade and destroy adjacent bone tissue. (merckmanuals.com)
  • Part of Developmental Cell , p. 450-460, 2023. (uu.se)
  • Allogeneic peripheral blood stem cell (PBSC) transplantation: Patients undergo allogeneic PBSC transplantation on day 0. (knowcancer.com)
  • The occurrence of varicella zoster virus (VZV) reactivation is increased after allogeneic transplantation, whereas limited data are available for herpes zoster (HZ) after autologous SCT (ASCT). (nature.com)
  • The donor first has to be treated with G-CSF, and then the stem cells can only be harvested a couple of days after the donor since time is needed for the donor's body to form more stem cells and transport these cells into the bloodstream. (differencebetween.net)
  • If a donor's HLAs match well with a person who needs a transplant, the donor must give a new blood sample to confirm the match. (medlineplus.gov)
  • Hematopoietic stem cell transplantation is also sometimes used for solid tumors (eg, some germ cell tumors) that respond to chemotherapy. (msdmanuals.com)
  • Gassas A , Grant R , Richardson S , Dupuis LL , Doyle J , Allen U , Predictors of viridans streptococcal shock syndrome in bacteremic children with cancer and stem-cell transplant recipients. (cdc.gov)
  • The high numbers of leukocytes remaining in a unit of pRBCs during the storage process can fragment, deteriorate, and release cytokines, and they have been implicated as a cause of reactions to a current and subsequent blood transfusions in some transfusion recipients. (utmb.edu)
  • Arvin AM . Varicella-zoster virus: pathogenesis, immunity, and clinical management in hematopoietic cell transplant recipients. (nature.com)
  • Although previous recommendations for preventing transmission of human immunodeficiency virus (HIV) through transplantation of human tissue and organs have markedly reduced the risk for this type of transmission, a case of HIV transmission from a screened, antibody-negative donor to several recipients raised questions about the need for additional federal oversight of transplantation of organs and tissues. (cdc.gov)
  • Hopefully, following the recommendations made in the guidelines will reduce morbidity and mortality from opportunistic infections in hematopoietic stem cell transplant recipients. (cdc.gov)
  • Thus, a comprehensive understanding of lung transplantation-related pathology is necessary for both tertiary care pathologists dealing with highly specialized lung transplantation teams and a much larger spectrum of healthcare providers who may be involved in the care of lung transplant recipients or candidates for lung transplantation. (medscape.com)
  • Subset analysis of the engrafted cells using a multiparametric system enabling a combined analysis of morphology, immunophenotyping and FISH showed that both T and B lymphocytes and myeloid cells were of donor origin in two patients, while T lymphocytes and myeloid cells were of donor origin in the third. (nih.gov)
  • 3 Autologous stem cell transplantation almost exclusively uses peripheral blood, while for allogeneic SCT, T-lymphocytes in the peripheral blood could pose some danger. (bdbiosciences.com)
  • A working group formed by the Public Health Service (PHS) in 1991 to address these issues concluded that further recommendations should be made to reduce the already low risk of HIV transmission by transplantation of organs and tissues. (cdc.gov)
  • This occurrence raised questions about the need for additional federal oversight of transplantation of organs and tissues. (cdc.gov)
  • The working group concluded that, although existing recommendations are largely sufficient, revisions should be made to reduce the already low risk of HIV transmission via transplantation of organs and tissues. (cdc.gov)
  • Nonetheless, the transplantation of organs and tissues does raise ethical concerns. (who.int)
  • Lung transplantation-related pathology encompasses a spectrum of disorders that include, but are not limited to, indications for lung transplantation (seen in explanted lungs), surgical complications (airway anastomotic and vascular complications), ischemia-reperfusion injury, rejection (acute and chronic), infections, and posttransplantation lymphoproliferative disorders (PTLDs). (medscape.com)
  • A potential future source of stem cells is induced pluripotent stem cells (certain cells taken from adults and reprogrammed to act like stem cells). (msdmanuals.com)
  • Create healthcare diagrams like this example called Leukemia - Stem Cell Transplantation in minutes with SmartDraw. (smartdraw.com)
  • [ 1 ] First described in 1848, MM is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance ( MGUS ) to plasma cell leukemia. (medscape.com)
  • Patrick Zweidler-McKay, M.D., Ph.D., assistant professor of pediatrics from the Children's Cancer Hospital at M. D. Anderson, has shown an effective method for expanding the number of NK cells from a single cord blood unit while retaining the cells' anti-leukemia effects, as presented at the American Society of Pediatric Hematology/Oncology annual conference on May 16. (biologynews.net)
  • However, Zweidler-McKay and co-senior investigator Elizabeth Shpall, M.D., professor in M. D. Anderson's Department of Stem Cell Transplantation and Cellular Therapy, have found a novel process to increase NK cells in cord blood more than 30-fold, generating more than 150 million NK cells from one cord blood unit while maintaining their activation to find and kill acute leukemia cells. (biologynews.net)
  • When given to mice with aggressive human leukemias, these NK cells reduced the circulating human acute lymphocytic leukemia (ALL) and acute myelogenous leukemia (AML) cells by 60 to 85 percent. (biologynews.net)
  • These NK cells demonstrate significant cytotoxic activity against human AML and ALL cell lines and patient leukemia blasts. (biologynews.net)
  • This study aims to monitor the long-term health of patients who have received a donor stem cell transplant from the NIH Clinical Center. (nih.gov)
  • The treatment of metastatic renal cell carcinoma is problematic, and, whenever possible, patients should be directed to approved and controlled clinical trials. (medscape.com)
  • Clinical features of lung transplantation-related pathology can range from an absence of symptoms to signs and symptoms of respiratory distress and/or infection and are not detailed in this article. (medscape.com)
  • The Registry of the International Society for Heart and Lung Transplantation (ISHLT) monitors and reports statistics on clinical lung transplantation. (medscape.com)
  • Leukocyte-reduced red blood cells are prepared using special filters and have special indications. (utmb.edu)
  • Pegfilgrastim is a leukocyte growth factor that works by binding to a receptor on immature cells called hematopoietic cells, which can develop into any type of blood cell. (drugs.com)
  • An increase in the peripheral leukocyte count was noted 56 months after the diagnosis of MFH was made. (karger.com)
  • Previous efforts to expand cord blood have resulted in ineffective NK cells. (biologynews.net)
  • However, in 1988, researchers found cord blood to be another source for stem cell transplantation. (biologynews.net)
  • Zweidler-McKay's study involves selecting out NK cells from cord blood. (biologynews.net)
  • As the cord blood is expanded to multiply in number, the NK cells are given a cytokine, interleukin-2, and a target cell, K562, which keep the NK cells active throughout the three week expansion. (biologynews.net)
  • These results support the evaluation of cord blood-derived NK cells as a potential immuno-therapeutic approach in acute leukemias. (biologynews.net)
  • Are you scheduled for a stem cell transplant with cord blood? (nih.gov)
  • The positive result came too late to save cord blood. (sunjournal.com)
  • One concern about the procedure is that immune cells in cord blood do not have experience with the viruses responsible for latent infections, leading to a higher percentage of naive T cells and thus increased vulnerability to reactivation of cytomegalovirus or Epstein-Barr virus infection. (msdmanuals.com)
  • This article contains highlights of "Guidelines for Pre- allogeneic or autologous, depending on the source of venting Opportunistic Infections among Hematopoi- the transplanted hematopoietic progenitor cells. (cdc.gov)
  • The myeloid-derived suppressor cells ( MDSC ) proportion in the pegfilgrastim group was significantly higher than that in the G-CSF group (P (bvsalud.org)
  • For the 20 OSMS patients, the overall EDSS score decreased significantly after transplantation (P = 0.016), while visual functions had no significant improvement (P = 0.716). (cellsurgicalnetwork.com)
  • High-risk MDS cases had a significantly higher percentage of apoptotic CD34+ cells and anti-apoptotic survivin+ cells than controls, particularly for trisomy 8 cases. (who.int)
  • For many hematopoietic malignancies, collection and infusion of CD34+ hematopoietic stem/progenitor cells following chemotherapy is critical. (bdbiosciences.com)
  • Hematopoietic stem cell transplantation has become a major treatment option for patients with hematopoietic malignancies and immune deficiencies. (cdc.gov)
  • 1 Improvements in transplantation techniques, including the wider use of cell selection, have contributed to a significant reduction in the morbidity and mortality associated with conventional transplantation. (bdbiosciences.com)
  • Access to transplantation entails more than the surgery itself, because success is measured by longer survival of the patient and a long-term improvement in the quality of life. (who.int)
  • Emphysema is end stage and generalized by the time the patient needs transplantation. (medscape.com)
  • After completion of study treatment, patients are followed weekly for 100 days post-transplantation and then periodically for survival. (knowcancer.com)
  • [ 18 ] A study by Alt et al found that complete resection of multiple renal cell carcinoma metastases may be associated with long-term survival. (medscape.com)
  • This applies as well in the adjuvant treatment of surgically resected renal cell carcinoma, for which no therapy has yet been found to offer survival benefit. (medscape.com)
  • Hematopoietic stem cell transplantation may be autologous (using the patient's own cells) or allogeneic (using cells from a donor). (msdmanuals.com)
  • citation needed] The transplantation may be autologous (an individual's own blood cells), allogeneic (blood cells donated by someone else with matching HLA), or syngeneic (blood cells donated by an identical twin). (wikipedia.org)